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Abstract 
Introduction: Leukaemia is cancer of white blood cells (WBCs) mainly affecting children.  
Defective WBCs are prominent in blood and cannot provide immune protection. Although 
chemotherapy treatments are effective, they have many adverse effects which are magnified 
in children, with treatment proving fatal for around 10-20% of children undergoing treatment. 
T-regulatory cells regulate inflammatory responses; in cancer raised levels of T-regulatory 
cells have been linked with immune evasion of cancer cells. Understanding chemotherapy 
effects on Treg populations is key to predicting therapy effectiveness. Ongoing research at 
KidsCan has identified the anti-tumour properties of novel glycosaminoglycan (GAG) 
compounds isolated from shellfish. However the effect of GAGs on normal lymphocyte 
populations is still unknown, identifying this action is essential in order to evaluate any 
potential use of GAGs as a cancer chemotherapy treatment in children. 
Aim: In order to further understand the potential use of GAGs for clinical applications the aim 
of this research is to evaluate T-cell and B-cell responses (in healthy lymphocytes) to GAG 
treatment and to compare them to control cancer cell lines (MOLT-4, K562 and U698).  
Methods: Phase 1 of the research isolated GAGs from cockles and whelks. Peripheral blood 
mononuclear cells (PBMCs) were extracted in bulk from whole blood from the NHS donor 
service.  GAG isolates were tested for activity on cell growth using MTT assay on PBMCs (naïve 
and activated) and three cancer cell lines (MOLT-4, K562, U698). Phase 2 tested the GAG 
isolates for their potency via a flow cytometric annexin V/ PI apoptosis assay on the cell lines 
and PBMCs both activated using either PHA or PMA/ionomycin and naïve. Phase 3 studies 
evaluated individual FPLC separated GAG fractions to establish potentially potent domains of 
the compounds. This work also focussed on T-regulatory cell (Treg) responses to the GAGs to 
provide an insight to their potential modulation of a population of cells associated with cancer 
progression.   
Results: The MTT assays identified that both GAG extracts had a profound effect on cancer 
cell growth, with cell viability inhibitions of up to 90% and IC50 values ranging between 0.7 
µg/ml and 12 µg/ml. This study also indicated that GAG extracts have little effect on the 
viability of  healthy lymphocytes (PBMCs) identifying the potential of GAGs as a therapeutic 
treatment for cancer. MTT assays aided with the design of the apoptosis assays. Apoptosis 
assays indicated that cancer cells responded to GAG extract treatment via the induction of 
apoptosis and identified which cell types were most at risk of being targeted in healthy 
lymphocyte populations (stimulated and unstimulated), they also identified the whelk extract 
as being the more effective GAG treatment. The Treg assays indicate that decreases in the cell 
population may be an additional benefit of the GAG compounds through reducing the risk of 
tumour progression. However further work with Treg populations in healthy lymphocytes 
would help to prove this principle and future studies would be useful to further optimise the 
fraction assays.  
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CHAPTER 1- INTRODUCTION 
1.0 Introduction 
Cancer is the result of several malfunctions in normal cellular systems which promote cellular 
proliferation and systems which aid the prevention of uncontrolled cellular proliferation 
(Sompayrac, 2015). This study seeks to undertake the preclinical evaluation of novel shellfish 
isolates on healthy lymphocytes, to advance the development of more effective and tolerable 
therapies, especially in children.  
1.1 Normal cell cycle 
The cell cycle is the mechanism which cells use to divide and grow, with the eventual outcome 
the production of two identical daughter cells (Schafer, 1998: Yang, 2012). Thus 
understanding the regulation of the cell cycle is essential in cancer therapy. In healthy cells 
two main events occur, firstly cellular DNA is replicated and secondly division occurs which 
results in two identical daughter cells (Yang, 2012). 
The cell cycle is made up of several phases each of which must be completed and progressed 
through in order, i.e. one phase cannot begin without the successful completion of the stage 
before it (Yang, 2012). The cycle has four phases, as shown in figure 1.1, the first three being 
G1, S phase and G2. In the G1 phase the cell enlarges and prepares for DNA synthesis to occur, 
at this stage the cell can be referred to as diploid meaning it contains two copies of each 
chromosome (Cooper, 2000: Yang, 2012).  S phase is the point where DNA is synthesised, and 
DNA content can vary between 2 copies and 4 copies of chromosomes depending on at which 
stage of replication the cell is at.  G2 is the second gap phase where cells get ready to divide, 
cells can be referred to as tetraploid (4 copies of chromosomes) at this stage. M phase is 
where actual cell division occurs and is made up of two sections. The first section is mitosis 
where the chromosomes are equally divided between the two daughter cells (Yang, 2012). 
The second stage is known as cytokinesis and is where the cytoplasm divides and forms the 
two distinct daughter cells. Typically, it takes 24 hours for cell division to occur, with mitosis 
and cytokinesis typically making up 1 hour of this time (Cooper, 2000). As well as the four 
stages of the cell cycle mentioned above there is a fifth stage which is known as G0 resting 
phase, this stage lies outside the cell cycle 
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(Cooper, 2000). Cells in this stage are said to be resting and have typically come out of the G1 
stage (Cooper, 2000: Yang, 2012). G0 phase is a resting phase where the cell can perform all 
its normal functions, but it does not divide. Usually a cell will enter the G0 phase if the 
surrounding environment is not promoting of the cell cycle, for example if there is a lack of 
nutrients or growth factors (Cooper, 2000). However fully differentiated cells such as 
neurones will also be in the G0 phase (Yang, 2012). Additionally, to these two cases it may 
also be possible for a cell to enter into the G0 phase if there has been DNA damage identified, 
the entering of the G0 phase in this case is as an alternative to cell destruction through 
apoptosis (Yang, 2012).    
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Figure 1.1 The phases of the normal cell cycle. The normal cell cycle is comprised of 4 phases, G1, S, G2 
and M. Interphase is the stage in which the cell continuously grows this includes the G1, S and G2 
stages. The availability of growth factors is responsible for the progression of the cell cycle at the 
restriction point of the G1 phase. There are several other checkpoints within the cell cycle which are 
responsible for ensuring the correct and complete genome is inherited by daughter cells. The G1, S 
and G2 checkpoints cause cell cycle arrest in response to damaged DNA. The G2 checkpoint also causes 
arrest due to incomplete DNA. The M phase stop point causes cell cycle arrest due to chromosome 
misalignment. The cell cycle is also driven by the presence of cyclin/CDK complexes, the position of 
these various complexes is demonstrated here. Adapted from Cooper, 2000: Schafer, 1998: Yang, 
2012. 
Interphase is the collective name for the initial three stages of the cell cycle. When a cell 
receives a signal to divide it enters into the first stage of interphase (G1 phase).  G1 is the first 
growth phase in which the cell prepares for division, as it performs its normal functions it also 
grows in size (Cooper, 2000). The cell also begins to make copies of its organelles (Canadian 
Cancer Society, 2016), and begins larger productions of protein. The cell can then enter into 
the S phase (synthesis stage).  Here the cell makes two copies of its DNA in order to gain two 
sets of chromosomes (one for each cell) (Cooper, 2000: Yang, 2012). The cell then progresses 
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onto the G2 phase which is the second growth phase in which the cell makes more protein to 
get ready for cell division. The cell moves onto the final stage of the cell cycle which is the M 
stage which is collective name for mitosis and cytokinesis. Mitosis can also be broken down 
into four stages: prophase, metaphase, anaphase and telophase. In mitosis DNA condenses 
and allows the visibility of chromosomes. This stage is then followed by the separation of 
chromosomes into two clear sets. Cytokinesis is often named the final stage of mitosis as it is 
the point that the two daughter cells separate (Yang, 2012). The initial stage of mitosis is the 
prophase which is the point where the nuclear membrane breaks down and the condensation 
of chromosomes occurs. It is also at this point the chromosomes separate at the centrosomes 
(Schafer, 1998).  A mitotic spindle then forms and attaches one end of the centrosome to a 
kinetochore, which is a protein structure located near the centromere (Yang, 2012). A delay 
signal may then be given in order to ensure that all the kinetochores are attached, and the 
chromosomes are all correctly aligned. These delay signals are also known as the spindle 
assembly checkpoint (SAC). Following this the chromosomes gather at the metaphase plate 
and this is known as metaphase. The chromosomes then separate at opposite poles of the 
cell which is known as anaphase (Hickson, Echard & O’Farrell, 2006). These stages are then 
followed by the final stage of mitosis which is telophase, in this stage new nuclear membranes 
are formed around the daughter nuclei and the chromosomes uncoil (Schafer, 1998).  These 
are the stages the cell goes through to divide into two new cells. After mitosis the cells either 
re-enter into the G1 phase or go into the resting G0 phase.  
 Regulation of the cell cycle occurs through signalling pathways (which monitor events 
occurring during the cell cycle) (Schafer, 1998: Cyclacel, 2016) and through environmental 
cues (Cooper, 2000) (such as growth factor and mitogen availability). The cell cycle also uses 
a variety of checkpoints (figure 1.1) which allow the cycle to be paused in order to detect and 
then correct errors which may have occurred during the cell cycle. If the mistakes cannot be 
rectified then, in a normal cell, apoptosis (cell death) would be induced. Cell death is induced 
via the recognition of the damaged DNA at the various cell cycle checkpoints by kinases and 
P53 protein which induce the production of pro-apoptotic factors such as BAX, FAS and PUMA 
(Roos and Kaina, 2006). The induction of cell death due to DNA damage is complex process 
which involves several enzymatic reactions which will ultimately lead to the termination of 
the damaged cell; apoptosis is discussed further in section 1.3.7.1.   
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It is essential that cellular functions such as cell growth, DNA replication and mitosis are 
regulated during the cell cycle (Cooper, 2000), and this is accomplished through several 
checkpoints throughout the cycle (Schafer, 1998). The restriction point is one of the main 
checkpoints responsible for cell cycle regulation and occurs in the late stages of the G1 phase 
(Cooper, 2000: Schafer, 1998). At this stage for the cell to progress through the cell cycle there 
must be adequate growth factor presence, if there are adequate amounts of growth factor 
then the cell progresses through the cell cycle (Cooper, 2000). However, if there is not enough 
growth factor presence then the cell enters into cell cycle arrest at the G1 phase and 
subsequently enters into the G0 rest phase and only re-enters the cell cycle upon the 
availability of the required growth factors (Schafer, 1998). If the restriction point checkpoint 
is passed then the cell must progress onto the S phase and continue through the cell cycle 
(Cooper, 2000). Damaged DNA can have progression through the S phase of the cell cycle 
delayed and arrested at the G1 checkpoint, which provides time for the damage to be rectified 
(Cooper,2000). A G1 Checkpoint arrest is generally mediated by the rapid elevation of the P53 
protein levels (Schafer, 1998) and its action, which is discussed further in section 1.1.2. There 
are other checkpoints within the cell cycle which hold the responsibility of identifying 
damaged or incomplete DNA and ensuring that it is not replicated or inherited by daughter 
cells (Cooper, 2000: Schafer, 1998) (Figure 1.1). The main checkpoint of this nature is in the 
G2 stage. Upon the detection of any un-replicated or damaged DNA then the G2 checkpoint 
prevents the progression of the cell from the S phase into the M phase by signalling for cell 
cycle arrest (Cooper, 2000). This allows time for the DNA damage to be repaired or for the 
un-replicated DNA to be replicated correctly. Another vital checkpoint occurs towards the 
end of the mitosis stage and is responsible for monitoring chromosome alignment at the 
mitotic spindle (Schafer, 1998). This ensures that each daughter cell acquires a complete set 
of chromosomes. If this fails then the cell cycle arrests at metaphase until the correct 
alignment and acquirement of a full set of chromosomes can be achieved for each daughter 
cell (Schafer, 1998). 
It is important that replication of the DNA of a cell only occurs once in the cell cycle, this is 
achieved by a family of proteins known as mcm proteins (Cooper, 2000). These proteins bind 
the replication origins with origin replication complex (ORC) proteins, this binding initiates 
replication (Schafer, 1998). As mcm proteins can only bind replication origins in the G1 phase 
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the process of replication can there for begin at the start of the S phase but is regulated so it 
can only bind once (Schafer, 1998). Once replication has begun mcm proteins are displaced 
from the origin and so no further replication is able to take place until the cell re-enters the 
G1 phase of the next cell cycle (Cooper, 2000).    
Cell cycle progression is also dependent on the activation and deactivation of regulatory 
molecules known as cyclins and cyclin dependent kinases (CDKs) (figure 1.1) (Cooper, 2000: 
Schafer, 1998: Yang, 2012). CDKs are not active unless they are in the presence of their cyclin 
counterpart. Cyclins are known as such due to their cyclic nature of synthesis and degradation 
in each cell cycle (Yang,2012). There are four classes of cyclins in total, three of which are 
directly involved in the regulation of the events within the cell cycle, these are G1/S cyclins, S 
cyclins and M cyclins, while G1 cyclins are responsible for the initiation of the cell cycle (Yang, 
2012). G1 cyclins act in response to extracellular factors such as growth factors or mitogens 
which are essential for the initiation and maintenance of the transition to the S phase (Yang, 
2012).   These complexes are also regulated by proteins which include P53 and are 
downstream targets of cyclin-CDK complexes such as E2F and retinoblastoma protein (pRb) 
(Schafer, 1998). Different cyclin/CDK complexes function at different stages of the cell cycle 
and their target protein depends on the cyclin/CDK complex (Yang, 2012). In the G1 phase the 
target protein is pRb (Schafer, 1998), hypo-phosphorylated pRb binds the E2F transcription 
factor which makes it inaccessible for transcription (Schafer, 1998). The G1 cyclin/CDK 
complex (E-CDK2) initiates the phosphorylation of pRb which causes the pRb to release E2F, 
allowing it to participate in the transcription of proteins required for the progression of the 
cell cycle (Kato, Matsushime, Hiebert, Ewen and Sherr, 1993: Yang, 2012). This allows for the 
progression of the cell from the G1 phase to the S phase, the restriction point is regulated by 
pRb (Schafer, 1998). Cyclin dependent kinase inhibitors (CKDI) are responsible for 
constraining the effects of CDKs, there are two types of CDKI (Sherr and Roberts, 1995). The 
first type inhibits CDK4 (INK4) proteins and bind and inhibit CDK4 and CDK6 proteins (Sherr 
and Roberts, 1995). The second type of CDKIs are CDK-interacting proteins cip/kip family of 
proteins and have a broader mechanism of action than INK4 (Sherr and Roberts, 1995). These 
CDKIs block the activity of CDKs by forming a trimeric complex. The cell cycle checkpoints are 
therefore also regulated by CDKIs as it is the checkpoints where the cell cycle is typically 
arrested. At the G1 checkpoint is typically regulated by both INK4 and cip/kip inhibitors in 
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order to be able to arrest cells in the G1 phase (Holland and Cleavland, 2009). This inhibition 
occurs via the binding of CDK4 to INK4 as opposed to D-cyclin, unbound cyclin therefore 
degrades and prevents the progression of the cell cycle (Diehl, Zindy and Sherr, 1997). This 
CDKI is activated upon the detection of DNA damage. The G2 checkpoint is P53 protein 
dependent (Levine, 1997).        
There are many diseases which include cancer which are the result of unregulated cell 
growth/ death which have occurred due to mutations within the cell cycle controlling 
molecules (Cooper, 2000). Therefore, understanding how a treatment interacts with the cell 
cycle could be key in predicting its success as an anti-cancer treatment. This research will aim 
to determine whether treatment with a GAG extract can induce apoptosis of cells which are 
going through the cell cycle in an uncontrolled manner (cancer cells).  
1.1.1 Pathological outcomes of uncontrolled progression through the cell cycle 
As the cell cycle is essential for cell proliferation control it is therefore understood that 
cancers can develop as a result of cells proliferating in an uncontrolled fashion (Sompayrac, 
2015). In genomic sequencing studies there have been several somatic mutations (occur in 
any cell apart from germ cells) within genes identified which contribute to the initiation of 
cancer (Wood et al., 2007). Amongst the mutations found the most highly ranked ‘cancer 
genes’ were noted to either be directly or indirectly involved with cell cycle regulation 
(Sjoblom et al., 2006). One example of this is the tumour suppressor gene P53.   
1.1.2 P53 tumour suppressor gene 
Levine (1997) reported that over 50% of all cancers were found to have a mutated copy of 
the P53 tumour suppressor gene. It has been estimated that cancers which derive from over 
50 human cell types and/or tissues have mutations in the P53 gene (Levine, 1997: Schafer, 
1998: Somapayrac, 2015: Yang, 2012).  
P53 is a protein which accumulates as a response mechanism to cellular stress caused by DNA 
damage, hypoxia or oncogenic activation (Helton & Chen, 2007). In a normal cell once the P53 
gene has been activated and stabilised a transcriptional program is initiated and apoptosis or 
cell cycle arrest ensues (Yang, 2012).  
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The P53 protein operates at the G1 phase of the cell cycle and causes cell cycle arrest upon 
recognition of DNA damage (Schafer, 1998). Upon recognition of DNA damage in the G1 
checkpoint there is an influx of P53 protein. The P53 protein then signals for the production 
of the P21 protein transcriptionally. The P21 family of proteins are highly important in the 
regulation of G1 cell cycle arrest (Deng, Zhang, Harper, Elledge and Leder, 1995). This is 
because the P21 protein family can inhibit most CDKs through the binding of cyclins (cyclin E, 
A or B-CKD complex) (Yang,2012), this effectively blocks the phosphorylation of pRb, meaning 
E2F cannot be released to continue with the cell cycle (Schafer, 1998). This is one method by 
which the P53 protein results in cell cycle arrest. There are other P53-responsive genes other 
than P21, these include the BCL2-associated X protein (BAX) (Yang, 2012), when production 
of this protein or FAS or PUMA are induced in response to DNA damage then apoptosis is 
induced thus halting the cell cycle (Roos and Kaina, 2006).  
Thus, a clear understanding of the mechanisms of regulating the cell cycle proliferation and 
differentiation of cells during cancer, along with their interactions with tumour suppressor 
genes such as P53 could be the key to finding an effective cure. Interestingly previous 
research carried out by KidsCan has identified GAG activity in a variety of cell lines including 
K562 which lacks the P53 gene (cells with a mutated P53 are less efficient at having apoptosis 
induced) (Roos and Kaina, 2006). This work aims to identify whether the extracts have activity 
on ‘healthy’ cells which go through the cell cycle in the usual manner and contain wild-type 
copies of the P53 gene.   
1.2. Cancer  
1.2.1. Cancer Pathology 
Cancer is a very common condition affecting one in three people in their lifetimes (Cancer 
Research UK, 2019). It is recognised as cells within a certain area of the body which expand 
and multiply in an uncontrollable fashion, due to mutations within the proliferation control 
systems or safe-guarding systems that prevent against uncontrollable cell growth 
(Pecorino,2012). These issues can also prevent ‘unhealthy’ cells from entering into the 
controlled cell death pathway known as apoptosis. Cancer cells can be divided into two types 
which are either blood cell cancers or non-blood cell cancers (Sompayrac, 2015). Blood cell 
cancers arise when the bone marrow fills with immature cells which continuously proliferate 
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or when clusters of immature cells collect in the lymph nodes or secondary lymph tissues 
(Sompayrac, 2015). In non-blood cell cancers cancerous cells accumulate and form a body 
known as a tumour. Some cancerous cells also possess the ability to invade and destroy 
healthy tissue in surrounding areas and can spread from one part of the body to another, this 
process is called metastasis. The progression of cancer can be seen in figure 1.2.   
 
Figure 1.2 The stages of tumour progression and metastasis. (Divoli, Mendonca, Evans and Zhetsky, 
2011). 
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1.2.1.1 Cells which can be affected by leukaemia 
 
Figure 1.3 The maturation of the different type of blood cells from the stem cell progenitor cells. The 
maturation of blood cells from stem cell progenitors into: the lymphoid lineage and ultimate 
maturation into white blood cells or the myeloid lineage and maturation into red blood cells, platelets 
or white blood cells.  (adapted from The National Institute of Cancer, 2018). 
Figure 1.3 shows the progression of a stem cell into a variety of blood cells. In leukaemia the 
white blood cells produced from the stem cells are defective and cannot provide immune 
protection (Sompayrac, 2015). Defective myeloid cells produce either chronic or acute 
myeloid leukaemia which is determined by the speed at which the cancer progresses 
(Rabbitts, 1991: Journal of Leukaemia, 2018). If the leukaemia is classed as acute it means 
that the disease is progressing at a rapid rate (if untreated it can become fatal within months, 
(Appelbaum et al, 2014), the opposite can be said for chronic leukaemia. Myeloid leukaemia 
is more common in adults than children; however, it is possible for children to have a myeloid 
cell derived leukaemia (Shepard et al, 2016). Similarly, leukaemia of the lymphoid cells can 
also be described as acute or chronic depending on the speed of the cancer progression, 
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however lymphoid leukaemia is the most common amongst children (Shepard et al, 2016: 
Ward, Desantis, Robbins, Kohler and Jemal, 2014).  
1.2.1.2 Cancer statistics  
According to Siegel, Miller and Jemal (2015) there are approximately 200 different forms of 
cancer each with a unique set of symptoms, diagnosis method and treatment regime. With 
around 331,500 people in the UK diagnosed with cancer each (Cancer Research UK, 2019: 
Siegel, Miller and Jemal, 2015).  
Ward et al., (2014) reported that approximately 1600 children are diagnosed with cancer each 
year, with leukaemia being the most prevalent (~500 new cases each year), and around one 
third of those cases prove to be fatal.  
1.2.2. Leukaemia 
Leukaemia mainly affects children with the most common incidence rate being before the 
age of 5 (Children with cancer UK, 2018: Ward et al, 2014). Survival rates for children with 
leukaemia have increased dramatically since the 1960s when it was deemed incurable for 
children, survival rates are now around 88% (Children with Cancer, UK, 2018: Ward et al, 
2014) Leukaemia is a cancer of the white blood cells (WBCs) where defective WBCs are 
prominent in the blood and cannot provide immune protection (Sompayrac, 2015). This 
means that circulating levels of functioning immune cells are low and therefore leukaemia 
patients are prone to infection (Shepard et al, 2016: Sompayrac, 2015).   
1.2.2.1 What causes leukaemia? 
Bone marrow produces stem cells which have the ability to differentiate into any cell type 
including the three main blood cell types; white blood cells, red blood cells and platelets 
(Mummery, 2014: Maton et al, 1993). In a normal system stem cells fully develop into a cell 
type before they are released into the blood stream (Mandavilli, 2013). However, in 
leukaemia this system is compromised and the bone marrow releases excessive amounts of 
immature white blood cells, known as blast cells (Calabretta and Perrotti, 2004). As the 
volume of blast cells increase it causes a corresponding drop in the amount of circulating red 
blood cells and platelets. This decrease is generally responsible for the symptoms of 
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leukaemia such as fatigue, increased infection and unusual/unexplained bleeding (Shepard et 
al, 2016); in addition, blast cells are less effective than mature white blood cells at defending 
the body against bacterial and viral infections (Sompayrac, 2015). Thus, leukaemia patients 
are more susceptible to infection (Shepard et al, 2016: Sompayrac, 2015).  
There are four main types of leukaemia (Shepard et al, 2016), which are dependent on the 
type of white blood cell affected, the speed of disease progression. These types are Acute 
lymphoblastic leukaemia (ALL), Acute myeloid leukaemia (AML), Chronic lymphoblastic 
leukaemia (CLL) and Chronic myeloid leukaemia (CML) (Sheppard et al, 2016). This research 
looked into CML and ALL responses to GAG extracts and fractions as control cancer cells.   
1.2.2.2 Chronic myeloid leukaemia (CML)  
Chronic leukaemia can be categorised according to which white blood cell (WBC) is affected 
by the cancer; lymphocytes which are responsible for fighting viral infection, myeloid cells 
which have many functions including aiding in fighting bacterial infection, defending against 
parasite infection and prevention of the spread of tissue damage (Kawamoto and Minato, 
2004). It can take many years for leukaemia to advance through the different stages of the 
disease from the chronic stage through to the accelerated phase and finally into the blast 
phase meaning the concentration of blast cells in the peripheral blood has exceeded 30% 
(Hehlmann, 2012).    
CML is a type of leukaemia which progresses slowly over a period of several years. It is a 
disease of haemopoietic stem cells, which results in the formation of cells which are un-
functional and are in a stage of developmental immaturity (De Lavallade, 2013). These 
immature cells congregate within the bone marrow and are dramatically overproduced. 
When the blast cells are released into the blood it causes a corresponding drop in the level of 
circulating red blood cells (RBC) and platelets (Hehimann, Hochhaus and Baccarani, 2007). 
CML is most commonly associated with a genetic mutation in which the breakpoint cluster 
region (BCR) gene which appears on chromosome 22 trans-locates and attaches to the ABL 
gene on chromosome (Kawamoto and Minato, 2004). This mutation is referred to as the 
Philadelphia chromosome (Goldman, 2008) and occurs in approximately 95% of CML cases 
(Harrison, 2001). This development leads to enhanced activity of tyrosine kinase, ultimately 
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leading to multiple signal cascades which involve cell growth, cell differentiation, cell 
adhesion and cell death (Kalidas, Kantarjian and Talpaz., 2001: Kabarowski and Whitte, 2000).  
1.2.2.2.1 Symptoms of CML 
CML consists of three main developmental stages. The first stage is the chronic phase where 
the cancer develops at a slow pace (Hehimann et al., 2007) and produces no noticeable 
symptoms.  Patients can remain in this stage for a prolonged period of time with little or no 
increase in symptom severity (Shepard et al, 2016). It is within this stage that most patients 
are diagnosed, usually as a result of a general health check or blood test and so is considered 
an ‘accidental’ diagnosis. If symptoms are experienced at this stage they are usually 
considered as minor symptoms which may include weight loss and fatigue (Shepard et al, 
2016). At this stage the patient will have a bone marrow blast cell level of <10% (Hochhaus et 
al, 2017).  
The second stage of CML is referred to as the accelerated phase. At this point the cancer is 
progressing with a bone marrow blast cell level of around 20% (Hochhaus et al, 2017: 
Goldman, 2008). Further symptoms may be experienced at this stage including fever, weight 
loss, night sweats and bruising (Shepard et al, 2016). When CML develops into the final stage 
patients are said to be in the blast phase or in blast crisis. Calabretta and Perrotti (2004) 
described blast crisis as the terminal stage of CML, where there is a typical peripheral blood 
concentration of blast cells of more than 30%. This stage of the disease typically lasts only a 
few months and has a characteristic accelerated expansion rate of defective myeloid cells 
(Calabretta and Perrotti, 2004).  At this point the symptom set is similar to acute leukaemia 
(discussed in section 1.2.2.2). The bone marrow is now full of blast cells and the circulating 
blood level of blast cells is also high (Goldman, 2008), the blast cells may also now be 
detectable in other organs. 
1.2.2.2.2 Diagnosis of CML 
Although diagnosis of CML is usually made via a blood test which shows elevated levels of 
blast cells (Hochhaus et al, 2017: Shepard et al, 2016), further tests should be carried out to 
confirm the diagnosis. Bone marrow aspirations allow the determination of the 
developmental stage the cancer is in through the measurement of the volume/ percentage 
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of blast cells present in the bone marrow in comparison to ‘normal’ cells. This can be done 
throughout the cancer to determine cancer progression. DNA analysis can also be carried out 
to detect the presence of the Philadelphia chromosome, as this is a strong indicator of CML 
and can determine a correct diagnosis as around 95% of CML patients have a positive result 
for the Philadelphia chromosome (De Lavallade, 2013). 
1.2.2.2.3 How common is CML? 
CML is a relatively rare form of cancer with approximately 680 people a year diagnosed in the 
UK (Siegel, Miller and Jemal, 2015). It mainly affects people within the 40-80 years old age 
bracket, but people of all ages can be affected. CML is a rare childhood leukaemia with less 
than 15 new cases each year (Ward et al., 2014).   
This research used a CML cell line (K562) as a representative of a variety of cancers which 
GAGs have the potential to treat. Current treatment methods for CML aim to return blood 
levels back to normal levels, however leukemic cells can still be detected at some level. GAGs 
could potentially provide a treatment which may completely irradiate the cancer cells.  
1.2.2.2.4 Treatment of CML 
The current chemotherapy drug for CML patients is Imatinib tablets which are taken every 
day for life (Hochhaus et al., 2009). Imatinib acts via the selective inhibition of tyrosine kinase 
which effectively halts the cancer cell growth, (Hochhaus et al., 2009: Shah et al, 2004) 
causing the cell to enter into cell death (Vigneri and Wang, 2001). Imatinib does this by 
effectively blocking the ATP binding site of the BCR-Abl protein (Gambacorti-Passerini et al, 
2003). This binding prevents tyrosine kinase being able to bind and therefore inhibits the 
activity (Gambacorti-Passerini et al, 2003). Imatinib however is not a cure for CML it simply 
aims to slow the progression of the cancer and tries to prevent the cancer entering into the 
next stage of the disease.  
The treatment is aimed at achieving a normal blood cell count within a three month period. 
By 12 months post treatment it is hoped that the patient should be completely clear of bone 
marrow cells which contain the mutated Philadelphia chromosome (Goldman, 2008). After 
18 months of treatment the patient should be at a stage where leukaemia cells can only be 
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detected by highly sensitive molecular testing (Goldman, 2008). At this point the patient is 
said to be in recovery. 
1.2.2.2.4.1 Treatment of early stage CML 
Imatinib is the primary treatment for early stage CML (Shah et al, 2004). Imatinib inhibits the 
production of abnormal WBCs through the inhibition of a tyrosine kinase and its reactions. 
Although between 10% and 40% of patients taking Imatinib are given alternative treatments 
after becoming resistant to its effects (Gambacorti-Passerini et al, 2003). An alternative would 
be Nilotinib, which works in a similar way to Imatinib by blocking the effects of proteins (Abl 
specific tyrosine kinase) responsible for cancer cell growth (Jobbour, Cortes and Kantarjian, 
2009). As imatinib works by effectively closing the ATP binding site for tyrosine kinase in the 
BCR-Abl protein, resistance can come about when the BCR-Abl protein adjusts its equilibrium 
to a more active conformation or to an open position (Gambacorti-Passerini et al, 2003). 
1.2.2.2.4.2 Treatment of advanced CML 
Once the cancer has progressed into more advanced stages, chemotherapy is considered as 
the next course of action (Daiziel, Round, Stein, Garside and Price, 2004: Cancer Research UK, 
2019). Oral tablets are given to begin with as side effects are considered to be milder, these 
tablets are generally imatinib if this was not the treatment used during the chronic phase 
(Daiziel, et al. 2004). If imatinib was used during the chronic phase then generally 
hydroxycarbamide is given orally, this drug aims to reduce the white blood cell count and 
control symptoms (Daiziel et al, 2004). Hydroxycarbamide does this via blocking the transfer 
of RNA to DNA through the inhibition of ribonucleotide reductase action effectively 
preventing cells from leaving the G1/ S-phase of the cell cycle (National Centre for 
Biotechnology Information, 2019). If symptoms persist or worsen then chemotherapy 
injections are required, however side effects are more severe. Chemotherapy choices would 
generally be a combination of cytarabine and daunorubicin, however other types may be 
considered (Virelizier et al., 2009: Cancer Research UK, 2019). If this treatment fails bone 
marrow transplants may be considered, but in most cases the risks associated outweigh the 
benefits (Cancer Research UK, 2019). 
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1.2.2.2.5 What is the outlook for a CML patient? 
The outlook is dependent on treatment tolerance and response. Around 60-65% of patients 
treated with Imatinib tablets tolerate the treatment and go on to see an improvement in 
symptoms (Shah et al., 2004). More than half of patients who don’t respond to Imatinib will 
respond to another chemotherapy drug (De Lavallade, 2013). If an improvement is not seen 
after the use of chemotherapy drug a bone marrow transplant may be considered. If the CML 
is diagnosed within the chronic stage almost 90% of patients will survive the 5-year mark post 
diagnosis (Goldman, 2008).  
1.2.2.2.6 The K562 cell line 
The K562 cell line originated from a 53year old female who was in the blast crisis phase of 
CML, which is Philadelphia chromosome positive (Drexler et al., 2000). In culture the cells 
appear rounded in shape and don’t exhibit the clumping that can be noted in other 
suspension cells lines.  
Klein et al (1976) examined the K562 cell line to look specifically into B cell and T cell 
properties of the cell line. They noted that the cells lacked B markers for immunoglobulins 
unlike B cells and drew more similarities to T cell lines. This was due to the fact the cells were 
lysed rapidly by C’/Fc receptor positive human blood leukocytes and also did not facilitate 
mixed lymphocyte culture (MLC) reactions. However, the K562 cell line doesn’t have T 
antigens and has high radiosensitivity and is also sensitive to thyamine growth inhibition 
(Klein et al. 1976). This makes it difficult to determine whether the K562 cell line is of B or T 
cell lineage. 
K562 cells also do not possess N-APase which is an enzyme that can be found in a cell line 
which has lymphoid lineage or in lymphoproliferative diseases (Klein et al., 1976). Klein et al. 
(1976) also concluded that the K562 cell line was not B cell derived and although they did 
contain some features of T cells. The general characteristics of the cells also suggested they 
were not lymphoid cells, due to the lack of or minimal differentiation making the nature of 
the cells difficult to determine with any degree of certainty. A cellular marker may be present 
for CML on the cell surface they also concluded it may be possible to describe the K562 cell 
line as granulocytic cells (Klein et al., 1976). 
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The research carried out by Klein et al. (1976) failed to determine the exact lineage of the 
K562 cell line due to the fact they demonstrated properties of both B and T cells.  
As the K562 cell line lacks the gene for P53 (Stuppia et al., 1997), assays carried out on this 
cell line may provide a clearer view on how GAGs target the cells, as any activity on this cell 
line would suggest activity may not be through the traditionally targeted P53 pathway.  
1.2.2.3 Acute Lymphoblastic Leukaemia (ALL)  
Acute leukaemia refers to a cancer which progresses both rapidly and aggressively and 
requires immediate treatment (Inaba, Greaves and Mullighan, 2013). Acute leukaemia is 
classified based on the type of white blood cell which has been affected by the cancerous 
mutations. There are two main types of white blood cell which can be affected by acute 
leukaemia; lymphocytes whose main function is to fight viral infection and neutrophils which 
have several functions within the body, to fight bacterial infection, to defend the body against 
parasites and finally to prevent the spread of tissue damage (Kawamoto and Minato, 2004).  
1.2.2.3.1 Symptoms of ALL 
Usually the symptoms of ALL progress slowly at the early stages but swiftly increase in severity 
as the number of blast cells within the circulating blood increases (Shepard et al., 2016: 
Grigoropoulos, Petter, Van’t Veer, Scott and Follows, 2013). The main symptoms of ALL are 
pale skin, fatigue and regular recurrent infections over short periods of time (Shepard et al, 
2016). Unusual but regular bleeding can also occur during the progression of ALL (Pui and 
Robinson, 2008) this is generally due to the drop in platelet levels associated with the increase 
in blast cells (Sompayrac, 2015). 
1.2.2.3.2 Diagnosing ALL 
In order to diagnose ALL blood tests are carried out first to identify whether there are high 
amounts of white blood cells and low amounts of red blood cells and platelets. Most patients 
with ALL have a platelet count of less than 150,000/µl, the normal level for platelets is 
150,000/µl (Jorge, Cortes, Hagop and Kantarjian, 1995). White blood cell counts can be 
variable in ALL patients and so the platelet count and bone marrow aspirations generally lead 
to the diagnosis of ALL (Jorge et al., 1995). Doctors may also use the blood tests or bone 
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marrow aspirations to identify the presence of blast cells which can allow a determination of 
the stage at which the cancer is at (Jorge et al, 1995: Shepard et al, 2016).  
Bone marrow aspirations may also be carried out; this will firstly allow the identification of 
leukemic cells. Secondly it will allow for the classification of the cells affected by the 
leukaemia into size, shape and also whether the leukaemia derived from B lymphocytes or T 
lymphocytes. This determination will allow a correct treatment regime to be developed 
(Hunger et al., 2012).  
X-rays, CT scans and ultrasounds may also be carried out in order to fully determine the 
development stage of the cancer and whether it has spread.  
1.2.2.3.3 How common is ALL? 
Around 654 people in the UK are diagnosed with ALL each year (Ward et al., 2014). ALL is also 
the most common form of childhood cancer affecting approximately 1 in 2000 children. 
Around 85% of children diagnosed are between the ages of 2 and 5 years old (Ward et al., 
2014).  
1.2.2.3.4 Treatment of ALL 
The treatment regime for ALL is generally a combination therapy of chemotherapy drugs 
which are given in hospital until symptoms improve and then on an outpatient basis 
thereafter. These combinations may begin with a steroid such as dexamethasone along with 
chemotherapy drugs such as vincristine and asparaginase (Pui and Evans, 2006). The addition 
of other chemotherapy drugs such as cytarabine may be required to alleviate symptoms (Pui 
and Evans, 2006). Once blood levels have returned to a normal level methotrexate and 
mecaptopurine may be used as chemotherapy to eradicate any remaining leukemic cells (Pui 
and Evans, 2006). Radiotherapy may also be given if the ALL has progressed onto an advanced 
phase. If chemotherapy and radiotherapy fail to treat the cancer a bone marrow transplant 
may be offered (Kersey et al., 1987). If a cure is not possible then the absence of healthy white 
blood cells will ultimately mean that the patient has a higher susceptibility to a life-
threatening infection. They may also be at risk of an uncontrolled serious bleed.   
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1.2.2.3.5 What is the outlook for an ALL patient? 
Usually the outcome for a patient post ALL diagnosis is good, almost all children diagnosed 
and treated for ALL will enter into a remission phase and will therefore be symptom free 
(Inaba et al., 2013). Also, around 85% of children diagnosed with ALL will be completely cured 
of the cancer, (Shepard et al, 2016: Children with cancer UK, 2018). The outlook for adults 
sees around 40% of those patients completely cured (Pui and Evans, 2006). It is thought that 
the poor prognosis in adults could be linked to further chromosome mutations such as the 
presence of the Philadelphia chromosome which is present in 50% of adult ALL patients 
(Kuhnl et al., 2010: Thomas et al., 2001). The poor adult prognosis has also been linked to the 
inability to tolerate the intensive treatment required in ALL (Goldstone et al., 2008). 
Philadelphia chromosome presence is also linked to poor prognosis in childhood ALL however 
it only occurs in approximately 5% of cases (Koo, 2011).  
1.2.2.3.6 The MOLT-4 cell line  
The MOLT-4 cell line was originally obtained from a 19 year old male patient who at the time 
was suffering from ALL. After a multi-chemotherapy drug regime the patient entered into 
relapse. In culture the MOLT-4 cell line appears circular and is a suspension cell line 
(Minowada et al., 1972). 
Klein et al., (1976) reported that the MOLT-4 cell line has T-cell characteristics as they had no 
surface immunoglobulins or Fc receptors. They also reported the presence of terminal 
deoxynucleotidyl transferase activity within the cell line. This enzyme activity is found within 
the thymus but not the bone marrow and so they concluded that the MOLT-4 cell line 
represented a leukaemia T-cell of thymocyte origin (McCaffrey, Smoler and Baltimore, 1973). 
Greenberg et al., (1988) carried out a Southern blot analysis of the cell line which identified 
an unusual rearrangement of the gamma chain gene in the T-cell antigen receptor. This 
discovery led the team to carry out further immunotypic and karyotype research, in which 
they discovered that the MOLT-4 cell line had the immunophenotypic characteristics of 
thymocytes (hematopoietic progenitor cells which are present in the thymus and whose main 
function is the production of mature T lymphocytes) and expressed CD1 and CD5 markers 
which further link MOLT-4 cells to T-cell origin (Greenberg et al., 1988).  
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As ALL is the most common form of childhood cancer, the potential of GAGs as a treatment 
method would not only benefit patients through a reduction of side effects as is expected in 
GAG treatment but they may also have the potential to treat those patients which have not 
responded to current treatment methods. Also the use of an ALL cell line may also show that 
GAGs carry the potential to treat a variety of cancers, which may suggest a broader 
mechanism of action which doesn’t target one particular type of cancer.  
1.2.2.4 Lymphoblastic Lymphoma (LL)  
Lymphoblastic lymphoma is a very aggressive form of non-Hodgkin lymphoma. It is a rare 
form of cancer and accounts for around 2% of non-Hodgkin lymphomas (NHL) diagnosed each 
year (Ward et al., 2014). LL is usually caused by a mutation in a T cells DNA but can also 
develop from B lymphocytes (Marcus, Sweetenham and Williams, 2013). LL is a cancer type 
which mainly affects children and teenagers (Wright, McKeever and Carter, 1997); the 
condition of lymphoblastic lymphoma is very similar to ALL as both involve mutations, 
abnormality and uncontrollable growth in white blood cells (Cortelazzo, Ponzoni, Ferreri and 
Hoelzer, 2011).  
LL is an uncommon cancer which develops in the lymphatic system. In a non-Hodgkin 
lymphoma affected lymphocytes multiply in an abnormal manner and collect in certain areas 
of the lymphatic system such as the lymph nodes (Cortelazzo et al., 2011). Affected 
lymphocytes as in ALL lose their infection fighting abilities and so the body is more susceptible 
to infections. 
1.2.2.4.1 Symptoms of LL 
The most common symptom of LL is painless swelling of the lymph nodes usually located in 
the neck, arm pit or groin (Sompayrac, 2015: Evans and Hancock, 2003). LL also has a similar 
symptom set to ALL with associated appetite and weight losses as well as fatigue and fever 
(Evans and Hancock, 2003). More specific symptoms will depend on where the lymphoma is 
growing. 
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1.2.2.4.2 Diagnosing LL 
A diagnosis of LL is only given once a biopsy of the lymphoma has been taken and scans have 
been performed. This allows for the determination of the abnormality and the spread of the 
cancer, this process is known as staging (Hoelzer and Gokbuget, 2003). LL diagnosis also 
involves using the biopsies to carryout immunophenotypic analysis in order to ensure the 
patient isn’t suffering from a different form of lymphoid malignancy or non-lymphoid 
malignancy (Bassan, Maino and Cortelazzo, 2016).   
1.2.2.4.3 How common is LL? 
More than 12000 people are diagnosed with NHL each year but only 240 of those cases are 
LL (Bassan, Maino and Cortelazzo, 2016: Evans and Hancock, 2003: Wright, McKeever and 
Carter, 1997). The condition can develop at any stage of life however people under the age 
of 35 appear to be more susceptible to developing LL (Bassan, Maino and Cortelazzo, 2016: 
Wright, McKeever and Carter, 1997). 
1.2.2.4.4 Treatment of LL 
As LL is an aggressive form of cancer, treatment is required immediately upon diagnosis, the 
treatment regime should also consist of multiple chemotherapy drugs. Intensive 
chemotherapy is given in hospital with the aim of killing the cancer (Cortelazzo et al., 2011). 
Once this initial intensive stage of treatment is over chemotherapy is given on an outpatient 
basis to prevent the return of the lymphoma. Treatment of LL can take up to 2 years and is 
very similar to that of ALL (Hoelzer and Gokbuget, 2003).  
As LL is a rare and aggressive form of cancer it would be interesting to identify whether the 
GAG extracts have any beneficial effect on the cell line, as efficient treatment could provide 
a better outlook for patients who have been diagnosed. As current treatment involves 
intensive chemotherapy this could prove detrimental for childhood patients. GAGs could 
therefore provide a milder treatment option if activity is identified. 
1.2.2.4.5 The U698 cell line 
The U698 cell line was originally obtained from the right tonsil of a seven year old boy who 
was suffering from lymphoblastic lymphoma (Nilsson and Sundstrom, 1974). Treatment had 
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not been administered when the biopsy was taken; the lymphoma was fairly resistant to 
chemotherapy and radiotherapy (Nilsson and Sundstrom, 1974: DSMZ, ACC4, 2016). The 
patient died around two months after the biopsy was taken. The cells are in suspension when 
culture and exhibit some clumping and adherence to the flask. 
Nilsson and Sundstrom (1974) analysed the U698 cell line and identified that the cells 
appeared to be differentiated lymphoid cells which had rounded nuclei. They also concluded 
the majority of the cells in culture resembled lymphoblasts although a small portion of the 
cells had normal lymphocyte features. 
The U698 cell line expresses surface IgM and resembles B cell morphology which would 
suggest that the cell line is of B-cell descent (Godal, 1982), as it also only produces one class 
of immunoglobulin it could also be assumed that the U698 cell line is a clone (Pollack et al., 
1973).  
GAG extracts have not yet been tested on a lymphoblastic lymphoma; any activity on this cell 
line could potentially suggest that GAGs may provide a milder treatment option for another 
type of cancer. 
1.2.3 Current Chemotherapy and radiotherapy treatment 
1.2.3.1 Chemotherapy 
In basic terms chemotherapy (in the treatment of the three cancers previously mentioned) is 
given to eradicate cancerous cells in the bone marrow (Cortelazzo et al., 2011). 
Chemotherapy can be administered orally in the form of tablets however one or more of the 
treatment drugs will be given in the form of injection. This is due to the poor oral 
bioavailability of most chemotherapy drugs, so administering the drugs intravenously is 
required (Corrie, 2008).  Side effects from chemotherapy can include tiredness, nausea and 
hair loss (Carelle et al., 2002). If at any point the side effects from chemotherapy become too 
severe steroidal therapy can be given to improve the side effects (Hu, Sun, Wang and Gu, 
2016). Steroids such as dexamethasone are generally given to help alleviate symptoms such 
as nausea and loss of appetite, they may also help with pain relief (Twycross, 1994). Therapy 
may also be stopped entirely if the side effects become too severe to allow the patient time 
to recover before treatment is started again.  
 23 
Chemotherapy is carried out in three stages; induction, consolidation and maintenance 
(Avendano and Menendez, 2015). 
1.2.3.1.1 Induction  
The first stage of treatment is the induction phase which is designed to kill leukemic cells in 
the bone marrow thus restoring the balance of the three blood cell types, white blood cells, 
red blood cells and platelets (Haddad et al., 2013). This stage should alleviate the symptoms 
of the cancer and typically last around two weeks to several months. The induction stage of 
treatment is usually carried out in hospital or at a specialist centre, at this point regular blood 
transfusions may also be necessary as it is unlikely that the patients’ blood will contain 
sufficient levels of healthy cells (WBC counts of 4500-11000/µl and platelet levels of 150,000-
450,000/µl) (Jorge et al., 1995). The chemotherapy drugs used will generally be selected 
based on the cancer type but may include imatinib (Daiziel et al., 2004), daunorubicin, 
cytarabine and vincristine (Virelizier et al., 2009: Pui and Evans, 2006). A steroid such as 
dexamethasone may also be administered (Pui and Evans, 2006). Chemotherapy drugs work 
via many mechanisms, some of which include disrupting enzymes required for DNA 
replication or progression through the cell cycle (Daizel et al., 2004: Goldman and Fyfe, 1974).  
1.2.3.1.2 Consolidation 
Stage two of chemotherapy treatment is the consolidation phase which aims to completely 
eradicate all remaining leukemic cells in the central nervous system, as if just one cell remains 
then it is entirely possible that the cancer can return (Avendano and Menendez, 2015). This 
stage of treatment can take several months to complete; regular chemotherapy injections 
are administered but this time on an outpatient basis. However hospital stays may be 
required if symptoms worsen or if an infection occurs. 
1.2.3.1.3 Maintenance  
The final stage of treatment is the maintenance phase, this stage involves regular oral 
chemotherapy drugs and check-ups to monitor the effectiveness of the treatment being 
administered (Avendano and Menendez, 2015). This stage can last up to two years and acts 
as an ‘insurance policy’ against the return of the leukaemia.  
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1.2.3.1.4 Side effects of chemotherapy   
Side effects from chemotherapy are generally experienced as chemotherapy targets any cells 
which are proliferating quickly. This could be cancerous or healthy cells as there is no 
differentiation between the two where chemotherapy is concerned. 
Side effects from early stage treatment can include bone and joint pain as well as loss of 
appetite and nausea (Oeffinger et al., 2006: Siegel et al., 2012). Hair loss and insomnia may 
also be experienced (Siegel et al., 2012). If side effects become too severe treatments may 
need to be halted to allow the patient to recover and have a rest period. Other complications 
may also require the treatment to be halted until they have been addressed; these include 
psychological effects and immunosuppression (Siegel et al., 2012: Holland et al., 2010).  
The side effects of advanced treatment include the above with more severe forms and also 
include infertility and bruising. Kidney, liver and heart damage may also occur in long term 
chemotherapy patients (Miller et al., 2016).  
1.2.3.2 Radiotherapy 
Radiotherapy is the use of controlled radiation in high doses. It is mainly used when the cancer 
is in an advanced stage and has migrated to the nervous system or brain (Miller et al., 2016). 
Radiotherapy can also be used to prepare the body for a bone marrow transplant (Quast, 
2006). Side effects experienced from radiotherapy treatment are similar to those of 
chemotherapy including hair loss, fatigue and nausea (Oeffinger et al., 2006). In young 
children radiotherapy can also restrict growth when puberty is reached (Miller et al., 2016). 
As cells within a child are proliferating at a faster rate than in adult’s radiotherapy can target 
and alter their healthy cells as well, preventing children from growing in the correct manner 
(Miller et al., 2016)  
A bone marrow transplant or stem cell transplant may be needed if the patient is non-
responsive to chemotherapy or radiotherapy.    
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1.2.3.3 Why are new chemotherapy drugs needed? 
Although current chemotherapy drugs are effective in the majority of patients, the side 
effects experienced can be detrimental to a patient (Holland et al., 2010: Siegel et al., 2012). 
Children in particular can prove to have fatal responses to chemotherapy treatment (Nurgali, 
Jagoe and Abalo, 2018). GAGs could provide new treatment methods which may potentially 
demonstrate the same if not better anti-cancer results while also exerting milder side effects 
which would provide a more beneficial treatment option for children in particular. GAGs may 
also potentially provide a treatment method which may prove effective for patients who have 
not responded to other treatment methods if their mechanism of action proves to be 
different to traditional treatment methods. 
1.3 Glycosaminoglycans (GAGs) 
GAGs are the most abundant heteropolysaccharide in the body, they are linear unbranched 
polysaccharides which contain a repeating disaccharide unit (Kubaski et al., 2017). The 
repeating units consist of an amino sugar (N-acetylglucosamine, glucosamine that is variously 
N-substituted and N-acteylgalactosamine) and either a uronic acid group or a galactose 
(Afratis et al. 2012). They are highly negatively charged and are mainly located on the 
extracellular matrix or on cell surface. The negative charge comes from highly sulphatated 
regions (Nelson and Cox, 2008) which are located at discrete positions along the GAG chains.  
The properties and action of the GAGs is dependent on their structure, and they can thus be 
categorised into two main subgroups (Glucosaminoglycans and Galactosaminoglycans) based 
upon the sugar group that makes up the repeating disaccharide unit (Weyer et al. 2012). The 
subgroups can be further narrowed down into the molecules that make up the units, 
glucosaminoglycans can consist of four molecules; heparin, heparan sulphate, keratin 
sulphate and hyaluronan (Weyer et al., 2012). Galactosaminoglycans are made up of two 
types of molecules which are chondroitin sulphate and dermatan sulphate (Kim et al. 1996).  
GAG actions are governed mainly by their disaccharide structures and the sulphation levels 
and patterns which facilitate the GAG function. These properties allow GAGs to conduct a 
wide range of different functions within the body, which relates to their presence on all cell 
surfaces (Gandhi and Mancera, 2008; Nadanaka et al, 2013).  They are a major component of 
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the extracellular matrix (Nelson and Cox, 2008) due to their ability to bind with and interact 
with proteins. It is understood that GAGs play an important role in the cellular functions 
responsible for inflammation, cell proliferation and cell differentiation (Hori et al, 1981). This 
is due to their ability to interact with various signalling molecules such as growth factors, 
cytokines and chemokines (Sasisekharan, Shriver, Venkataraman and Narayanasami, 2002).  
The biological activity of GAGs is also dependent on their side chains as it is the side chains 
that facilitate any interactions with protein ligands via their saccharide units (Salmivitra, 
Lidholt and Lindahl, 1996). Linear GAGs are mainly made up of heparan sulphate and 
chondroitin sulphate (Nadanaka et al, 2013). Hyaluronan is the only GAG component which 
contains no sulphur (Yip, Smollich and Gotte, 2006; Nakano, Beth and Pietrasik, 2009). 
As GAGs can also be located on the surface of cancerous cells they could potentially be a 
target for cancer therapies (Sugahara and Kitagawa, 2000). Any anti-tumour effect the GAGs 
exhibit will be likely to depend on the individual growth factors affected, the cell type and the 
specific regulation for the sulphate group position.  
It is not yet known which GAGs make up the cockle and whelk extracts and what 
concentration of each individual GAG is present however it is likely to be a mixture of HS, CS 
and DS. Therefore the activity of the extracts which has been noted could be due to the 
combination of numerous GAGs.  
1.3.1 Glycosaminoglycan biosynthesis 
GAGs from both glucosaminoglycans and galactosaminoglycans are synthesised at the golgi 
apparatus and all types of GAG apart from hyaluronan are further modified by O-
sulphotransferases to add sulphate groups to the disaccharide units (Afratis et al, 2012). 
When GAGs are synthesised the free GAG chains are secreted to the extracellular space and 
distributed further to the pericellular space and the extracellular matrix (Nikitovic et al, 2004).  
The side chains of GAGs are covalently bonded to a core protein via the GAG protein linkage 
region. The synthesis of GAGs is a step by step addition of monosaccharides (Nadanaka et al, 
2013) and is completed by specific glycosyltransferases (DeAngelis, 2002). During this 
formation a xylose residue is also phosphorylated (Nadanaka et al., 2013).  
 27 
The number of side chains is very important in GAG biosynthesis as it depicts which 
component of the GAG family is synthesised (Koike et al 2009). Honda et al (1982) suggested 
that the inhibition of sulphate and glucosamine could decrease GAG synthesis. They also 
deduced that abnormalities within the GAG level would also affect the synthesis of 
proteoglycans.  
1.3.2 Proteoglycans (PG) 
GAGs are commonly found to be interacting with proteins in the body; they do this through 
forming molecules known as proteoglycans (PG). A PG is a heavily glycosylated protein which 
is made up of a core protein with one or more GAGs covalently bonded to it (Meisenberg and 
Simmons, 2006) as can be seen in figure 1.4.  
 
Figure 1.4 The structure of a proteoglycan. The generic structures required and the binding points to 
make a proteoglycan (adapted from Buzzle,2015). 
In order to link a GAG to a protein core it requires a specific trisaccharide sequence that is 
composed of two galactose residues and a xylose residue (Gandhi and Mancera, 2008). This 
trisaccharide unit then covalently attaches to a serine residue via an O-glycosidic linkage 
(Jackson et al, 1991). When a GAG joins onto a core protein a tetrasaccharide bridge is 
created. Upon covalently bonding with its complementary cell surface protein the GAG 
creates a PG. Therefore a PG macromolecule consists of several GAG chains covalently bound 
to a cell surface protein (Chatzinikolaou et al, 2008). PGs are highly variable in both structure 
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and function; this is due to the level of variation in the composition of the protein core. The 
protein core differences are dependent upon the exons which are used to create the protein 
during the genomic sequence translation (Varki et al,. 2009). 
Proteoglycans are known to function as cofactors in several biological functions (Nadanaka et 
al, 2013). It is the GAGs bound to the cell surface proteins which create the interactions with 
biological functions which include angiogenesis (discussed further in section 1.4), cell 
adhesion and the regulation and production of growth factors (Nadanaka et al, 2013: Yip, 
Smollich and Gotte, 2006).  
PGs also function as fillers between cells and other complexes; these could be other PGs or 
fibrous proteins like collagen (Meisenberg and Simmons, 2006). Finally PGs are also heavily 
involved with the regulation of molecule movement and affect the stability of signals and 
proteins within the cellular matrix (Meisenberg and Simmons, 2006: Weyer et al, 2012).   
1.3.3 Heparin and Heparan Sulphate (HS) 
Both heparin and heparan sulphate (HS) are made up of repeating disaccharide units of 
hexuronic acid (Hex A) and glucosamine (GlcN), these units are sulphated at various positions 
along the disaccharide unit (Gandhi and Mancera, 2008). Heparin possesses a higher level of 
sulphation and is also more homogenous when compared to HS; it also lacks a domain 
structure (Gandhi and Mancera, 2008). There is a large amount of variation which occurs 
within the polysaccharide structures and high volumes of complex sulphation patterns 
(Skidmore et al., 2008). It is these patterns that create potential protein interaction sites. The 
structures of heparin and heparan sulphate can be seen in figure 1.5. 
 
Figure 1.5 The structure Heparan Sulphate (left) and Heparin (right) respectively. (Gandhi and 
Mancera, 2008). 
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Heparin and HS are both very anionic and have linear disaccharide units. They are both also 
joined via 1-4 linkages (Skidmore et al, 2008). The glucosamine residues found in both can be 
sulphated to form an N-sulphated glycosamine (Glc NS) (Afratis et al, 2012). They can also be 
acetylated to form an N-acteylated glycosamine (Glc NAc).  
Although heparin and HS are very similar in relation to disaccharide structure there are also 
several differences between the two. Firstly heparin is generally smaller measuring between 
7-20 KD compared to HS which is 10-70 KD in size (Gandhi and Mancera, 2008). In comparison 
to HS, heparin possesses higher levels of sulphation, it also has significantly higher affinity in 
binding to antithrombin. Finally HS is generally synthesized in virtually all cell types whereas 
heparin is synthesized only in connective tissue mast cells (Varki et al, 2009).  
1.3.3.1 Heparin and Heparan Sulphate biosynthesis 
Heparin is exclusively produced by mast cells whereas HS is produced by virtually all cell types. 
Heparin also differs to HS through the amount of sugar residue modification. The modification 
is carried out by a series of enzymes which include sulphotransferases and epimerases (Varki 
et al, 2009).  
The biosynthesis of HS GAGs begins in the golgi apparatus where four monosaccharides link 
and attach to a core protein. In HS synthesis N-acteylglucosamine (GlcNAc) is transferred to 
the linkage region (Nadanaka et al. 2013). The HS backbone is subsequently formed through 
the alternate addition of glucuronic acid (GlcUA) and GlcNAc via transferases (Nadanaka et 
al., 2013). The disaccharide unit additions are carried out by two different 
glycosyltransferases which effectively form a stable heterodimeric complex within the golgi 
apparatus (DeAngelis, 2002). This chain can then be modified, which can be done 
concurrently or independently and occurs by a series of enzymes sequentially. The main 
enzymes which modify the polysaccharide chain include; N-deacteylases, N-
sulphotransferases and 2-O, 3-O and 6-O sulphotransferases (Nadanaka et al., 2013: 
DeAngelis, 2002).  
The modification reactions which occur in heparan sulphate biosynthesis happen in clusters 
along the chain in regions which have no sulphates. The resulting HS chains are then 
organised into polymetric structures (larger structures made up of several repeating 
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monomer patterns) which have S-domains containing N-sulphated residues. It is these 
domains that give the GAGs their abilities to bind with growth factors and other proteins 
(Sugahara et al, 2000: Varki et al, 2009).  
1.3.3.2 The role of heparin and heparan sulphate in health and disease 
Heparin is used as an anticoagulant drug (Ludwig, 2009); it prevents and treats blood clots 
which may occur in the arteries, veins or lungs. It can also be given pre-surgery to reduce any 
risk of blood clots. Heparin is also given to patients who suffer from deep vein thrombosis or 
pulmonary embolisms (Ludwig, 2009).  
In the inflammation process L-selectin is expressed by leukocytes and binds to HS expressed 
by endothelial cells (Parish, 2006). This binding initiates the attachment and rolling of 
leukocytes into blood vessels towards the area which has tissue damage or infection (Barthel, 
Gavino, Descheny and Dimitroff, 2007). This process of leukocyte extravasation has also been 
linked to inflammation and the metastasis of cancer cells (Barthel et al., 2007). It is thought 
that cancer cells achieve this through exploiting the selectin-dependent mechanism used by 
lymphocytes migrated to the source of tissue damage (Witz, 2006).  
HS is a molecule that is present within all cell types and has numerous regulatory roles within 
normal and pathological conditions (Afratis, 2012). Cancer cells target HS as they need large 
amounts of space in order to grow past their normal limits. The cancer does this by releasing 
heparinises that degrade any HS located on the membranes of adjacent tissues (Sanderson, 
2001). Once the HS is degraded the cancer cells can invade adjacent tissues and potentially 
enter into blood vessels. This gives the cancer cells the ability to metastasise and re-locate to 
other areas of the body (Bogenrieder and Herlyn, 2003; Jia, 2009). The invasion of blood 
vessels also allows angiogenesis of the cancer which allows it to grow in size. Sanderson 
(2001) identified that HS present on the cell membranes promoted cell adhesion, if the HS 
was not present then migration and invasion of malignant cells was promoted.  
1.3.4 Chondroitin Sulphate and Dermatan Sulphate 
Chondroitin sulphate (CS) and Dermatan sulphate (DS) GAGs are composed of alternating 
units of N-acetyl-D-galactosamine (GalNAc) and then either glucuronic acid (GlcA) or iduronic 
acid (idoA) (Afratis et al., 2012: Yamada and Sughara, 2008) shown in figure 1.6. The sugar 
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backbone of CS and DS can be sulphated which occurs mainly at the C2 position of the uronic 
acid residue. On the GalNAc residues sulphation can occur at the C4 and/or C6 positions 
(Yamada and Sughara, 2008). Diverse modifications of the sugar chains can also happen 
through C5 epimerase and O-sulphotransferases, this is responsible for the structural 
heterogenicity of CS and DS chains (Gandhi and Mancera, 2008: Yamada and Sugahara, 2008).  
 
Figure 1.6 The structures of chondroitin sulphate and dermatan sulphate. (Gandhi and Mancera, 
2008). 
The CS and DS chains that are formed in the body have extensive sulphation modifications, 
there are also six different disaccharide units which come together to make up the CS and DS 
polysaccharide chains (Thelin et al, 2013). In order for the biosynthesis of CS and DS to begin 
a primary precursor polysaccharide must first be formed. This polysaccharide is made up of 
alternating glucuronic acid (GlcA) and N-acetyl-D-galactosamine residues (Maccarana et al, 
2006). The addition of a α-GalNAc residue serves as a stop signal and prevents any further 
chain elongation (Koike et al, 2009).  
The assembly of CS and DS chains happens in the endoplasmic reticulum but can also happen 
in the golgi apparatus. This process is initiated by the formation of the GAG linkage region. 
The linkage region is covalently bonded by serine residues which are located in different core 
proteins to eventually form CS and DS proteoglycans (Mikami and Kitagawa, 2013).  
In previous research CS has exhibited anti-angiogenic properties by inhibiting 
transendothelial monocyte migration, which is the movement of monocytes through the 
blood vessel walls (Yip, Smollich and Gotte, 2006). CS can also be linked to cancer as it 
promotes an increase in the expression and activation of matrix metalloproteinases (MMPs) 
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and ADAMT (a disintergin and metalloproteinase with thrombospondin motif) during the 
extracellular matrix remodelling (Kaur and Reinhardt, 2015). Both molecules have been linked 
to angiogenesis, migration and roles within the degradation (MMP) or remodelling (ADAMT) 
of the extracellular matrix (Kelwick, Desanlis, Wheeler and Edwards, 2015: Van Lint and Libert, 
2007). This expression and activation has been linked to several types of cancers (Kaur and 
Reinhardt, 2015).  
DS adds flexibility to many normal bodily responses as well as many pathological responses 
which include development, growth and wound repair as well as infection and tumorgenesis 
(Trowbridge and Gallow, 2002). A DS proteoglycan known as decorin influences the receptors 
for epidermal growth factor, which plays a vital role in cell proliferation (Yip et al, 2006). As 
well as playing a role in many biological processes CS and DS also have interactions with key 
molecules within the body such as cytokines, chemokines and growth factors (Malavaki et al, 
2008).  
1.3.5 Keratan Sulphate 
Keratan sulphate is a GAG composed of alternating 3 linked β-galactose and 4 linked N-acetyl-
β-glucosamine to form a disaccharide unit (seen in figure 1.7). These units are then further 
linked together to form a GAG polysaccharide. The presence of β-galactose makes keratan 
sulphate unique as it is the only GAG which doesn’t contain an acidic sugar instead it contains 
a pH neutral sugar in β-galactose (Pomin, 2015).  
 
Figure 1.7 The structure Keratan sulphate. (Gandhi and Mancera, 2008). 
The keratan sulphate chain is lengthened via glycosyltransferases which in an alternate 
fashion add β-galactose and GlcNAc to the extending polysaccharide chain until the chain is 
completely formed (Funderburgh, 2000). Keratan sulphate disaccharides can be unsulphated, 
monosulphated or disulphated. Sulphotransferase enzymes carry out the sulphation of 
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keratan sulphate disaccharides through the addition of sulphate groups at the carbon 6 
position on both β-galactose and N-acetyl-β-glucosamine residues (Pomin, 2010).  
Keratan sulphate is commonly found attached to proteins in the body. Which proteoglycan is 
produced is entirely dependent on what protein the GAG has bound to. Keratan sulphate is 
capable of forming two proteoglycans known as KS1 and KS2. KS1 is an N-linked from of 
keratan sulphate which is attached to asparginine. KS2 is an O-linked keratan sulphate which 
is linked to a serine or threonine (Pomin, 2010).  
Keratan sulphate is found in the extracellular matrix of certain tissue types in the body such 
as bone and cartilage as well as in the cornea (Pomin, 2015). In cartilage keratan sulphate 
plays a major role in the maintaining of hydration levels within the tissue (Pomin, 2015). 
Keratan sulphate also has some involvement in cellular signalling and migration and 
developmental biology.   
1.3.6 Hyaluronan 
Hyaluronan is a linear non-sulphated GAG which has a composition of repeating units of D-
glucuronic acid and N-acetylglucosaine (demonstrated in figure 1.8). These two are linked via 
alternating β-1, 4 and β-1,3 glycosidic bonds (Rah,2011). 
 
Figure 1.8 The structure of hyaluronan/ hyaluronic acid. (Gandhi and Mancera, 2008). 
Hyaluronan is synthesised on the plasma membrane which is in contrast to other GAGs which 
are mainly synthesised in the golgi apparatus. The synthesis of hyaluronan is carried out by 
hyaluronan synthases which are specialised membrane proteins. In the human body there 
are three types of hyaluronan synthases named HAS1, HAS2 and HAS3 (Itano and Kimata, 
2002). There are other enzymes which are located in the cytoplasm that play an integral role 
in the synthesis of hyaluronan through the creation of a UDP-sugar precursor molecule 
(Vigetti et al, 2014). The value of the UDP-sugar as a precursor is as a polymerisor of the 
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hyaluronan chain, it also extrudes it from the cell without requiring a primer or an anchor 
protein or lipid (Vigetti et al, 2014).  
Post production, hyaluronan disaccharides are then polymerised at the interface of the 
plasma membrane (Dicker et al, 2014). The levels of hyaluronan synthesis and degradation 
are controlled during embryonic development as well as in many homeostatic processes. 
Hyaluronan interacts with many cell surface receptors and binding proteins in order to 
activate intracellular events and mediate cell functions. Hydrated hyaluronan makes the 
extracellular matrix an optimum environment in which cells can proliferate and move. It is 
this ability that allows hyaluronan to participate in tissue metabolism (Varki et al, 2009).  
Increased levels of hyaluronan have been identified in correlation with elevated growth factor 
activity and increased cytokine levels normally associated with rapidly remodelling tissue, like 
those found in wound healing and embryonic development. In elevating growth factor levels 
hyaluronan is also known to cause several pathological conditions which include blood vessel 
thickening, inflammation and tumour progression (Dicker et al, 2014).  
Some cancers can transform hyaluronan synthases in order to maximise the production of 
hyaluronan (Karbownik and Nowak, 2013). As the environment hyaluronan creates is pro 
proliferation and inhibits differentiation it also promotes an optimum environment for 
malignant cell proliferation and thus the progression of cancer.   
1.3.7 Cell death pathways 
Cell death is a key component in several cellular systems which include development, immune 
regulation and homeostasis (Duprez, Wirawan, Vanden Berghe and Vandenabeele, 2009). As 
with the cell cycle, if cell death is not controlled correctly pathologies can ensue this can 
include too little cell death which can result in conditions such as cancer, lupus or 
osteoporosis. Or too much cell death which can lead to Parkinson’s disease rheumatoid 
arthritis or multiple sclerosis (Zhivotovsky and Orrenius, 2010).   In some instances, cell death 
may also be used as a defence mechanism against pathogen infection, however pathogens 
have evolved, and many can now modulate host cell death.  
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There are several mechanisms of cell death, these being apoptosis, necrosis, autophagy and 
mitotic catastrophe related (Duprez et al., 2009). It is believed that caspase-dependent 
apoptosis is the predominant form of cell death in healthy cells (Galluzzi et al., 2007).  
1.3.7.1 Apoptosis 
In 1972 apoptosis was first described as a type of cell death with distinct morphological 
features. These include cell shrinkage, membrane blebbing and chromatin condensation 
(Youle and Strasser, 2008), which result in controlled and programmed cellular suicide of 
unrequired cells. Apoptosis results in the controlled breakdown of apoptotic bodies which 
can be recognised and engulfed by surrounding cells and phagocytes (Fuentes-Prior and 
Salvesen, 2004). In adults the amount of cell death is balanced with the level of cell division, 
to ensure that there are minimal changes to either tissue growth or shrinkage (Becker et al., 
2003). 
During the early stages of apoptosis the cell shrinks and the chromatin condenses. Cells then 
become smaller and the cytoplasm becomes dense, which in turn tightly packs the cell 
organelles (Youle and Strasser, 2008). Plasma blebbing occurs and is then followed by 
karyotthexis which fragments the nucleus. With the nucleus fragmented the cell is separated 
into apoptotic bodies and fragments through budding (Elmore, 2007). Macrophages engulf 
and phagocytose the apoptotic bodies. As it is phagocytes which take up the apoptotic bodies, 
it is thought the process occurs before the cell loses the integrity of its plasma membrane and 
is therefore believed to be immunologically silent (Krysko and Vandenabeele, 2008). Meaning 
that unlike necrosis, apoptosis does not produce inflammation and doesn’t release cellular 
contents into circulation. Phagocytosis occurs quickly which has two main benefits: it 
prevents secondary necrosis from occurring and as mentioned it also prevents pro-
inflammatory cytokines from being released (Elmore, 2007). 
In apoptotic cells phosphatidyl serine (PS) is expressed on the outside of the cell instead of its 
normal inward facing position, this acts as a marker for phagocytes (Elmore, 2007). PS on the 
outside of a cell also allows Annexin V, a recombinant binding molecule to bind with quite a 
high affinity to it (Elmore, 2007). This binding can be used to detect cells undergoing 
apoptosis. Propidium iodide (PI) cannot cross the cell membrane in live cells, it also binds to 
nucleic acids and can therefore be used to detect cell death (Lecoeur, 2002). Therefore the 
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amount of bound Annexin V and PI can be used to predict what stage of apoptosis a cell is in, 
this can be seen in figure 1.9.  
 
Figure 1.9 The binding of annexin V to PS and the binding of PI to nucleic acid and the stage of 
apoptosis at which the cell would be.  Adapted from University of Dundee, Cell death and apoptosis, 
(2016). 
Apoptosis is a naturally useful process which induces cell death in normal cells which have 
developed a mutation. If apoptosis doesn’t balance out with cellular proliferation then 
diseases such as cancer or autoimmune diseases may occur (Duprez et al., 2009). Apoptosis 
is also a useful process which can be targeted by drugs to artificially induce apoptosis to slow 
cancer progression or stop progression all together. 
Yue et al., (2009) identified that GAGs may play a role in the regulation of apoptosis in cells 
undergoing oxidative stress. They deduced this was most likely through protection from the 
disruption of the lysosome membrane via reducing intracellular ROS levels and cytochrome C 
and caspases -3 and -9 release. It has also been concluded that GAGs do not affect the 
extrinsic pathway of apoptosis (Yue et al., 2009).  
 It is not yet known whether GAGs affect the cancer cell lines through the induction of 
apoptosis and whether the GAG extract treatment would induce apoptosis in ‘healthy’ cells 
also. Through the use of the annexin V/ PI apoptosis assay my research aims to identify 
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whether and how much apoptosis is induced in both the cancer cells lines and the ‘healthy’ 
lymphocytes.  
1.3.7.1.1 Intrinsic and extrinsic apoptosis 
Apoptosis is a caspase dependent cell death pathway and these caspases can become 
activated in two ways (Danial and Korsmeyer, 2004). Intrinsic apoptosis is where the caspases 
have been activated via the mitochondria. Extrinsic apoptosis is when cell death has been 
activated through a cell death receptor (Danial and Korsmeyer, 2004). 
The intrinsic apoptosis pathway is determined through mitochondria permeabilisation and 
subsequent cytochrome C release (Kroemer, Galluzzi and Brenner, 2007). Once cytochrome 
C has entered the cytoplasm a quaternary protein complex known as an apoptosome is 
formed. The apoptosome formation results in a caspase cascade through the activation of 
caspase-9 (Taylor, Cullen and Martin, 2008). Intrinsic apoptosis plays a crucial role in 
development and tissue homeostasis as well as being critical in immunoregulation. Intrinsic 
cell death also plays a role in neurodegeneration and cancer (Xiong, Mu, Wang and Jiang, 
2014). The BCL-2 protein family also play a vital role in the intrinsic apoptosis pathway via the 
regulation of the proapoptotic proteins effluxing from the mitochondria (Ricci and Zong, 
2006). BCL-2 proteins which contain four BH domains (BCL-2 homology) are antiapoptotic and 
include BCL-2 and BCL-W (Ricci and Zong, 2006). Proapoptotic members lack the BH4 domain 
and include BAX and BAK which usually exist as inactive monomers (Ricci and Zong, 2006). In 
many forms of cancer, the BCL-2 family of proteins have found to contain mutations and in 
some cases overexpression has been noted and is also linked to chemotherapy resistance 
(Ricci and Zong, 2006).    
Extrinsic apoptosis is triggered by death receptors which are members of the tumour necrosis 
factor (TNF) receptor superfamily (Hirsova and Gores, 2015). Upon activation these receptors 
then result in the development of a death inducing signalling complex (DISC). This complex 
constitutes of caspase-8 and adaptor proteins (Hirsova and Gores, 2015).    
1.3.7.2 Necrotic cell death 
Previously necrotic cell death has been described as an accidental and uncontrolled pathway 
which lacks signalling events (Duprez et al., 2009). However evidence now suggests that a 
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caspase-independent pathway exists, whose function is to strictly regulate necrotic cell death 
in a developmental way, like in interdigital cell death (Chautan, Chazal, Cecconi, Gruss and 
Golstein, 1999). The defining necrotic factors are cytoplasm and organelle swelling, followed 
by the loss of cell membrane integrity and thus the cellular contents are released into the 
surrounding extracellular space (Elmore, 2007). It has now become apparent that necrosis is 
the result of highly regulated signalling events which can be initiated through a variety of 
stimuli (Duprez et al., 2009). For most cells the death receptor ligand will always activate the 
apoptotic pathway in favour of the necrotic one (Duprez et al., 2009). However, there are 
cases where caspase activation may be damaged or ineffective and necrotic cell death will 
provide a back-up route for cell death (Chautan et al., 1999). Generally, a cell will enter 
necrosis as opposed to apoptosis if there is a lack of intercellular energy supply or if there is 
direct damage to the cellular membranes such as would be found during injury or 
hypothermia (Elmore, 2007). 
Necrosis also plays an important physiological role in signalling processes such as ovulation 
and cellular turnover in both the large and small intestines (Festjens, Vanden Berghe and 
Vandenabeele, 2006). In addition to this necrosis also plays a role in activation-induced cell 
death (AICD) of T-lymphocytes which is very important when T-cell numbers require reducing 
after an immune response (Holler et al., 2000). Another factor which supports the idea that 
necrotic cell death acts as a back-up mechanism for apoptosis is that necrosis occurs 
alongside apoptosis or in the presence of caspase inhibitors (Elmore, 2007). Necrosis rarely 
occurs as a sole mechanism of cell death.  
In contrast to apoptosis, necrotic cell recognition and uptake via macropinocytosis is much 
slower and inefficient (Neumar, 2000). The plasma membrane also loses its integrity before 
uptake occurs, this then elicits a pro-inflammatory response (Krysko, Brouckaert, Kalai, 
Vandenabeele and D’Herde, 2003). This is done through the release of damage associated 
molecular patterns (DAMPs) and through the release inflammatory cytokines (Fadok, Bratton, 
Guthrie and Henson, 2001).  
1.3.7.3 Autophagic cell death 
Autophagy is a highly conserved catabolic pathway which gives eukaryotes the ability to 
degrade and recycle their cellular components. Autophagy plays an important role in many 
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cellular processes such as cellular stress, differentiation and development (Maiuri, Zalckvar, 
Kimchi and Kroemer, 2007). Although it is now accepted that autophagy does play some form 
of a survival role it has become a debate topic as to whether autophagy plays a causative role 
in cell death. As autophagic vacuoles have been identified in dying cells it has led to the 
introduction of autophagic cell death. However it is also accepted that autophagy 
accompanies cell death rather than actually causing it (Maiuri et al., 2007).  
1.3.7.4 Pyroptosis/ mitotic related catastrophe 
Pyroptosis is known to be a programmed cell death which has its own distinct set of 
morphological and biochemical features which are distinctly different to those of necrosis and 
apoptosis (Labbe and Salen, 2008). Generally, pyroptosis has been described after infection 
with a range of microbial pathogens, cells which have been noted to be affected include 
monocytes, macrophages and dendritic cells (Bergsbaken, Fink and Cookson, 2009). 
Pyroptosis has unique characteristics in that it is dependent on caspase-1, further to this 
although usually associated with infection, non-infectious stimuli like DMAPS can induce 
pyroptosis but only in non-macrophage cells (Bergsbaken et al., 2009).  
Pyroptosis like apoptosis is also a cellular suicide and forms a section of a hosts defence 
system against pathogens. As the death of the host cell also destroys the pathogen, microbial 
replication is slowed and allows for other immune mechanisms to occur (Johnston, 2005). 
However there are also some limitations of pyroptosis as host cell death may also be 
beneficial to the pathogen for example if it occurs in and destroys immune cells.   
It has become apparent in recent years that apoptosis is the main mechanism for cell death 
in mammals however it is not the sole form of destruction and removal of unwanted cells 
through a cell death pathway. Necrosis is also now known to be as a result of signalling events 
which result in the rupture of the plasma membrane however there are cases in which 
necrosis occurs without the underlying signalling events (Ricci and Zong, 2006).  
Although it was previously thought that apoptosis was the primary form of cell death brought 
about by chemotherapy treatment, there is more evidence to suggest that other forms of cell 
death may be elicited (Ricci and Zong, 2006).  
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However, as apoptosis is the favoured form of cell death in regard to chemotherapy 
treatment, this research will evaluate the role GAG induced apoptosis plays in cancer cell 
death. Also, if GAG treatment results in apoptosis in ‘healthy’ activated and naïve PBMCs, as 
this is still unknown. Through the use of Annexin V and Propridium iodide using the flow 
cytometry assay the research identified any apoptosis induced cell death post GAG treatment 
in either cancer cell lines or PBMCs (naïve and activated).   
1.4 Angiogenesis 
Angiogenesis is known to play a role in the growth and metastasis of tumour cells, via a multi-
step process which involves the extracellular matrix degrading and the activation and 
proliferation and finally the migration of endothelial cells (Agauayo et al., 2000: Pule et al., 
2002: Trujillo, McGee and Cogle, 2012). However multiple studies have now identified that 
angiogenesis and angiogenic factors may also play a role in the progression of several types 
of leukaemia (Trujillo, McGee and Cogle, 2012: Agauayo et al., 2000: Mangi and Newland, 
2008). Pathological angiogenesis can persist over a long period of time and can be noted in 
several diseases such as rheumatoid arthritis, diabetic retinopathy and in cancer (Folkman, 
1995: Koch, 1998).  
1.4.1 Angiogenesis and cancer 
When a new blood vessel is created from a pre-existing vessel the process is termed as 
angiogenesis (Birbrair et al. 2013). Angiogenesis is a normal biological function and plays a 
vital role in development and growth (Birbrair et al. 2013).  
Although angiogenesis is a normal process it also plays an integral part in the progression of 
a benign tumour into a malignant cancerous tumour (Penn, 2008). The work carried out by 
Agauayo et al., (2000) also suggests that angiogenesis and angiogenic factors play a significant 
role in the process of leukaemia as well. The nature of cancer cells is to divide uncontrollably 
without entering into any cell death pathways (apoptosis or necrosis). A tumour can be 
defined as a population of cancerous cells which are growing and dividing both uncontrollably 
and rapidly. While leukaemia is the saturation of the bone marrow and blood with 
proliferating defective WBCs (Calabretta and Perrotti, 2004). If a tumour is going to grow 
beyond two millimetres in size the cancer cells require a dedicated blood supply to provide 
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them with oxygen and nutrients (Mcdougall, Anderson and Chaplain, 1971). During their rapid 
growth phase tumour cells release chemical signals to trigger angiogenesis (Folkman, 2004).  
Muthukkaruppan, Kubai and Auerbach (1982) proved that where angiogenesis stimulation 
did not occur then tumour cells did not surpass one to two millimetres in size after which 
growth ceased entirely. However if the tumour cells were able to secure a blood supply then 
they also exceeded a diameter of two millimetres.  
In the same way Holmegren et al, (1995) demonstrated that if angiogenesis did not occur 
then tumour cells could actually enter into the uncontrolled cell death pathway of necrosis 
or even into the controlled cell death pathway of apoptosis. It can therefore be concluded 
that tumour progression is dependent on angiogenesis. As tumour cells secrete chemical 
signals which stimulate the production of growth factors. This can be seen in elevated levels 
of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) in the serum 
of cancer patients (Cross and Claesson-Welsh, 2001). The release of these growth factors in 
turn induces blood vessel growth, this demonstrates that angiogenesis is an important factor 
in cancer progression (Birbrair et al, 2013).  
Perez-Atayde et al., (1997) demonstrated increased micro-vessel density (MVD) in ALL 
patients when compared to the control samples, Folkman, Browder and Palmblad (2001) also 
described increased MVD in ALL patients. This level of increased MVD has also been noted in 
several other bone biopsies taken from a variety of patients with different forms of leukaemia 
(Agauayo, 2000: Trujillo, McGee and Cogle, 2012). Increased microvessel density was also 
noted in CML patient bone biopsies (Kini et al., 1998: Agauayo et al., 2000). Pule et al., (2002) 
also noted that MVD were increased in most childhood ALL patients tested upon presentation 
with the disease in comparison to the controls. They also demonstrated that the levels of 
MVD were reduced almost back to normal levels with patients who had entered into 
remission. Hussong, Rodgers and Shami (2000) also noted that in a similar fashion to tumour 
cells that leukemic cells rely on angiogenesis in the bone marrow in acute myeloid leukaemia 
(AML) patients. They too linked the presence of MVD with the overall survival of the 
leukaemia and linked a higher level of MVD in AML patients with a poor prognosis. (Hussong, 
Rodgers and Shami, 2000).   
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Therefore, angiogenesis must also play a role in the disease process of some forms of 
leukaemia as well as in the progression of solid tumour cancers.  
There has also been reported increases in levels of two specific potent angiogenic regulators 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) in both 
leukaemia and in solid tumours (Agauayo et al., 2000).  
1.4.2 Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) 
1.4.2.1 FGF 
In basic terms FGF is a heparin binding protein (Stegmann, 1999). FGF also has the ability to 
interact with heparan sulphate proteoglycans which are found on the surface of cells. In terms 
of signal transduction and tissue and cell differentiation the interaction of GAGs with FGF has 
proven to be a key component (Stegmann, 1999).  
The fibroblast growth factor receptor (FGFR) is composed of several domains; which include 
extracellular: three immunoglobulin-like domains, a single transmembrane helix domain and 
an intracellular domain which has the ability to facilitate tyrosine kinase activity (Porta et al., 
2017).   
The main function of FGF is to initiate the organisation of cells into tubular structures, FGF 
also promotes the proliferation of endothelial cells (DeCicco-Skinner et al., 2014). The 
interaction of FGF and endothelial cells is what promotes angiogenesis (Cross and Claesson-
Welsh, 2001). Stegmann (1999) discovered that in the cardiac system FGF is a far more potent 
angiogenic factor when compared to VEGF. 
FGF does not possess the ability to migrate and so the growth factor can be released in a 
highly regulated fashion (Cross and Claesson-Welsh, 2001). Ultimately FGF secretion results 
in a pool of un-migrated growth factor (Localised). 
FGFR/FGF interactions have the ability to regulate several biological processes which include 
cellular proliferation and differentiation (Tiong, Mah and Leong, 2013). The signalling 
pathways between FGF and FGFR have also been identified to play a role in the progression 
of several types of cancer (Porta et al., 2017: Tiong, Mah and Leong, 2013).   
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1.4.2.2 VEGF 
VEGF and the vascular endothelial growth factor receptor (VEGFR) have major physiological 
roles and play a part in pathological angiogenesis such as can be found in cancer (Shibuya, 
2011). VEGF is an angiogenesis stimulating protein (Nishida et al, 2006). VEGF can also 
promote capillary growth (Gonzalez, Ruben and Rueda, 2013) this means VEGF has a vital role 
in angiogenesis. VEGF can be present on both normal tissues and on neoplastic tissues. On 
cancerous tissue VEGF is present adjacent to the stroma (Nishida et al, 2006). In combination 
with growth factors and cytokines VEGF can also be a very powerful anti-angiogenic factor.  
VEGF secretion from tumour cells into blood vessels and surrounding tissue can induce 
capillary growth and ultimately the production of new blood vessels (Gonzalez et al., 2013). 
VEGF production can also produce vascular leakage which when teamed with hypoxia can be 
regulated during tumour expansion (Cross and Claesson-Welsh, 2001).  
Studies have shown that if a mutation occurs in the gene responsible for the production of 
VEGF then the blood vessels produced are abnormal in shape and can lead to embryonic 
death (Schoenfelder and Einspanier, 2003). This re-enforces the idea that VEGF is a highly 
potent angiogenic factor.  
The VEGF/VEGFR pathway has become an important target for therapeutic treatments 
including anti-angiogenic treatments in cancer and pro-angiogenic treatments in neuronal 
degeneration and ischemic diseases (Shibuya, 2011).  
1.4.3 Angiogenesis, FGF and VEGF 
Cross and Claesson-Welsh (2001) determined that VEGF and FGF exhibited their angiogenic 
effects by binding to receptors on the cell surface which contain tyrosine kinase activities. 
Upon binding the kinase receptors become activated and enable a downstream signal 
transduction production this regulates endothelial cells. FGF and VEGF can also stimulate 
endothelial cells to secrete proteases responsible for membrane degradation.  
Once endothelial cell membranes have been degraded the cell can then migrate into 
surrounding cell matrixes, there they deposit a new cell membrane. The new membrane then 
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begins secreting both VEGF and FGF in order to secure the new vessels stability (Cross and 
Claesson-Welsh, 2001). 
It has been noted that elevated levels of both FGF and VEGF have been identified in several 
forms of leukaemia including ALL and CML (Agauayo et al., 2000: Fielder et al., 1997: Trujillo, 
Mcgee and Cogle, 2012: Hussong et al., 2000). Perez-Atayde et al., (1997) also noted an 
increase in FGF in childhood ALL patients however they also found the increase to be 
insignificant to the prognosis. Kini et al., (1998) also reported an increase in the levels of 
urinary FGF and VEGF in CML patients.   
Suggesting that angiogenic factors VEGF and FGF may also play a role in the progression of 
several types of leukaemia which include ALL and CML.  
1.4.4 Angiogenesis and GAGs 
GAGs are present on the surface of cells as well as in the extracellular matrix of endothelial 
cells (Pardue, Ibrahim and Ramamuth, 2008). GAGs have a vital role in signalling and 
structural cues which are essential for many physiological processes within the body and 
these include angiogenesis (Schoenfelder and Einspanier, 2003).  
In the serum of cancer patients, a dramatic increase in the GAG hyaluronan can be noted 
(Chanmee, Ontong and Itano, 2015). The increase of hyaluronan can be linked to an increase 
in not only the production of but also the release of growth factors (Schoenfelder and 
Einspanier, 2003).  
GAGs can also have interactions with cell receptors in order to aid with the migration and 
proliferation of angiogenesis related endothelial cells (Deed, Rooney and Kumar, 1997). 
However in basic terms GAGs have extremely varying effects on angiogenesis. Long chain 
GAGs bind to the CD44 receptors which are present on the surface of all cell types. The 
binding of GAGs onto the receptor interrupts cell proliferation, which conclusively halts 
angiogenesis (Gao et al, 2008). In contrast short term oligosaccharides binding to cell surface 
receptors promotes the production of growth factors which in turn promotes angiogenesis.  
Heparin and heparan sulphate are most likely to exert an effect on angiogenesis however 
chondroitin sulphate, dermatan sulphate, keratan sulphate and hyaluronan may also interact. 
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Further studies may be able to identify specifically which GAG interacts with angiogenesis the 
most.  
1.4.4.1 GAG interactions with angiogenesis and growth factors 
GAGs are essential in signal transduction in receptor-ligand reactions; this is due to their 
ability to act as co-receptors for VEGF and FGF. GAGs also play a crucial role in angiogenesis 
of tumours (Raman, Ninomiya and Kuberan, 2011). Angiogenesis associated with tumours can 
be initiated through inhibiting the formation of proteoglycans in endothelial cells (Raman, 
Ninomiya and Kuberan, 2011). 
The sulphation patterns located in the structures of GAGs is what allows growth factors like 
FGF and VEGF to bind onto them (Raman, Ninomiya and Kuberan, 2011: Cross and Claesson-
Welsh, 2001). For the angiogenesis process to begin it is essential for GAG units and growth 
factors to bind which results in the binding of endothelial cells (Cross and Claesson-Welsh, 
2001). This binding series results in the initiation of angiogenesis. 
GAGs which are excreted externally enter into competition with endogenous proteoglycans, 
the competition results in the prevention of further GAG production by the cells, this inhibits 
angiogenesis (Raman, Ninomiya and Kuberan, 2011). Exogenous GAGs are incapable of 
binding growth factors (Cross and Claesson-Welsh, 2001). Exogenous GAG does however bind 
to the cells and so it effectively blocks any further binding of GAGs to growth factors which 
further prevents angiogenesis from occurring (Cross and Claesson-Welsh, 2001). With 
angiogenesis effectively blocked the blood supply to the tumour is cut off and would 
therefore cause the cancer to shrink and it could also potentially enter the tumour into a cell 
death pathway.  
The GAGs obtained from shellfish therefore may potentially exert their anti-cancer through 
the binding to cancer cells or to the growth factors, however the mechanism of action for 
shellfish originated GAGs is still unknown.       
1.4.5 Inhibition of angiogenesis in cancer 
If angiogenesis is prevented then the formation of new blood vessels is inhibited. Inhibitors 
can be found in two forms, endogenous inhibitors are one form of angiogenesis inhibitor and 
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they play a normal role in the control of bodily functions (Hayden, 2009). Another form an 
angiogenesis inhibitor can take is in the form of a pharmaceutical drug or from the diet, this 
type of inhibitor is gained via an external source (Hayden, 2009).  
Tumour cells which have secured a blood supply can produce pro-angiogenic substances to 
stimulate further angiogenesis; these can include FGF and VEGF (Folkman, 2004). To inhibit 
angiogenesis, it is necessary to use anti-angiogenesis substances, these aim to minimise the 
effect that the pro-angiogenic factors are producing. This treatment is given to prevent and/ 
or block any ligand-receptor binding (Cao, 2001).  
The major focus of anti-angiogenic drugs is to block or inhibit the VEGF pathway. The main 
reason for this target is the raised levels of VEGF which can be seen in the serum of patients 
who have a malignant tumour (Folkman, 2004). There are various ways in which the VEGF 
pathway can be inhibited. One way to block the VEGF pathway is through the use of tyrosine 
kinase inhibitors. The pathway can also be blocked through the use of antibodies which are 
specific to the VEGF ligand; this treatment prevents VEGF from being able to bind proteins on 
the cell surface.  
The epidermal growth factor receptor (EGFR) is a transmembrane protein which is activated 
by specific ligands including tyrosine kinase (Zhang et al., 2007). Mutations in the EGFR have 
been linked to several diseases including Alzheimer’s and cancer (Zhang et al., 2007). 
Inhibitors which target tyrosine kinase via the EGFR can result in the inhibition of 
angiogenesis. 
Endogenous inhibitors are naturally produced by the body to aid with angiogenesis 
regulation. If a patient is suffering from a tumour then the regulation pathway is defective. 
Due to this defect the volume of pro-angiogenic factors outweighs the anti-angiogenic effects 
and so new blood vessels are formed in an uncontrollable fashion (Nyberg, Xie and Kalluri, 
2005).  
Natural anti-angiogenic agents can provide a good treatment option as a cancer therapy 
target as the noted side effects could have significantly milder toxicity than alternative 
treatment methods. 
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In some animal studies it has been determined that the most beneficial treatment would be 
using a large dose for a prolonged period. However, it has not yet been determined if this 
type of treatment would be safe or beneficial in humans. As the VEGF pathway is being 
disrupted through the use of angiogenic inhibitors side effects can include raised blood 
pressure and bleeding (Elice and Rodeghiero, 2012).  
1.4.6 Angiogenesis inhibitors 
An angiogenesis inhibitor is a substance which can prevent the growth of a new blood vessel 
(Hayden, 2009). Angiogenesis can be prevented through the tyrosine kinase pathway or 
through the blockage of growth factor binding. After the discovery of VEGF in 1989 it became 
expected for VEGF to be the driving force of tumour angiogenesis. It was then further 
predicted that pharmaceuticals which specifically targeted VEGF as a molecule or its binding 
receptor would be a big breakthrough in the treatment of cancer (Hayden, 2009: Arbor and 
Garber, 2002). However it has now come to light that that type of treatment has its limitations 
which put doubt into their use as a cancer therapy. In spite of the discovery of issues with this 
treatment method some anti-angiogenic drugs are still used in cancer therapy and can work 
quite effectively (Hayden, 2009).  
Approximately 60% of malignant tumours have been shown to express VEGF (Cao, 2001) 
which is why most anti-angiogenic drugs have a mechanism of action aimed at blocking the 
VEGF pathway. Several methods are used to block the VEGF pathway which include 
antibodies against VEGF, tyrosine kinase inhibitors and using VEGF itself as a target (Folkman, 
2004). Agauayo et al., (2000) suggested that the evidence to suggest angiogenesis play a role 
in leukaemia that angiogenic inhibitors may prove to be a useful treatment in leukaemia 
patients. 
Tarceva is an angiogenic inhibitor which has entered into clinical trials. It inhibits angiogenesis 
through first inhibiting tyrosine kinase and its effects can be seen on the epidermal growth 
factor receptor (EGFR) (Raymond, Faiure and Armond, 2000). When tarceva has inhibited the 
initiation signal for angiogenesis to occur the growth of new blood vessels is halted. However 
tarceva has shown limitations as eight to twelve months after the start of treatment drug 
resistance has generally occurred. This resistance happened through a mutation in the EGFR 
binding pocket, which prevented the drug from being able to bind the receptor. 
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Another angiogenesis inhibitor is endostatin which was proposed to exert its action through 
blocking FGF and VEGF which would have made it a potential candidate in cancer therapy 
(Folkman, 2006). Trials of endostatin found it to be in-effective when used as a sole treatment 
method. Nexavar (sorafenib) is a treatment for kidney and liver cancers, which is another 
tyrosine kinase inhibitor (Zhang, 2014). Other tyrosine kinase inhibitors which are treatments 
for cancer include; sunitinib, a treatment for renal cell carcinoma, gastrointestinal and 
pancreatic tumours, (Motzer, Escudier, Gannon and Figlin, 2017). Pazopanib is also a multi-
targeted tyrosine kinase receptor inhibitor which has been approved for the treatment of 
metastatic renal cell carcinoma (Mendez-Vidal et al., 2018).  
SU5146 is an anti-angiogenic drug which is aimed at inhibiting tyrosine kinase through 
blocking the VEGF receptor (O’Donnell et al., 2005). It is an unlicensed drug which has entered 
into clinical trials and was expected to have anti-cancer activity. However patients in the trials 
who were treated with SU5146 experienced an unexpected level of toxicity. Two patients 
treated suffered from strokes while other patients experienced blood clots (Arbor and 
Garber, 2002). This toxicity put their future as a cancer therapy drug into doubt.  
The most common angiogenesis inhibiting drug is bevacizumab which is sold under the name 
of Avastin (Rini, 2007). Unlike the other drugs Avastin exerts its action through directly 
binding with VEGF. Avastin was the first drug that binds VEGF to make it through to phase 3 
clinical trials. However, Avastin failed to meet its trial targets, although it did shrink tumours 
it did not delay the cancer progression or improve survival rates (Arbor and Garber, 2002). 
After the failure of SU5146 and Avastin the use of VEGF as an anticancer therapy target was 
questionable. It has now been suggested that using VEGF as a sole target may not be enough 
to exert a permanent effect on tumour growth. 
It is predicted that GAGs will target multiple pro-angiogenic factors and thus they have been 
suggested as a possible cancer therapy and may potentially also be effective at avoiding the 
drug resistance which has been seen after the use of other angiogenic inhibitors. However 
GAGs may also act via an unknown mechanism and so further research is required into the 
mechanism of GAG action in cancer.  
The side effects of GAG treatment are expected to be minimal due to the fact that GAGs are 
naturally found in the human body therefore should not produce many adverse side effects 
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upon treatment. However the effect of GAGs on ‘healthy’ cells is not yet known, this research 
aims to identify what effect if any the GAG extract treatment has on both activated 
lymphocytes and naïve lymphocytes. These results should provide some information on what 
effect the GAGs may have on ‘healthy’ blood cells in a patient.   
1.5 Physiology of white blood cells  
A peripheral blood mononuclear cell (PBMC) can be described as any blood cell which 
contains a round nucleus such as; lymphocytes, macrophages or monocytes (Delves, Martin, 
Burton and Rositts, 2017: De Mello et al., 2012). PBMCs play a vital role within the immune 
system allowing it to adapt to foreign bodies and fight infections.  
PBMCs can be extracted from whole blood using lymphosep and gradient centrifugation to 
separate out the different layers of blood. The bottom layer will be a mixture of lymphosep 
and red blood cells. The next layer is known as the buffy coat and contains the PBMCs and 
the top layer is plasma cells. The PBMCs can be further characterised into lymphocytes such 
as; T-cells, B-cells and natural killer (NK) cells, monocytes and dendritic cells also (Delves et 
al., 2017). For humans the volumes of these types of cells vary from individual to individual. 
As a general composition 70-90% of PBMCs ae made up of lymphocytes, monocytes make up 
around 10-30% of PBMCs and dendritic cells account for a minimal amount of PBMCs making 
up only around 1-2% (Kleiveland, 2015). The lymphocyte population can be further divided 
down. Generally, 70-85% of lymphocytes are CD3+ T-cells, 5-20% are B-cells and 5-20% are 
NK cells (Kleiveland, 2015). CD3+ cells can also further be divided down into CD4+ and CD8+ 
cells which occur in a 2:1 ratio (Kleiveland, 2015). Both CD4+ and CD8+ cells can occur in a 
naive or antigen-experienced memory and effector memory forms (Sanguine Biosciences, 
2012). The cells which make up the lymphocyte population can be seen in figure 1.10.   
1.5.1 Lymphocytes 
Lymphocytes are mononuclear cells which account for 33% of all white blood cells circulating 
in the blood (Moore, Knight and Blann, 2010). It is lymphocytes which provide specific 
immunity for the body against molecules it has previously been exposed to. Upon analysis 
two individual populations of lymphocytes can be identified. One population is small and of 
similar size to red blood cells and contains a minimal amount of cytoplasm; these cells are 
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referred to as small lymphocytes. The other population found in blood analysis are known as 
large lymphocytes due to their size and large volume of cytoplasm (Pallister and Watson, 
2011).  
 
Figure 1.10 The subsets of lymphocytes which derive from haematopoietic stem cells. The lymphocyte 
subsets which derive from haematopoietic stem cells, and whether they are myeloid or lymphoid 
lineage. Adapted from, National Cancer Institute 2018: Skak, Kragh, Hausman, Smyth and Sivakumar, 
(2008). 
There are two main types of lymphocytes which make up the adaptive immune system these 
are T-cells and B-cells. 
1.5.1.1 T-Cells (CD4+ T-helper cells, CD8+ T-effector/ cytotoxic T-cells) 
T-cells are formed in the bone marrow in adults and can be found in the liver of foetuses 
(Becker et al, 2003). T-cells are then formed from lymphoid stem cells; in order to mature T-
cells must enter the thymus (Hannigan, Moore and Quinn., 2009). On the migration to the 
thymus from the bone marrow, immature T-cells gain surface glycoproteins which enable 
them to develop specific functions (Hannigan, Moore and Quinn., 2009). It is the surface 
glycoproteins which determine their effect and function.  
 
Macrophage 
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The main two types of T-cell surface glycoprotein are CD4 and CD8 (Pallister and Watson, 
2011). CD4+ T-cells are known as T-helper cells and are responsible for recognising major 
histocompatibility complex (MHC) II molecules. Another function of T-helper cells is to release 
cytokines which trigger naïve B cells to differentiate; the cytokines can also activate 
macrophages and cytotoxic T-cells (Becker et al, 2003). CD8+ T-cells are responsible for the 
recognition of MHC I molecules and are referred to as cytotoxic T-cells. Cytotoxic T-cells also 
have the ability to kill foreign cells by binding to them and releasing enzymes into the foreign 
cell which in turn induce apoptosis (Becker et al., 2003).  
1.5.1.2 Regulatory T-cells (TReg) 
T-regulatory cells are a family of T cells which function to naturally regulate any inflammatory 
response the body has. They do this through several mechanisms which included cell-cell 
contact through CTLA-4 (Cederbom, Hall and Ivars, 2000) and via cytokine release, specifically 
IL-10 and TGFβ1 (Lui et al, 2010). There are two vital populations of CD4+ Treg cells which 
originate from different sources: natural Tregs (nTreg) which are derived from the thymus and 
peripherally induced Tregs (iTreg). Natural Tregs have a more potent regulatory ability and also 
express FOXP3 which is a transcription factor (Zhang and Zhao, 2007). As CD4+ helper T-cells 
and CD8+ cytotoxic T-cells have immunoregulatory activity they may be useful therapeutic 
targets.  
In cancer, immune evasion is linked to elevated levels of circulating Treg cells within the 
microenvironment of the tumour (Facciabene, Mortz and Coukos, 2012: Elkord et al., 2010). 
Facciabene, Motz and Coukos (2012) described how Tregs are found in the microenvironment 
of many tumours and can be linked to poor prognosis. As Tregs are potent immune suppressors 
it is thought that tumour cells target and elicit Treg functions and secretions (Facciabene et al., 
2012). Through utilising Treg function tumour cells can promote cancer progression through 
angiogenesis stimulation and through the promotion of peripheral tolerance towards the 
cancer cells. This effectively allows the tumour cells to evade the immune system (Facciabene 
et al., 2012). In the circumstance of cancer, raised Treg levels actually negatively impact the 
outcome of immunotherapy on tumour progression (Elkord et al, 2010). Children who are 
suffering from ALL have been reported to have raised levels of circulating Treg cells (Stasiak-
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Barmuta et al, 2009). This has led to the suggestion that understanding chemotherapy effects 
on Treg cells is key to predicting the effectiveness of a therapy.  
1.5.1.3 B-cells 
B-cells are also formed from lymphoid stem cells derived from adult bone marrow and in the 
liver of foetuses (Becker et al, 2003). B-cells mainly derive from adult bone marrow, B-cells 
move through numerous stages and eventually become naïve B-cells. The development to 
the naïve stage happens via a process known as antigen independent differentiation (Pallister 
and Watson, 2011). Naïve B-cells are then capable of being activated through antigens which 
are released by foreign cells which have entered the body. Upon binding the foreign antigens 
naïve B-cells then further differentiate and can become either a memory B-cell or a plasma 
cell (Pallister and Watson, 2011). Memory B-cells provide a long term record for the immune 
system against antigens to which it has been previously exposed. It is memory cells that allow 
the body to respond quickly to an antigen upon reinfection (Becker et al, 2003). Plasma cells 
secrete clones of antibodies which are specific to the antigen that originally initiated the 
immune response and activation of the naïve B-cell (Moore et al., 2010).  
1.5.1.4 The role of Tregs in cancer 
Treg cells play a major role in autoimmune disease as they can inhibit any immune response 
against both non-self and self-antigens (Wang, 2008). However Treg cells can promote tumour 
growth through the suppression of anti-tumour immunity. There is increasing evidence to 
suggest CD4+ Treg cells supress anti-tumour immunity and are also present in several cancer 
types.  
A host’s immune system plays an important role in immunosurveillance and destruction of 
cancer, however immune cells such as T-cells also play a vital role in tumour growth during 
the early stages of cancer (Wang, 2008). CD4+ and CD8+ Tregs become suppressive after over 
stimulation and tumour interaction which promotes tumour progression and cancer 
development. 
It has been reported that elevated levels of CD4+ Treg cells have been identified in cancer 
(Griffiths et al., 2007). Although little is known about CD8+ Tregs in cancer there is increasing 
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evidence to suggest that CD8+ Tregs also accumulate in the tumour microenvironment (Wang, 
2008).  
High levels of CD8+ and CD4+ Tregs in cancer create a microenvironment which is 
immunosuppressive and therefore promotes tumour growth (Wang, 2008). Understanding 
how Tregs can be generated within the tumour microenvironment and furthermore how their 
suppressive activity can be blocked is required to better improve the therapeutic potential of 
cancer therapies (Wang, 2008).  
CD4+ T-cells are responsible for the control of the function, maintenance and memory of CD8+ 
T-cells. In the absence of CD4+ T-cells immunotherapy of cancer through the use of CD8+ T-
cells against the tumour was enhanced (Antony et al, 2005). As most cancer patients cannot 
produce enough of an immune response to the tumour it suggests there may be a tumour 
specific immune evasion strategy (Wolf et al, 2003).  
Tumour metastasis has previously been linked to a drop in MHC I expression and also in the 
proteins responsible for recognising antigen peptides. This effectively downregulates the 
epitopes which activate T-cells from being presented (Wolf et al, 2003). It has also been 
suggested that tumours may also express immune-suppressive elements like IL-10 and TGF-
β (Wolf et al, 2003).   
1.6 Previous research 
1.6.1 Previous preclinical research evaluating GAG actions for the development in cancer 
diagnosis and therapy 
Vallen et al. (2012) identified that an increase in the level of CS circulating in the stroma in 
ovarian cancer patients could be identified using a single chain antibody. This could make it a 
potential biomarker which would make it ideal for diagnosing ovarian cancer. 
Chatzinikolaou et al. (2008) identified that upon treatment with exogenous heparin, colon 
cancer cells had proliferation stimulated, this suggested that heparin may bring about 
behavioural changes in cells. The cells remained unaffected by endogenous GAGs. This may 
suggest that GAGs can exert changes in cancer cell function after treatment  
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Nikitovic et al. (2004) determined that the production of GAGs and PGs within the 
osteosarcoma (MG-63) cell line was stimulated by transforming growth factor (TGF-β2). They 
also noted that the growth factor exerted no effect on the osteosarcoma (SA0S2) cell line. 
The differences between the cell lines continued as the GAGs that were produced inhibited 
cell growth in the MG-63 cells while growth was actually stimulated in the SA0S2 cells. The 
group eventually determined that the changes within the GAG synthesis were due to the 
heparan sulphate produced. Their research identified TGF-β2 as a vital component in GAG 
and PG biosynthesis as well as regulating cell growth and cancer progression.  
Pye and Kumar (1998) determined that HS chains have differing affinity for binding growth 
factors and activity levels which could be due to the differing levels of sulphation within the 
structural domain. They also concluded that the spacing of the sulphated domains proved to 
be important for both the binding of HS chains to growth factors and for the biological activity.  
Makatsori et al., (2001) concluded that all cell lines they tested excreted HS and CS in both 
the cellular membrane and in the culture medium. They also determined that the volume of 
distinct GAGs that were secreted by the cancer cell lines was different to that of normal PBML 
cells and therefore GAGs could have a major role in the malignant transformation of human 
monocytes and lymphocytes.   
Various studies have identified the involvement of GAG extracts in cancer therapy either as a 
biomarker for diagnosis or as targets themselves for therapy.  
Ongoing research headed by Dr David Pye at Kidscan has identified the anti-tumour 
properties of GAG compounds which are isolated from shellfish: cockles and whelks (Aldairi, 
Ogundipe and Pye, 2018). Rigorous testing on a variety of cell lines including: breast cancer, 
colon adenocarcinoma and leukaemia cell lines have shown GAG isolates are effective at the 
reduction of cancer cell populations within the cell lines.  
Aldairi, Ogundipe and Pye (2018) found that the anti-cancer activity noted in the cockle 
extract was affected by the digestion of the extract with heparinase, while digestion with 
chondroitinase ABC had little effect on the antiproliferative activity of the cockle extract. They 
therefore suggested that the heparin/ heparan sulphate component of the cockle extract was 
in part responsible for the level of activity noted. It was also suggested that due to a lack of 
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antiproliferative effect of mammalian GAGs that the GAG structures present in the cockle 
extract were unique and partly responsible for the antiproliferative effects (Aldairi, Ogundipe 
and Pye, 2018). Murphy Mclay and Pye (2008) also suggested that the conformation and 
sulphation patterns within HS chains could be directly linked to the biological activity of the 
GAG.  
Both the cockle and whelk extracts have been shown to be potent against the K562 cell line 
(CML line). This cell line lacks the P53 gene. Various modes of action have been proposed 
based on GAG structures and their adhesive properties interacting with structures on tumour 
cell surfaces which include heparan sulphate (Murphy, Mclay and Pye, 2009). However the 
mechanism of action of the GAGs is still unknown. This research also interestingly identified 
that commercially available GAGs did not possess any anti-cancer activity against the cancer 
cell lines. It is likely that the alterations in the sulphation patterns within the shellfish GAGs 
and commercial GAGs is responsible for the differences in anti-cancer activity. 
Ongoing KidsCan research is aiming to identify the most potent fraction from the FPLC 
separation. Their research has also confirmed that the composition of the shellfish GAGs is 
likely to be a mixture of HS, CS and DS.  
GAGs may be the key to providing a ‘kinder’ alternative anti-tumour therapy for children with 
cancer. Further in vitro studies are still required to identify GAG action on healthy 
lymphocytes including CD4, CD8 and T-regulatory populations to truly determine the 
feasibility of GAGs as a cancer therapy.  
Ongoing KidsCan placement studies are looking into lymphocytes and have established a 
source for units of blood from the clinical donor services and PBMC isolation from the whole 
blood via filtration methods. Identification of CD4, CD8 naive (CD45ROA+) and memory T-cells 
(CD45RO+) and Treg cells (CD4+FOXP3+) by flow cytometry has been achieved in the KidsCan 
labs. A model for thorough interrogation for each cell family in response to GAG doses over 
time has now been established.  
The effect of GAGs on ‘healthy’ lymphocyte populations is still unknown. This research aimed 
to identify what effect the GAGs have on both activated and naïve lymphocytes. The effect of 
GAGs on individual lymphocyte populations was also unknown; this could provide a clearer 
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view on whether the GAG extracts are a viable treatment option that will not produce severe 
side effects. 
1.6.2 Treg interactions with cancer 
Beyer and Schultze (2006) found that Tregs block anti-tumour immune responses and in terms 
of T-cell function and frequency Treg cells are important as elevated levels favour tumour 
growth and development. This can have a huge effect on the progress of the disease.  
In mouse colon fibrosarcoma and adenosarcoma models un-fractioned tumour draining 
lymph nodes cells were isolated on day 9 post tumour challenge; this resulted in the rejection 
of the established tumours (Bayer and Schultze, 2006). Even removing four times the volume 
of cells on day 12 did not prevent lethal tumour progression. Bayer and Schultze (2006) 
concluded that the failure of treatment was due to the transfer of tumour induced Tregs. They 
determined that there was a short time span in which tumour development and the induction 
of suppressive Treg populations. Bayer and Schultze (2006) concluded their findings show Treg 
cells were vital regulators of tumour immunity. Tumour immunity could be defined as the 
host’s ability to produce Tregs which would function to alert the immune system to the 
invasion of tumour cells, allowing the immune system to eradicate the tumour.  Bayer and 
Schultze (2006) demonstrated tumour immunity has a finite window of opportunity before 
the tumour cells recruit Tregs which downregulate an immune response making the tumour 
effectively invisible to the immune system.  
Woo et al, (2002) reported high percentages of Treg cells in small cell carcinoma and ovarian 
cancer. They determined that Tregs excreted TGF-β which contributed to the immune 
dysfunction that cancer patients suffer. However, they concluded that this induction of TGF-
β could have been in part through interaction with CTLA-4 molecule. The CTLA-4 interaction 
could have led to the production of TGF-β by Treg cells, but it could also be a biomarker for 
Treg cells (Woo et al., 2002). 
Bayer and Schultze (2006) also determined in malignant melanoma patients that Treg levels 
were linked to raised H-ferritin levels. H-ferritin lead to the activation of IL-10 which produced 
functional Treg cells as a potential mechanism of Treg production in cancer patients. Poor 
prognosis and decrease in survival rate have been linked to Treg cell frequencies.     
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1.7 Aims and Objectives 
Firstly this research aimed to determine if normally proliferating lymphocytes may be at risk 
of being targeted by these novel compounds (shellfish isolates) in a similar way that 
leukaemia cells are targeted. As T-regulatory (Treg) cells have been linked to the progression 
and immune evasion of cancer as well as the eradication of cancer (Beyer and Schultze, 2006: 
Elkord, 2010). The second aim was to evaluate the action of these novel GAG compounds on 
Treg cells, in order to determine if the clinical use of GAGs may be helpful in reducing the levels 
of Treg cells in leukaemia patients or if, in fact, treatment is likely to exacerbate tumour evasion 
by promoting Treg activation/ potency. 
The primary aim of this research was to progress the pre-clinical assessment of novel GAG 
compounds for the treatment of leukaemia. This was achieved through the evaluation of 
cancer cell line responses and healthy lymphocyte responses to the GAG compounds.  
Phase 1 of the research involved isolating the GAG compounds in bulk using a method similar 
to that set out by Kim et al., (1996). Peripheral mononuclear cells (PBMCs) were extracted 
from whole blood in bulk. Cell viability assays (MTT) were performed in order to assess 
responses of cancer cells (acute lymphoblastic leukaemia (MOLT-4), chronic myeloid 
leukaemia (K562) and lymphoblastic lymphoma (U698)) and activated (PHA or PMA/ 
Ionomycin) or naïve PBMCs to the novel GAG compounds. These assays allowed for the 
identification of a suitable dose and treatment incubation time point to be assessed in 
subsequent flow cytometry assays.  
Phase 2 studies used the obtained IC50 GAG isolate dose, from the MTT assays, to test for 
their potency via flow cytometric analysis in the annexin V/ PI apoptosis and CFSE 
proliferation assays, on the cancer cell lines and PMA/ Ionomycin activated or naïve PBMCs. 
In order to determine GAG isolate effect on cell death and proliferation in cancer cells and 
healthy lymphocytes (activated or naïve). Phase 2 studies also used the FPLC technique to 
isolate potentially potent fractions of the crude whelk extract, in order to determine if a 
smaller chemotherapeutic molecule for potential clinical use was possible. 
Phase 3 of the research evaluated individual FPLC fractions to establish potentially potent 
fragments of the compounds, through the use of the cell viability MTT assay. This work also 
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focussed on T-regulatory (Treg) cell and cytokine responses to the crude GAG isolates, to 
provide insight into their potential modulation of a population of cells associated with cancer 
progression.     
The quest for new therapies is ever pressing and this study aims to undertake preclinical 
evaluation of novel marine mollusc derived GAG compounds, in order to further advance the 
development of these compounds into more effective and tolerable therapies, especially for 
children.  
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CHAPTER 2- METHODS 
2.0 Methods 
2.1 Cell culture 
2.1.1 Freezing/ Thawing manipulations 
The thawing of cryo-frozen human cancer cell lines MOLT-4 (acute lymphoblastic leukaemia), 
K562 (chronic myeloid leukaemia), U698 (lymphoblastic lymphoma) and PBMCs (gained from 
the NHS blood bank, upon ethical approval, which were from healthy patients and screened 
by the donor service) occurred in 30 second intervals at 37 oC. The cellular solution was added 
drop wise, to ensure even distribution of cells, to 10X (v/v) culture RPMI-1640 medium with 
1g/L glucose (Lonza group ltd., Basel, Switzerland), 10% (v/v) inactivated FBS (labtech 
international ltd., Heathfield, UK), 1% (v/v) L-glutamine (labtech international ltd.,) and 1% 
(v/v) penicillin streptomycin (labtech international ltd.,) supplements. The cell: medium 
solution was centrifuged at 200xg for 5 minutes. The cell pellet was retrieved and re-
suspended in fresh medium and seeded into 25 cm2 flasks at a dilution of 1:10 ratio of cells: 
medium or 2:10 ratio. All cells were maintained and humidified atmosphere of air 95% and 
5% CO2 at 37 oC. 
2.1.2 Suspension cell subculture 
Suspension cell subculture was carried out every 2-3 days depending on cell confluency. This 
was done through centrifuging cells from the flasks for 5 minutes at 400xg. The cell pellets 
were re-suspended into 3 mL of media made up as explained in method 2.1.1. 1 mL of cells 
was added to one flask and 2 mL of cells were added to another new flask, media was then 
added to the flasks to make the final flask volume 10 mL. Cells were frozen periodically, via 
re-suspension of the cell pellet into 9 parts FBS to 1-part DMSO (final concentration of 10% 
(v/v)). The solution was then stored in cryovials and frozen at -80 oC for 24 h in “Mr frosty” (a 
freezing container which utilises 100% isopropyl alcohol to gain a constant cooling rate of 1 
oC/minute), allowing for optimum cell preservation. The cells were then transferred to liquid 
nitrogen and archived into the liquid nitrogen store records.  
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2.2 PBMC isolation 
To isolate the PBMCs whole blood was diluted at a 1:1 ratio with RPMI-1640. The diluted 
blood was layered onto lymphosep at a 1:1 ratio in falcon tubes. The tubes were then 
centrifuged at 400xg for 30 minutes with brake setting zero. Upon completion of the 
centrifugation the blood had separated into layers. The bottom layer of lymphosep and red 
blood cells, a buffy coat containing the PBMCs and a top layer containing plasma. The buffy 
coat was carefully retrieved via pasteur pipette and further diluted at a ratio of 1:1 with RPMI-
1640. The RPMI acts as a washing solution in this step. The cell solution was centrifuged at 
400xg for 10 minutes and the cell pellet retrieved and re-suspended in culture medium. A cell 
count was then performed by mixing a 1:1 (v/v) ratio of cells and tryphan blue for the 
assessment of cell viability. The cell: tryphan blue solution was then pipetted onto a 
haemocytometer and the cells were counted. Once the cell count had been performed the 
cells could be used in an assay or frozen as previously described.    
2.3 GAG extraction 
Marine polysaccharides were extracted from the common cockle (cerastoderma edule) and 
whelk (Buccinum undatum), obtained from the Irish sea, British Isles, using a standard 
protocol (Kim et al., 1996). Both cockles and whelks were obtained with the shells removed 
(2.5 kg each). The soft bodies of the shellfish were chopped and placed into separate beakers. 
The cockles and whelks were then defatted over a period of 72 hours in acetone, the acetone 
was replaced every 24 hours. After 72 hours the acetone was decanted off and the defatted 
shellfish were dried in a fume hood for a further 72 hours. Once dry, the cockles and whelks 
were ground into a fine powder.  
The powder (50 g) was incorporated into 500 mL of 0.05 M sodium carbonate buffer pH 9.2 
and 25 ml of alcalase enzyme (Merk, Millipore, Watford, UK). The samples were then placed 
into oil baths and incubated at 60 oC and stirred constantly at 200 rpm for 48 hours. This step 
aims to digest protein within the shellfish powder.  
After 48-hour incubation the shellfish mix was cooled to 4 oC. 5% (w/v) trichloroacetic acid 
(Sigma Aldrich, Gillingham, UK) was added. The solution was centrifuged for 20 minutes at 
10400xg and 4 oC. The supernatant was stored in the fridge. Three times the sample volume 
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of ethanol was used to make a 5% (w/v) potassium acetate solution. This was combined with 
the sample supernatant and stored overnight at 4 oC. The mix was centrifuged at 10400xg for 
30 minutes. The pellet was re-suspended in 480ml of 0.2 M NaCl buffer and centrifuged (30 
minutes, 10400xg), to remove insoluble material.  
A 5% cetylpyrimidinechloride (CPC) (Sigma Aldrich) was added to the supernatant and mixed. 
This solution was centrifuged (10400xg for 30 minutes). The pellet was re-suspended in 125 
ml of 2.5 M NaCl buffer, five volumes of ethanol was then added to the mix and combined. 
This solution was then centrifuged (16300xg for 30 minutes) and the pellet retained and re-
suspended in distilled water.  
2.3.1 Desalting the GAG extracts 
GAG extract samples which were obtained through the procedure described in method 2.3 
were then desalted using dialysis. Dialysis tubing (Fisher scientific, UK) was treated with 100 
mM EDTA. The molecular weight cut off point for the dialysis tubing was 8 kDa. 
The polysaccharide: d2O mix was then dialysed against (100X the sample volume) distilled 
water over a 72-hour period, with the distilled water being replaced every 24 hours. The 
resulting sample was then frozen at -20 oC and freeze dried to obtain a crude extract powder 
(approximately 0.145 g retrieved from 2 kg of cockle or whelk) which could then be used in 
subsequent assays.     
2.4 MTT/ cell viability assay 
MTT assays were all performed in triplicate and repeated 3 times.  The MTT assay used was 
an adaptation of the method set out by Mossman (1983).  
Cell viability was determined through the use of the MTT assay (3-(4,5-dimethylthiazol2-yl)-
2,5diphenyltetrazoliumbromide) (Sigma Aldrich). First a viable cell count was carried out 
using trypan blue and viable cells subsequently seeded into a 96-well plate to a final 
concentration of 3x105 cells per well in order to ensure the cancer cell line and PBMC assays 
were matched.  
For PBMC assays the cells were supplemented with PHA (Sigma Aldrich) (10 µg/ml) (for 
optimisation assays), PMA/ionomycin (Sigma Aldrich) (10 ng/ml/ 1 µg/ml) or media (1:1 ratio 
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(v/v)) dependent on whether the assays were stimulated (+PHA or +PMA/ionomycin) or 
unstimulated (+media) assay. Cancer cell assays were also supplemented at a 1:1 ratio (v/v) 
with media.  
Cockle, whelk or cisplatin (Sigma Aldrich) doses were prepared in serial dilutions in culture 
medium. The final drug concentrations used in the wells is shown in table 2.1. The drug 
concentrations are displayed in µg/ml to allow the comparison of cockle and whelk 
polysaccharide treated cells to the control cisplatin (Sigma Aldrich), as a molar concentration 
is not yet achievable for the polysaccharide extracts as there is not currently an accurate 
molecular weight for the GAG samples. 
Table 2.1 The final concentrations (µg/ml) of each drug (cisplatin, cockle extract and whelk 
extract) dose in the well of an MTT plate. 
Cisplatin (wells 2-14) Cockle extract (wells 
5-7) 
Whelk extract (wells 
8-10) 
15.00 µg/ml 25.00 µg/ml 25.00 µg/ml 
7.50 µg/ml 12.50 µg/ml 12.50 µg/ml 
3.75 µg/ml 6.25 µg/ml 6.25 µg/ml 
1.88 µg/ml 3.13 µg/ml 3.13 µg/ml 
0.94 µg/ml 1.56 µg/ml 1.56 µg/ml 
0.47 µg/ml 0.78 µg/ml 0.78 µg/ml 
0.23 µg/ml 0.39 µg/ml 0.39 µg/ml 
0.00 µg/ml 0.00 µg/ml 0.00 µg/ml 
 
The cells were initially incubated for a given time period between 1-5 days in a humidified 
atmosphere of 95% air and 5% CO2 at 37 oC. All assays were carried out in triplicate and 
repeated three times. Following initial optimisation studies, a three-day incubation period 
was decided upon for all remaining assays.  
Following drug dosing (plus activation in the PBMCs) incubation, 50 µl of MTT solution (3 
mg/ml in PBS) (Fisher Scientific) was added to each well. The plate was incubated for a further 
3 hours. After incubation the supernatant was carefully aspirated to leave purple formazan 
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crystals. 200 µl of DMSO (Fisher Scientific) was then added to each well and the plate was 
gently agitated in order to dissolve the crystals. The plate was then read using a plate reader 
at 540 nm and 690 nm to eliminate background noise (Ascent software). Cell viability and the 
effects of the cisplatin control and the cockle extract and whelk extract treatments were then 
analysed as a percentage of the untreated control cell absorbance. The average cell viability 
was obtained from 3 sets of triplicate data at each drug concentration and was subsequently 
plotted as a dose-response curve. IC50 values were obtained using non-linear regression 
analysis (Microsoft excel). 
2.4.1 MTT assay using fractions obtained from the FPLC assay 
The MTT assay protocol described in method 2.4 was used for the fraction MTT assays. 
Fractions were obtained as per method 2.8 and fractions were identified as shown in figure 
2.2.   
The final concentrations of the fractions used are shown in table 2.2, cisplatin was used in the 
same concentration as seen in table 2.1. The fractions used for the MTT assay were fraction 
3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14 and run off.  
Table 2.2 The final concentrations (mg/ml) of each fraction (3,4,5,6,8,9,10,11,12,13,14 and 
run off sample) dose in the well of an MTT plate.  
Fraction concentration 
(mg/ml) 
(3,4,5,6,8,9,10,11,12,13) 
Fraction concentration 
(mg/ml) 
(14) 
Fraction concentration 
(mg/ml)   
(run off) 
1 0.5 2 
0.5 0.25 1 
0.25 0.13 0.5 
0.13 0.06 0.25 
0.06 0.03 0.13 
0.03 0.02 0.06 
0.00 0.00 0.00 
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2.5 Antibody staining of cancer cell lines and PBMCs for use in flow cytometry assays 
A cell count was performed, and the cell solution was adjusted to give a cell concentration of 
1x106 cells/ml. Cells were then seeded at a concentration of 1x105 cells/well of a 24 well plate 
and incubated for 24 hours. All doses were carried out three times in triplicate. For PBMCs a 
1:1 ratio (v/v) of cells and either PHA (Sigma Aldrich) solution (10 µg/ml) or PMA/ionomycin 
solution (Sigma Aldrich) (10 ng/ml PMA & 1 µg/ml Ionomycin) (made up as per 2.7 method 
protocol) were added to the wells of stimulated assays. A 1:1 ratio (v/v) of media was added 
to the cells in unstimulated assays. After appropriate incubation (24 hours for cancer cell 
assays and unstimulated assays mirrored to PHA stimulated assays, or 4 hours for 
PMA/ionomycin stimulated assays and unstimulated PBMC assays mirrored to the stimulated 
assays (incubated with media for 4 hours or 24 hours, as opposed to PMA/ionomycin or PHA 
stock respectively).  
An equal volume of drug solution (made up to 2x the IC50 values established from the MTT 
assays) was added to the wells to achieve the IC50 value in the assay. Media was added to 
control wells as opposed to a drug dose. The drug and cells were gently mixed and incubated 
for a 3-day period.  
The samples were then transferred from the plate into Eppendorf tubes, antibodies (all from 
BD bioscience, Oxford, UK) were added to the tubes according to the manufacturer’s 
instructions, PBS was added instead of antibodies to one set of untreated triplicate wells as a 
control. Cell labelling profiles can be seen in table 2.3, plate layout can be seen in table 2.4. 
Table 2.3 The antibodies and their stains and with which apoptosis assay they were used in 
Antibody Florescent Stain Assay used in 
CD3 APC MOLT-4 & K562 
CD4 APC-Cy7 PBMC (stimulated & unstimulated) 
CD8 PerCp-Cy 5.5 PBMC (stimulated & unstimulated) 
CD45RO PeCy7 PBMC (stimulated & unstimulated) 
CD45RA APC PBMC (stimulated & unstimulated) 
CD19 APC-Cy7 U698 
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Table 2.4 The layout of a typical apoptosis assay plate dosed with media for control wells +/- 
Ab, dosed with the IC50 values for drug doses cisplatin (6 µg/ml), cockle and whelk extracts 
(12 µg/ml) +Ab. 
Cells + Media control 
Ab- 
Cells + Media control 
Ab- 
Cells + Media control 
Ab- 
Cells + Media control 
Ab+ 
Cells + Media control 
Ab+ 
Cells + Media control 
Ab+ 
Cells + cisplatin 
Ab+ 
Cells + cisplatin 
Ab+ 
Cells + cisplatin 
Ab+ 
Cells + Cockle extract 
Ab+ 
Cells + Cockle extract 
Ab+ 
Cells + Cockle extract 
Ab+ 
Cells + Whelk extract  
Ab+ 
Cells + Whelk extract  
Ab+ 
Cells + Whelk extract  
Ab+ 
 
The antibody: cell solutions were then incubated at room temperature for 30 minutes in the 
dark. The tubes were then pulsed in a micro-centrifuge (Accuspin Micro R, Fisher Scientific 
UK) to maximum speed until the cells had pelleted. The supernatant was discarded, and the 
cell pellet was then washed twice with cold PBS. The cell pellet could then be re-suspended 
in the desired medium. (Annexin V binding buffer for apoptosis assays, PBS for proliferation 
assays).   
2.5.1. Apoptosis assays 
After following method 2.5 for antibody staining the pellet was then re-suspended in 1X 
Annexin V binding buffer (BD bioscience). Cells were then stained with Annexin V and 
propidium iodide (PI) (according to manufacturer’s instructions) (BD bioscience) with the 
exception of the antibody free controls which had 10 µl of PBS added. The cells were then 
gently vortexed and incubated in the dark for 15 minutes.  
The flow cytometer (BD FACSVerse, Franklin lakes, NJ, USA) was calibrated using CS&T beads 
(BD bioscience). After incubation 400 µl of 1X Annexin V binding buffer was added to each 
tube. The tubes were then gently vortexed. Gates were set up to capture FSC and SSC cell 
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basic properties and the appropriate fluorescence for the assay being used. Voltages were 
adjusted based on the antibody free and stained controls respectively and software 
automatic compensation was employed. The samples were analysed by the cytometer to 
identify the presence of individual cell types and to quantify cell numbers undergoing 
apoptosis in response to the compounds.  
The use of stimulated and unstimulated PBMCs in the assays allowed for the comparison of 
healthy naïve and rapidly proliferating PBMCs to simulate an infection. PHA or 
PMA/ionomycin were used as they effectively activate the T-cell division. PHA works via 
forming cross-links with glycosylated proteins on the cell surface of T-cells. PMA/ionomycin 
stimulation is a ‘cleaner’ method of activation as it works via an intracellular target as 
opposed to a cell surface target. PMA stimulated assays followed the stimulation method as 
set out in method 2.7.         
2.5.2. CFSE proliferation assay 
A cell trace stock solution was prepared by adding 18 ul of DMSO to one vial of cell trace (5 
mM stock concentration) (fisher scientific) in dark conditions and mixed well. A working 
concentration of 5 µM was added to cell suspension in PBS (1 ul stock/1 ml cells). Cells were 
incubated at room temperature for 20 minutes in the dark.  
Five times the original staining volume of culture medium (v/v) was added to the cells and 
was then incubated at room temperature for 5 minutes. This step aimed to remove any free 
dye remaining in solution. Cells were pelleted via centrifugation (400xg for 5 minutes) and re-
suspended in culture medium. Cells were then incubated for at least 10 minutes before 
proceeding to seeding or stimulation. Cancer cells and PBMCs being used in unstimulated 
assays proceeded to seeding as per method 2.5. PBMCs being used in stimulation assays 
proceeded to be stimulated as per method 2.7 and then continued onto method 2.5. The 
delay in using the CFSE stained cells allowed the cell trace reagent to undergo acetate 
hydrolysis.         
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2.6 Antibody staining of PBMCs (naïve and stimulated) for cytokine and Treg response assays 
A cell count was performed, and the cell solution was adjusted to give a cell concentration of 
1x106 cells/ml. Cells were then seeded at a concentration of 1x105 cells/well of a 24 well plate 
and incubated for 24 hours. All doses were carried out three times in triplicate. A 1:1 ratio 
(v/v) of cells: PMA/ionomycin solution (Sigma Aldrich) (10 ng/ml PMA & 1 µg/ml Ionomycin) 
(made up as per 2.7 method protocol) were added to the wells of stimulated assays. A 1:1 
ratio (v/v) of media was added to the cells in unstimulated assays. After appropriate 
incubation (4 hours for PMA/ionomycin stimulated assays and unstimulated PBMC assays 
performed in tandem).  
An equal amount of drug solution (made up to the IC50 values obtained from the MTT assays) 
was added to the wells: cisplatin: 6 µg/ml, cockle extract: 12 µg/ml and whelk extract: 12 
µg/ml. Media was added to control wells as opposed to a drug dose. The drug and cells were 
mixed and incubated for a 3-day period at 37 oC and 5% CO2. The plate layout can be seen in 
table 2.6. 
The samples were then transferred from the plate into Eppendorf tubes, cells were pulsed in 
a micro-centrifuge (Accuspin Micro R, Fisher Scientific UK) to maximum speed, then washed 
twice with PBS. Cells were then resuspended in flow cytometry staining buffer (Fisher 
Scientific). 50 µl of brilliant stain buffer (BD biosciences) was then added to each sample in 
order to prevent non-specific binding. Extracellular stains were then added (as seen in table 
2.5) (CD4, CD8, GARP) (5 µl each), the anti-body free samples had 15 µl of PBS added instead 
of antibody. Samples were then incubated for 30 minutes in darken conditions in the fridge 
(4 oC).  
Cells were again pulsed in a micro-centrifuge (Accuspin Micro R, Fisher Scientific UK) to 
maximum speed. Cells were washed with flow cytometry staining buffer (Fisher Scientific UK). 
1 ml of fixation and permeabilization solution (fisher scientific UK) was then added to each 
sample (1 ml of fixation/permeabilization concentrate + 3 ml of fixation/permeabilization 
diluent, and 1 ml of 10X fixation/permeabilization solution in 9 ml of distilled water). Cells 
were then incubated for 30 minutes in the fridge. Cells were transferred to 15 ml falcon tubes 
(Fisher Scientific UK) and 2 ml of flow cytometry buffer was added to each sample. Cells were 
centrifuged for 5 minutes at 400xG.  
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100 µl of flow cytometry buffer was added to each cell pellet, and 2 µl of normal rat serum 
(Fisher Scientific UK) was added to each sample to block the cells. Cells were then incubated 
in the fridge for 15 minutes. Intracellular stains: FOXP3, IL-4 and IFN-γ (5 µl, 1 µl and 5 µl 
respectively) were added to the appropriate samples (not Ab free or FMO samples), PBS was 
added to samples which did not get antibodies (11 µl). Cells were then incubated for 30 
minutes in the fridge. 2 ml of flow cytometry buffer were added to each sample. Cells were 
then centrifuged for 5 minutes at 400xG. Cells were resuspended in 1 ml of flow cytometry 
buffer and transferred to Eppendorf tubes. Cells were then ready to be analysed by flow 
cytometry.  
Table 2.5 The antibodies and their stains used in the FOXP3/ cytokine staining. And whether 
it is an intracellular or extracellular stain. 
Antibody Florescence Stain Intracellular or Extracellular stain 
CD4 PeCy7 extracellular 
CD8 APC-Cy7 extracellular 
GARP APC-A extracellular 
IL-4 FITC intracellular 
IFN-γ PerCpCy 5.5 intracellular 
FOXP3 PE intracellular 
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Table 2.6 The layout of a FOXP3/cytokine assay plate dosed with media for control wells +/- 
Ab, dosed with the IC50 values for drug doses cisplatin (6 µg/ml), cockle and whelk extracts 
(12 µg/ml) +Ab. Where FMO cells have all the extracellular stains but no intracellular stains. 
Cells + Media 
control 
Ab- 
Cells + Media 
control 
Ab FMO 
Cells + Media 
control 
Ab+ 
 
Cells + cisplatin 
Ab+ 
Cells + cisplatin 
Ab+ 
Cells + cisplatin 
Ab+ 
Cells + cisplatin  
FMO 
Cells + Cockle 
extract 
Ab+ 
Cells + Cockle 
extract 
Ab+ 
Cells + Cockle 
extract 
Ab+ 
Cells + Cockle 
extract 
FMO 
Cells + Whelk extract  
Ab+ 
Cells + Whelk 
extract  
Ab+ 
Cells + Whelk extract  
Ab+ 
Cells + Whelk extract 
FMO  
 
2.7 PMA stimulation of PBMCs  
PHA is a lectin which stimulates T-cell proliferation through the formation of multiple cross-
links of glycoproteins present on cell surfaces. PMA however is a small organic compound, 
which stimulates proliferation through the activation of protein kinase C. It does this by 
diffusing into the cytoplasm of the cell through the cell membrane and directly activates 
protein Kinase C. Ionomycin addition provides the trigger for the release of calcium. 
Initial assays were carried out using the PHA stimulation in order to set up the stimulation 
assays; however, as PHA is a lectin it may interact with the GAGs, therefore the 
PMA/ionomycin stimulation method was adopted to provide a cleaner assay. 
PMA powder was reconstituted in DMSO to a 0.1 mg/ml concentration. The PMA stock was 
then frozen at -20 oC in 20 µl aliquots. For use in assays the stock was diluted 1:100 (v/v) in 
sterile PBS. PMA was used at a working concentration of 10 ng/ml of cell suspension. 
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Ionomycin powder was reconstituted in ethanol to a 0.5 mg/ml concentration and stored in 
smaller aliquots at -20 oC. Stock ionomycin was diluted 1:10 (v/v) in sterile PBS for use in 
assays. Final working concentration of ionomycin was 1 µg/ml of cell suspension.  
A combination of ionomycin and PMA at the working concentrations was used to dose each 
well of PBMCs which were to be stimulated at a 1:1 ratio (v/v). 
2.8 The purification of crude whelk extract via fast pace liquid chromatography (FPLC)  
Crude whelk extracts were fractionated using an AKTA Start FPLC system (GE life sciences, 
Buckinghamshire, UK) via an anion exchange protocol. Samples were applied to an ion-
exchange column (X16x20cm) (Fisher Scientific UK, Loughborough, UK) packed with 10 ml of 
DEAE-sepharose (GE life sciences). The column was equilibrated, and samples were eluted 
and dissolved in a 50 mM sodium phosphate buffer (50 mM sodium dihydrogen phosphate 
monohydrate (Fisher Scientific) and 50 mM sodium phosphate dibasic anhydrous (Fisher 
Scientific), pH 7.0). Whelk samples were eluted off the column initially using a linear gradient 
of 0-3 M NaCl (Fisher Scientific) in 50 mM sodium phosphate buffer. This was carried out over 
145 minutes using a 1 ml/minute flow rate. Elution was spectrophotometrically monitored at 
232 nm.  
After initial analysis of the FPLC graph it became apparent that the gradient was not sufficient 
to bring about any level of separation in the whelk sample.  
In a subsequent attempt whelk extract was diluted using a 0-0.75 M NaCl gradient over a 60-
minute period. The gradient was held for 5 minutes and then further increased to a final 
concentration of 2M NaCl over a 30-minute period. This gradient was still insufficient to 
separate the whelk extract, although a slight level of separation had occurred.  
A further assay was carried out using a 0-0.5 M NaCl gradient achieved over a 60-minute 
period and held for 5 minutes. The gradient was then further increased over a 30-minute 
period to 1.5 M NaCl. Although further separation was achieved it was deemed a further 
change to the gradient may have brought about a higher level of separation.  
Therefore, an initial gradient to be achieved over a 30-minute time frame was set to 0-0.25 
M NaCl and was held for 5 minutes when the maximum concentration was reached. The 
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gradient was then increased to 0.5 M NaCl over 30 minutes and held for 5 minutes. The 
gradient was then further increased to 1 M NaCl and achieved over 60 minutes. This method 
obtained the highest level of separation achieved to date and so fractions were collected 
every 2.5 minutes. The fractions were then pooled into peak sections according to the 
recorded graph. The FPLC graphs obtained using this method and the fractions identified and 
taken can be seen in figure 2.1. Pooled samples were then de-salted via PD-10 columns (Fisher 
scientific) (as per manufacturer instructions) and freeze dried.  
 
Figure 2.1 FPLC absorbance vs time graph of whelk extract sample. Whelk sample applied to a DEAE-
sepharose packed X16-20cm column, eluted using a 0-0.25 M, 0.25-0.5 M and 0.5-1 M NaCl step 
gradient over a 130-minute time period. Elution was monitored at 232 nm. 
The gradient achieved over a longer period of time appeared to help with the level of 
separation. As the longer time taken to achieve a gradient the more likely it is to pull the 
components of the whelk extract through the column at different speeds due to differing 
levels of negative charge, therefore achieving higher levels of separation.   
The graphs which were obtained through the optimisation of the FPLC technique used on the 
whelk extract and the steps taken to achieve the further level of separation can be found in 
the appendix. 
Graphs and tables displayed in the chapter 3 and 4 results were created using Microsoft excel 
and in chapter 5 were created using excel and Prism 8.0. Error bars shown demonstrate the 
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SEM. In chapters 4 and 5 the percentage differences were calculated through the subtraction 
of treated cell data from untreated cell data or subtraction between treatment types.       
2.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8.0 and GraphPad InStat 3.0.  
In all chapters statistical analysis was performed between the treatment groups using the 
Two-way ANOVA test and a non-paired T-test analysis. Significance where multiple 
comparisons were carried out i.e. control and three treatment methods, a two way ANOVA 
was performed. In the case of single comparisons, a two tailed student t-test was used. 
Significant differences are indicated using * or equivalent depending on the level of 
significance, i.e: P<0.05 (*) and if a result was very significant P<0.01 (**) and extremely 
significant P<0.001 (***). 
In chapter 3. The IC50 values were used to perform statistical analysis, if an IC50 value was 
not obtained in one of the treatments then the maximum dose of that treatment was used in 
order to provide a comparison to the treatment method. 
In chapter 4 and 5 the percentage differences, in comparison to the untreated control, or 
treatment method comparison, were used to perform the statistical analysis.  
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CHAPTER 3- MTT/ CELL VIABILITY ASSAY 
3.0 MTT/ Cell Viability Assay 
3.1 Introduction  
There have been numerous studies which have identified potential medicinal properties of 
marine GAGs, some have also identified cytotoxic activity both in vitro and in vivo models (de 
Jesus Raposo, 2015). The study conducted by Aldairi, Ogundipe and Pye (2018) identified for 
the first-time that marine polysaccharides isolated from the common cockle, which had 
similarities to mammalian GAGs, demonstrated anti-cancer activity on cancer cell lines in 
vitro. However the effects of GAGs on healthy cells were unknown, this research aimed to 
identify the effects of GAG compounds isolated from the common cockle and the common 
whelk on healthy lymphocytes (naïve and stimulated, PBMCs), in order to establish potential 
side effects of the novel compounds.  The MTT assay is widely used in vitro in order to 
measure the cytotoxicity of compounds on cells lines or in primary patient cells (Van Meerloo, 
2011). The use of the MTT assay allowed for the rapid identification of a suitable dose range 
and incubation time period for the isolated GAGs (from both the cockle and whelk sources), 
via testing on three cancer cell lines, to be tested on naïve and stimulated PBMCs. As the MTT 
was not a time-consuming assay it allowed for a wide range of doses and incubation periods 
to be tested on a variety of cell lines as well as the PBMCs in a short period of time. 
3.1.1 Principle of the MTT assay 
The MTT assay is a colorimetric assay used to measure the reduction of thiazolyl blue 
tetrazolium bromide (MTT dye), which is yellow in colour, by mitochondrial succinate 
dehydrogenase (Berridge, Herst and Tan, 2005). This occurs when the MTT dye enters the 
mitochondria of a cell and is reduced into a formazan salt, which is purple in colour, 
(Mossman, 1983). As this reduction only occurs in cells which are metabolically active the 
assay can be used to determine cell viability. The cells and formazan salt are solubilised using 
an organic solvent such as DMSO and can be measured using spectrophotometry (540 nm 
and 690 nm). 
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3.2 Method 
For this research marine GAGs were isolated from both the common cockle and the common 
whelk via a typical extraction method using cetylpyridinium chloride (Kim et al., 1996) as set 
out in the methods section 2.3.  
Cells were seeded for the MTT assays at a volume of 3 x 105 cells per well for the cancer cell 
assays and for the PBMC assays. In all assays cisplatin was used as a control comparison drug.  
As effects of the GAG compounds on PBMCs were unknown, initially both cockle and whelk 
extracts were tested for anti-cancer activity against three cancer cell lines: two leukemic lines 
(MOLT-4 and K562) and a lymphoma cell line (U698) over a time course of 1-5 days in order 
to first establish an effective dose range to then carry forward onto testing in the lymphocyte 
assays. Once a suitable range of doses was established the healthy human lymphocyte 
(unstimulated PBMCs) and activated/ proliferating lymphocyte (stimulated PBMCs) assays 
were performed over a period of 1-5 days in order to determine a suitable incubation time 
point.   
An initial maximum dose of 25 µg/ml was used for both the cockle extract and the whelk 
extract, a maximum dose of 15 µg/ml of cisplatin was used for the control. However, after 
the initial assay it became apparent that the cisplatin treatment was having little effect on 
the U698 cell line at the smaller doses and so the maximum dose of cisplatin was increased 
in the U698 assays to 30 µg/ml. The U698 cells demonstrated a better response to cisplatin 
at the new dose. The maximum dose of 25 µg/ml was effective in the MOLT-4 assays and so 
was used as the maximum dose for subsequent repeats. However, the maximum dose of 25 
µg/ml had little effect on the K562 cell line and so the dose was increased to 100 µg/ml to try 
to elicit a response from the cells. In the U698 cell line the maximum dose of cockle and whelk 
GAGs of 25 µg/ml did appear to exert a response however the drop in cell viability was very 
large and so made the determination of an IC50 value difficult and so an increased maximum 
dose of 200 µg/ml was used to aid the capturing of an IC50 value, which proved to be effective 
and IC50 values were obtained.  As the maximum dose of 25 µg/ml was only used for the 
MOLT-4 cell line, a maximum dose of 100 µg/ml was used in the PBMC assays as this 
represented a dose which exerted an effect on all the cell lines.  
 75 
Slight batch-to-batch variability was identified by Aldairi, Ogundipe and Pye (2018). This is 
likely to be due to the complex nature of the mixture of polysaccharide chains present in the 
extracts, therefore for this research a large batch was generated in the initial stages of 
research in order to avoid this issue.  
All MTT assays were carried out in triplicate and repeated three times, therefore data 
displayed in figures and tables are average values, error bars within the figure represent 
standard error. IC50 values were obtained using a non-linear regression analysis performed 
in Excel. 
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3.3 MTT/ cell viability results  
Cell viability response assays were tested over a range of cancer cell lines to the novel GAG 
extracts. Cell viability response assays were also performed on naïve PBMCs and on PHA 
activated PBMCs in initial assay and PMA/ ionomycin activated PBMCs in subsequent assays, 
to identify the effects of the novel GAG compounds on healthy lymphocytes.  
3.3.1 Cancer cell MTT assays 
3.3.1.1 MOLT-4 cell line assays   
Both cockle and whelk extracts demonstrated similar and, in some cases, exceeded the 
reduction of MOLT-4 cell viability exerted by the known chemotherapy drug cisplatin.  
The cell viability graph (figure 3.1) identifies little effect on cell viability one and two days post 
incubation with cisplatin (green and light blue lines). At later time points doses from 1.8 µg/ml 
upwards show up to 80% reduction in MOLT-4 cell viability (dark blue, purple and red lines 
on figure 3.1) post cisplatin treatment. After a 3-day incubation period cisplatin appeared to 
have exerted its maximum effect as viability reduction was almost identical across 3-5-day 
incubation periods as can be seen in figure 3.1. Table 3.1 supports the cell viability data 
displayed in figure 3.1 as an IC50 value could not be reached after 1-day incubation with 
cisplatin, meaning MOLT-4 cell viability did not drop below 50%. IC50 values were then 
achieved in correspondence with the increase in incubation period. Although as 
demonstrated in table 3.1, in a similar way to the data presented in figure 3.1, there were 
marginal differences in IC50 values obtained between 3-5-day incubation periods post 
cisplatin treatment. Therefore, it can be concluded that cisplatin exerts it maximum effects 
at low doses post three-day incubation periods. 
After 1-2-day incubation periods the cockle extract did not exert much effect (as seen in figure 
3.2). In a similar way the whelk extract didn’t exert much effect after 1-day incubation 
although an IC50 value was achieved after 2 days incubation (seen in figure 3.3 and table 3.1). 
The cockle and whelk extract both achieved 50% MOLT-4 cell viability reduction or more after 
3-5 days incubation period with IC50 values ranging from 9.81 µg/ml- 15.56 µg/ml and 0.27 
µg/ml- 10.4 µg/ml respectively (table 3.1, figures 3.2 and 3.3 respectively). The whelk extract 
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exerted the largest effect on the MOLT-4 cell line by reducing cell viability by up to 90% at the 
lowest doses (seen in figure 3.3 red and green lines).  
Table 3.1 Average IC50 values obtained using the MTT assay for the MOLT-4 cell line treated 
with cisplatin, cockle extract and whelk extract with maximum doses 15 µg/ml, 25 µg/ml and 
25 µg/ml respectively. With incubation periods between 1-5 days where N=3. IC50 values 
were obtained using a non-linear regression analysis (Microsoft Excel). Significance (shown 
via the asterisk system) - after 1 day incubation is noted by ⌂ significance in after 2 day 
incubation denoted by *, significance after 3 day incubation denoted by ×, significance after 
4 day incubation is denoted by ο and significance after 5 day incubation is denoted by ∆. 
Absence of significance markers indicates no significance.  
Incubation time 
(days) 
1 2 3 4 5 
Treatment 
Maximum dose 
(µg/ml) 
     
Cisplatin (15) Not 
possible 
11.03 
(** p= 
0.0032) 
4.74 5.31  
(ο p= 
0.0134) 
5.17 
(∆ p= 0.03) 
Cockle extract 
(25) 
Not 
possible 
Not 
possible 
15.56 9.81 
(ο p = 
0.0134)  
13.15 
(∆ p= 
0.0103) 
Whelk extract (25) Not 
possible 
20.33 
(** p= 
0.0012) 
10.4 0.34 
(ο p= 
0.0134) 
0.27 
(∆ p= 
0.0306) 
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Figure 3.1 Anti-proliferative activity of cisplatin on the MOLT-4 cell line. Average cell viability for the 
MOLT-4 cell line treated with increasing doses cisplatin (with a maximum dose of 15 µg/ml) and 
incubation period ranging 1-5 days using the MTT assay. Where N=3, changes in cell viability were 
calculated as a percentage in comparison to untreated control cells. Error bars show SEM, significance 
after 1 day incubation is noted by ⌂ significance in after 2 day incubation denoted by *, significance 
after 3 day incubation denoted by ×, significance after 4 day incubation is denoted by ο and 
significance after 5 day incubation is denoted by ∆.   
 
 
 
 
ο ∆ 
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Figure 3.2 Anti-proliferative activity exerted by the cockle extract on the MOLT-4 cell line. Average cell 
viability for the MOLT-4 cell line treated with increasing doses of the cockle extract (with a maximum 
dose of 25 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆. 
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Figure 3.3 Anti-proliferative activity exerted by the whelk extract on the MOLT-4 cell line. Average cell 
viability for the MOLT-4 cell line treated with increasing doses of the whelk extract (with a maximum 
dose of 25 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆. 
3.3.1.2 K562 cell line assays 
From the results obtained through the MTT assay there appeared to be little difference in the 
reduction of K562 cell viability between chemotherapy drug cisplatin and the cockle and 
whelk extract treatments. The K562 cell line did appear to be slightly more resistant to the 
GAG therapies than the MOLT-4 or U698 cell lines. But as the same is true for standard 
therapies it may be that mutations have occurred within the cell line as the passage number 
increased.  
IC50 values demonstrated in table 3.2 show that cisplatin reduced cell viability by a minimum 
of 50% between 2-5 days incubation with IC50 values between 13.91 µg/ml and 10.71 µg/ml. 
However, the cell viability graph (figure 3.4) demonstrates that there is no real further drop 
in cell viability beyond 50% even with increasing doses of cisplatin.  
ο 
∆ 
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The cockle and whelk extracts both exerted an effect on the K562 cell line from the first day 
of incubation which can be identified in table 3.2. The cell viability graphs (figure 3.5 and 
figure 3.6) show that the exerted cockle extracts effects were similar on the K562 cell line 
regardless of the incubation time and reduced cell viability by up to 50%. The lowest dose 
required to do this was 32.80 µg/ml (seen in table 3.2). The whelk extract exerted a similar 
effect to the cockle extract on cell viability which can be seen in table 3.2. The cell viability 
graphs identified that the five-day incubation period was where the whelk extract exerted 
the most prolific effect on the K562 cell line (light blue line in figure 3.6).  
Table 3.2 Average IC50 values obtained using the MTT assay for the K562 cell line treated with 
cisplatin, cockle extract and whelk extract with maximum doses 15 µg/ml, 100 µg/ml and 100 
µg/ml respectively. With incubation periods between 1-5 days where N=3. IC50 values were 
obtained using a non-linear regression analysis (Microsoft Excel), significance (shown via the 
asterisk system) - after 1 day incubation is noted by ⌂ significance in after 2 day incubation denoted 
by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is denoted 
by ο and significance after 5 day incubation is denoted by ∆. Absence of a significance marker 
indicates no significance. 
Incubation time 
(days) 
1 2 3 4 5 
Treatment 
Maximum dose 
(µg/ml) 
     
Cisplatin (15) Not 
possible 
13.91  
(* p= 
0.0312) 
12.88 
(×× 
p=0.002) 
14.98 10.71 
(∆ p=0.0074) 
Cockle extract 
(100) 
186.06 118.29 69.95 32.80 46.74 
Whelk extract 
(100) 
142.81 121.73 71.49 
(× p=0.047) 
87.31 57.97 
(∆ p=0.0074) 
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Figure 3.4 Anti-proliferative activity of cisplatin on the K562 cell line. Average cell viability for the K562 
cell line treated with increasing doses cisplatin (with a maximum dose of 15 µg/ml) and incubation 
period ranging 1-5 days using the MTT assay. Where N=3, changes in cell viability were calculated as 
a percentage in comparison to untreated control cells. Error bars show SEM, significance after 1 day 
incubation is noted by ⌂ significance in after 2 day incubation denoted by *, significance after 3 day 
incubation denoted by ×, significance after 4 day incubation is denoted by ο and significance after 5 
day incubation is denoted by ∆. 
 
 
 
 
 
* 
×× 
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Figure 3.5 Anti-proliferative activity exerted by the cockle extract on the K562 cell line. Average cell 
viability for the K562 cell line treated with increasing doses of the cockle extract (with a maximum 
dose of 100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆, absence of asterisk system 
indicates no significance. 
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Figure 3.6 Anti-proliferative activity exerted by the whelk extract on the K562 cell line. Average cell 
viability for the K562 cell line treated with increasing doses of the whelk extract (with a maximum 
dose of 100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆. 
3.3.1.3 U698 cell line assay 
Both IC50 data (table 3.3) and cell viability data (figures 3.7, 3.8, 3.9) demonstrate that cell 
viability is affected in similar ways post treatment with cisplatin and cockle and whelk extract 
treatments.  
Initial U698 responses to cisplatin were small so a higher maximum dose (30 µg/ml) was used 
to ensure IC50 values could be captured. This allowed for the identification of the drugs effect 
on U698 cell viability. A higher starting dose was also used for both GAG extracts to ensure 
IC50 values could be captured. The larger doses were carried out in order to identify the large 
drop in cell viability as this was difficult to identify in assays carried out with a maximum GAG 
dose of 25 µg/ml.  
× 
∆ 
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Cisplatin exerted an effect on cell viability which can be noted after only one day of incubation 
(figure 3.7). This effect can also be seen in table 3.3 as the dose of cisplatin reduced cell 
viability by a minimum of 50% after day one of incubation. The IC50 table 3.3 identifies low 
IC50 values for all cisplatin incubation periods, with values ranging between 5.63 µg/ml-0.8 
µg/ml. The percentage viability graph in figure 3.7 also shows a rapid decline in U698 cell 
viability of up to 90%.  
Both the cockle and whelk extract treatments exerted an effect on U698 cell viability. The 
cockle extract reduced cell viability by approximately 80-90% (seen in figure 3.8) at doses 
between 102.55 µg/ml and 6.31 µg/ml (as per table 3.3). This can be seen in the cell viability 
graphs also as even at the minimum dose of cockle extract cell viability is reduced by around 
30%. The whelk extract reduced U698 cell viability by 60-90%, which is demonstrated in figure 
3.9, with doses between 71.17 µg/ml and 9.54 µg/ml, seen in table 3.3.   
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Table 3.3 Average IC50 values obtained using the MTT assay for the U698 cell line treated 
with cisplatin, cockle extract and whelk extract with maximum doses 30 µg/ml, 200 µg/ml 
and 200 µg/ml respectively. With incubation periods between 1-5 days where N=3. IC50 
values were obtained using a non-linear regression analysis (Microsoft Excel), significance 
(shown via the asterisk system) after 1 day incubation is noted by ⌂ significance in after 2 
day incubation denoted by *, significance after 3 day incubation denoted by ×, significance 
after 4 day incubation is denoted by ο and significance after 5 day incubation is denoted by 
∆. Absence of a significance marker indicates no significance. 
Incubation time 
(days) 
1 2 3 4 5 
Treatment 
Maximum dose 
(µg/ml) 
     
Cisplatin (30) 5.63 
(⌂⌂ p= 
0.0021) 
1.80 
(* 
p=0.0282) 
1.27 
(×× 
p=0.0048) 
0.95 
(ο p=0.0211) 
0.80 
Cockle extract 
(200) 
102.55 
(⌂⌂ 
p=0.0021) 
26.79 
(* 
p=0.0282) 
7.51 
(× 
p=0.0117) 
11.47 
(ο p=0.0218) 
8.40 
Whelk extract 
(200) 
71.17 
(⌂ p=0.05) 
51.33 
(* 0.0282) 
18.00 
(××× p= 
0.0001) 
16.15 
(οο p=0.001) 
13.30 
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Figure 3.7 Anti-proliferative activity of cisplatin on the U698 cell line. Average cell viability for the U698 
cell line treated with increasing doses cisplatin (with a maximum dose of 30 µg/ml) and incubation 
period ranging 1-5 days using the MTT assay. Where N=3, changes in cell viability were calculated as 
a percentage in comparison to untreated control cells. Error bars show SEM, significance after 1 day 
incubation is noted by ⌂ significance in after 2 day incubation denoted by *, significance after 3 day 
incubation denoted by ×, significance after 4 day incubation is denoted by ο and significance after 5 
day incubation is denoted by ∆. 
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Figure 3.8 Anti-proliferative activity exerted by the cockle extract on the U698 cell line. Average cell 
viability for the U698 cell line treated with increasing doses of the cockle extract (with a maximum 
dose of 200 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆. 
 
 
 
 
⌂⌂ 
** 
×× 
οο 
 89 
 
Figure 3.9 Anti-proliferative activity exerted by the whelk extract on the U698 cell line. Average cell 
viability for the U698 cell line treated with increasing doses of the whelk extract (with a maximum 
dose of 200 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes 
in cell viability were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day incubation 
denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day incubation is 
denoted by ο and significance after 5 day incubation is denoted by ∆. 
3.3.2 MTT assay using isolated PBMCs 
3.3.2.1 Unstimulated/ naïve PBMC MTT assays 
As demonstrated in table 3.4 neither the cisplatin, cockle extract or whelk extract treatments 
were able to reduce the naïve PBMC population by 50%, as an IC50 value could not be 
achieved for any treatment method at any incubation time point.  
Figure 3.10 identifies a marginal decrease in cell population at a higher dose of cisplatin, but 
never more than 50% therefore as demonstrated in table 3.4 an IC50 value was not obtained. 
For the cockle extract treated cells as demonstrated in figure 3.11 the naïve PBMCs remained 
fairly unaffected and cell population was only reduced by a maximum of 10%. Whelk extract 
treated naïve PBMCs (seen in figure 3.12) showed the largest effects to cell population after 
⌂⌂ 
** 
×× 
οο 
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2 or 4-day incubation periods. The maximum doses of whelk extract almost reduced the cell 
population by 50% however the reduction was still lower than 50% thus an IC50 value was 
not obtained for any incubation period (table 3.4). This data demonstrates that at higher 
doses the GAGs extracts, in particular the whelk extract, exert a marginal effect on naïve 
lymphocytes. The apoptosis assay however would allow for a better determination of how 
the extract treatments were affecting the naïve lymphocytes.  
Table 3.4 Average IC50 values obtained using the MTT assay for unstimulated PBMCs treated 
with cisplatin, cockle extract and whelk extract with maximum doses 15 µg/ml, 100 µg/ml 
and 100 µg/ml respectively. With incubation periods between 1-5 days where N=3. IC50 
values were obtained using a non-linear regression analysis (Microsoft excel). 
Incubation time 
(days) 
1 2 3 4 5 
Treatment 
Maximum dose 
(µg/ml) 
     
Cisplatin (15) Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
Cockle extract 
(100) 
Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
Whelk extract 
(100) 
Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
Not 
possible 
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Figure 3.10 Anti-proliferative activity of cisplatin on naïve PBMCs. Average cell viability for naïve 
PBMCs treated with increasing doses cisplatin (with a maximum dose of 15 µg/ml) and incubation 
period ranging 1-5 days using the MTT assay. Where N=3, changes in cell viability were calculated as 
a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.11 Anti-proliferative activity exerted by the cockle extract on naïve PBMCs. Average cell 
viability for naïve PBMCs treated with increasing doses of the cockle extract (with a maximum dose of 
100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes in cell 
viability were calculated as a percentage in comparison to untreated control cells. Error bars show 
SEM. 
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Figure 3.12 Anti-proliferative activity exerted by the whelk extract on naïve PBMCs. Average cell 
viability for naïve PBMCs treated with increasing doses of the whelk extract (with a maximum dose of 
100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes in cell 
viability were calculated as a percentage in comparison to untreated control cells. Error bars show 
SEM. 
3.3.2.2 PHA activated/ stimulated PBMC MTT assays 
As the PBMCs were stimulated by PHA they were expected to react/ behave like activated 
lymphocytes upon infection. I.e. proliferate.   
For the PHA stimulated PBMCs it could be noted that all three treatment methods cisplatin, 
cockle and whelk extracts had very little effect on the cells during 1,4 and 5 day incubation 
periods. However, cisplatin appeared to exert less effect on the cell populations during the 2-
day incubation period as no IC50 value could be reached (table 3.5), whereas an IC50 value 
was obtained for both the cockle and whelk extract treatments. All three treatment methods 
achieved an IC50 value post 3-day incubation with PHA activated cells thus that incubation 
period was decided upon for all subsequent assays.  
The IC50 values seen in table 3.5 show that cisplatin reduced the stimulated PBMC population 
by 50%, this occurred after 3 days of incubation with cisplatin with an IC50 value of 10.69 
µg/ml. This result is mirrored in the percentage growth data seen in figure 3.13. The 
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percentage growth graph (figure 3.13) also indicated that the simulated PBMCs were 
inhibited by almost 50% after 2 and 5-day incubation periods also post cisplatin treatment, 
although it did not quite meet a 50% decrease.   
The cockle and whelk extract treatments both demonstrated the largest effect on the 
stimulated PBMCs after 2-3-day incubation, obtaining IC50 values ranging between 45.69 
µg/ml and 29.80 µg/ml and 20.31 µg/ml and 15.49 µg/ml respectively (which can be seen in 
table 3.5). This is also represented in the cell viability graphs as the cockle extract reduced 
cell viability by around 60% both after 2 and 3-day incubation periods at maximum dose 
(figure 3.14). While at 1, 4 and 5-day incubation periods there appears to be minimal effect 
on the stimulated PBMCs. Similarly, in the whelk extract treated cells after 2 and 3-day 
incubation periods the stimulated PBMC population was reduced by up to 70% at maximum 
dose (figure 3.15). However, after 1, 4 and 5-day incubation periods even at maximum dose 
little effect could be seen on the population of stimulated PBMCs. Again, the apoptosis assays 
will provide more detail about the effect that the GAG extracts have on stimulated PBMCs. 
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Table 3.5 Average IC50 values obtained using the MTT assay for PHA stimulated PBMCs 
treated with cisplatin, cockle extract and whelk extract with maximum doses 15 µg/ml, 100 
µg/ml and 100 µg/ml respectively. With incubation periods between 1-5 days where N=3. 
IC50 values were obtained using a non-linear regression analysis (Microsoft Excel), 
significance (shown via the asterisk system) - after 1 day incubation is noted by ⌂ significance 
in after 2 day incubation denoted by *, significance after 3 day incubation denoted by ×, 
significance after 4 day incubation is denoted by ο and significance after 5 day incubation is 
denoted by ∆. 
Incubation time 
(days) 
1 2 3 4 5 
Treatment 
Maximum dose 
(µg/ml) 
     
Cisplatin (15) Not 
possible 
Not 
possible 
11.54 
(×× 
p=0.0052) 
Not 
possible 
Not 
possible 
Cockle extract 
(100) 
Not 
possible 
45.69 
(** p= 
0.0027) 
29.80 
(×× 
p=0.0077) 
Not 
possible 
Not 
possible 
Whelk extract 
(100) 
Not 
possible 
20.31 
(** 
p=0.0069) 
15.49 
(×× 
p=0.0052) 
Not 
possible 
Not 
possible 
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Figure 3.13 Anti-proliferative activity of cisplatin on PHA stimulated PBMCs. Average cell viability for 
PHA stimulated PBMCs treated with increasing doses of cisplatin (with a maximum dose of 15 µg/ml) 
and incubation period ranging 1-5 days using the MTT assay. Where N=3, changes in cell viability were 
calculated as a percentage in comparison to untreated control cells. Error bars show SEM, significance 
after 1 day incubation is noted by ⌂ significance in after 2 day incubation denoted by *, significance 
after 3 day incubation denoted by ×, significance after 4 day incubation is denoted by ο and 
significance after 5 day incubation is denoted by ∆, absence of asterisk system indicates no 
significance. 
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Figure 3.14 Anti-proliferative activity exerted by cockle extract on PHA stimulated PBMCs. Average 
cell viability for PHA stimulated PBMCs treated with increasing doses of cockle extract (with a 
maximum dose of 100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where 
N=3, changes in cell viability were calculated as a percentage in comparison to untreated control cells. 
Error bars show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day 
incubation denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day 
incubation is denoted by ο and significance after 5 day incubation is denoted by ∆, absence of asterisk 
system indicates no significance. 
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Figure 3.15 Anti-proliferative activity exerted by the whelk extract on PHA stimulated PBMCs. Average 
cell viability for PHA stimulated PBMCs treated with increasing doses of the whelk extract (with a 
maximum dose of 100 µg/ml) and incubation period ranging 1-5 days using the MTT assay. Where 
N=3, changes in cell viability were calculated as a percentage in comparison to untreated control cells. 
Error bars show SEM, significance after 1 day incubation is noted by ⌂ significance in after 2 day 
incubation denoted by *, significance after 3 day incubation denoted by ×, significance after 4 day 
incubation is denoted by ο and significance after 5 day incubation is denoted by ∆, absence of asterisk 
system indicates no significance. 
3.3.2.3 PMA/ ionomycin stimulated PBMC MTT assays 
Results obtained from previous MTT assays using all three cancer cell lines and in both the 
PHA activated and naïve PBMC assays identified that a 3-day incubation period appeared to 
be the most suitable incubation period to carry forward into further assays. This was mainly 
due to the level of activity noted in the PBMC assays at this incubation period. Although the 
4 and 5-day incubation periods also appeared effective in the assays they could be deemed 
to be too long an incubation time in order to evaluate apoptosis. The PBMC assay had been 
optimised using PHA, the PMA/ionomycin stimulation method will now be used, at the 
chosen incubation period for subsequent assays. 
** 
×× 
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The PMA/ionomycin stimulation method was chosen as opposed to PHA due to its ability to 
provide a more specific stimulation to T-cells. In a comparison assay it was noted that the 
percentage of viable cells increased from 100% to 176.3% in PBMCs treated with PHA. 
However, the percentage of viable cells increased from 100% to 221.5% in PBMCs treated 
with PMA/ionomycin. Due to these results the PMA/ionomycin stimulation method was 
chosen as this replication level may provide a better insight into GAG action on rapidly 
proliferating cells.  
For PMA/ionomycin stimulated PBMCs the cockle and whelk extracts exerted less of an effect 
on the cell population than the known drug cisplatin as an IC50 value could be obtained in 
the cisplatin treated cells (table 3.6), whereas both the cockle and whelk extract treated cells 
did not produce an IC50 value. Although the cockle extract cells did exert similar population 
reduction to cisplatin, the whelk extract exerted much less of an effect on the population 
(p=0.0108). 
In table 3.6 cisplatin is identified as the only treatment method to have reduced the 
PMA/ionomycin treated PBMC population by 50% achieving an IC50 value of 7.35 µg/ml. This 
is supported by the cell growth data in figure 3.16 as cisplatin can be seen as reducing cell 
growth by 50%. The cockle and whelk extracts did not reduce the cell population by 50% and 
thus did not achieve an IC50 value as can be seen in table 3.6.  
The cockle extract results seen in figure 3.17 identify that even at maximum treatment dose 
the cell population is not reduced by 50% therefore an IC50 value could not be calculated. 
Although the cell population was decreased to 51% post cockle treatment which was close to 
reaching an IC50 value. Figure 3.18 demonstrates that the whelk extract reduced the cell 
population of PMA/ionomycin stimulated PBMCs to 72%. This treatment method proved to 
exert the least effect on the PMA/ionomycin activated cells and had an almost 40% difference 
in unaffected cells compared to the cells treated by cisplatin.  
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Table 3.6 Average IC50 values obtained using the MTT assay for PMA/ionomycin stimulated 
PBMCs treated with cisplatin, cockle extract and whelk extract with maximum doses 15 
µg/ml, 100 µg/ml and 100 µg/ml respectively. With an incubation period of 3 days, where 
N=3. IC50 values were obtained using a non-linear regression analysis (Microsoft Excel), 
significance after 3 day incubation denoted by ×. Significance in the cisplatin group was in 
comparison to the cockle and whelk extract.    
Incubation time (days) 3 
Treatment Maximum 
dose (µg/ml) 
 
Cisplatin (15) 7.35 (×××× p= 
0.0001)  
Cockle extract (100) Not possible (× 
p=0.0108) 
Whelk extract (100) Not possible (× p= 
0.0108) 
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Figure 3.16 Anti-proliferative activity of cisplatin on PMA/ionomycin stimulated PBMCs. Average cell 
viability for PMA/ionomycin stimulated PBMCs treated with increasing doses cisplatin (with a 
maximum dose of 15 µg/ml) and an incubation period of 3 days using the MTT assay. Where N=3, 
changes in cell viability were calculated as a percentage in comparison to untreated control cells. Error 
bars show SEM, significance after 3 day incubation denoted by ×. Significance in the cisplatin treated 
cells was in comparison to the cockle and whelk extract. 
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Figure 3.17 Anti-proliferative activity exerted by the cockle extract on PMA/ionomycin stimulated 
PBMCs. Average cell viability for PMA/ionomycin stimulated PBMCs treated with increasing doses of 
the cockle extract (with a maximum dose of 100 µg/ml) and an incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell viability were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM, significance after 3 day incubation denoted by ×. 
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Figure 3.18 Anti-proliferative activity exerted by the whelk extract on PMA/ionomycin stimulated 
PBMCs. Average cell viability for PMA/ionomycin stimulated PBMCs treated with increasing doses of 
the whelk extract (with a maximum dose of 100 µg/ml) and an incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell viability were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM, significance after 3 day incubation denoted by ×. 
3.3.3 FPLC Fraction MTT/ Cell viability results 
The study conducted by Aldairi, Ogundipe and Pye (2018) identified that fraction 5, of a cockle 
extract, obtained via FPLC had the most anti-proliferative activity of the fractions they 
obtained. For this research the whelk extract fractions obtained via the FPLC (method 2.8) 
assay were tested for any anti-proliferative activity using the MTT assay. Fractions 3, 4, 5, 6, 
8, 9, 10, 11, 12, 13, 14 and the fraction run off were tested on all three cancer cell lines (MOLT-
4, K562 and U698). Fractions were also tested on PBMCs both naïve and PMA/ionomycin 
stimulated, however formazan crystals were difficult to obtain during this set of assays in 
most plates across all three repeats. In all assays cisplatin was used as the control comparison 
drug. Cells were incubated post treatment with the drug for three days.  
As there were not sufficient volumes of fraction 14 obtained during the FPLC assays, the 
maximum dose used for fraction 14 was half that of the other fractions. While the amount of 
× 
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run off fraction obtained was higher and as it was expected to contain little quantity of GAGs 
the maximum dose was double that of the other fractions. 
All MTT assays were carried out in triplicate and replicated three times. Therefore data 
displayed in the figures are average values, error bars within the figures represent standard 
error. IC50 values could not be obtained for any of the initial MTT results. If an IC50 was 
obtained this was through a linear regression analysis performed in excel.   
3.3.3.1 MOLT-4 Cell line GAG fraction assays 
None of the fractions tested exerted much of an effect on the MOLT-4 cells in comparison to 
the known drug cisplatin. This therefore led to an increase in fraction dose to be considered.  
The cell viability graph in figure 3.19 identifies that cisplatin treatment reduced MOLT-4 cell 
growth by almost 50%. Whilst figure 3.20 demonstrates that treatment with fraction 3 (blue 
line), fraction 4 (orange line), fraction 5 (grey line) and fraction 6 (yellow line) exerted very 
little effect on the MOLT-4 cells. With a maximum reduction in cell viability of around 20%. 
Fraction 5 in figure 3.20 appears to be exerting the most effect on the MOLT-4 cells. In figure 
3.21 it can be seen that the isolated fraction 8 (blue bar), fraction 9 (orange bar) and fraction 
10 (grey bar) exert little effect on the MOLT-4 cell line with the doses that had been selected. 
In this instance all the fractions appear to be exerting similar effects with a maximum cell 
viability reductions of around 15%. Fraction 11 (blue line), fraction 12 (orange line) and 
fraction 13 (grey line) in figure 3.22 have little effect on the MOLT-4 cell line. Fraction 11 and 
fraction 13 appear to have promoted cell proliferation slightly in the MOLT-4 cells, as 
percentage cell viability is consistently above 100%. Fraction 12 (orange line, figure 3.22) 
appears to have exerted the most effect with cell viability reductions of around 20% post 
treatment. Figure 3.23 identifies some antiproliferative activity in fraction 14 treated MOLT-
4 cells, with cell viability reductions of around 15%. The run off sample (figure 3.24) also 
appears to exert some effect on the MOLT-4 cells with cell viability reductions of around 15%, 
in a similar manner to that seen in the other fraction treated cells.  
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Figure 3.19 Anti-proliferative activity exerted by cisplatin treatment on the MOLT-4 cell line. Average 
cell growth for the MOLT-4 cell line treated with increasing doses of cisplatin (with a maximum dose 
of 15 µg/ml) and incubation period of 3 days using the MTT assay. Where N=6, changes in cell growth 
were calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.20 Anti-proliferative activity exerted by FPLC fractions 3,4, 5 and 6 (of the whelk extract) 
treatment on the MOLT-4 cell line. Average cell growth for the MOLT-4 cell line treated with increasing 
doses of whelk extract fractions 3 (blue line), 4 (orange line), 5 (grey line) and 6 (yellow line) (with a 
maximum dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes 
in cell growth were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM. 
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Figure 3.21 Anti-proliferative activity exerted by FPLC fractions 8, 9 and 10 (of the whelk extract) 
treatment on the MOLT-4 cell line. Average cell growth for the MOLT-4 cell line treated with increasing 
doses of whelk extract fractions 8 (blue line), 9 (orange line) and 10 (grey line) (with a maximum dose 
of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell growth 
were calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
 
 
 
 
 108 
 
Figure 3.22 Anti-proliferative activity exerted by FPLC fractions 11, 12 and 13 (of the whelk extract) 
treatment on the MOLT-4 cell line. Average cell growth for the MOLT-4 cell line treated with increasing 
doses of whelk extract fractions 11 (blue line), 12 (orange line) and 13 (grey line) (with a maximum 
dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell 
growth were calculated as a percentage in comparison to untreated control cells. Error bars show 
SEM. 
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Figure 3.23 Anti-proliferative activity exerted by FPLC fraction 14 (of the whelk extract) treatment on 
the MOLT-4 cell line. Average cell growth for the MOLT-4 cell line treated with increasing doses of 
whelk extract fraction 14 (blue line) (with a maximum dose of 0.5 mg/ml) and incubation period of 3 
days using the MTT assay. Where N=3, changes in cell growth were calculated as a percentage in 
comparison to untreated control cells. Error bars show SEM. 
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Figure 3.24 Anti-proliferative activity exerted by FPLC run off sample (of the whelk extract) treatment 
on the MOLT-4 cell line. Average cell growth for the MOLT-4 cell line treated with increasing doses of 
whelk extract run off sample (blue line) (with a maximum dose of 2 mg/ml) and incubation period of 
3 days using the MTT assay. Where N=3, changes in cell growth were calculated as a percentage in 
comparison to untreated control cells. Error bars show SEM. 
3.3.3.2 K562 cell line GAG fraction assays 
The whelk extract fractions exerted little effect on the K562 cell line, however did exert more 
of an effect that the known drug cisplatin due to the poor response of the K562 cell line to 
treatment as had been noted in all previous assays. This was the reason that the K562 cell 
line had been discounted from previous assays.  
It can be noted that cisplatin treatment in the K562 cell line brought about no more than a 
4% decline in K562 cell viability (figure 3.25). Treatment with fractions 3 (blue line), fraction 
4 (orange line), fraction 5 (grey line) and fraction 6 (yellow line) (figure 3.26) brought about 
cell viability reductions of around 5-10% in the K562 cell line. With all the fractions appearing 
to result in similar effects on the cell line. Figure 3.27 demonstrates that fraction 8 (blue line) 
exerted the best effect on the K562 cell line with a reduction of around 15% in cell viability. 
Fraction 9 (orange line, figure 3.27) exerted the next best effect on the K562 cell line in this 
figure, however didn’t actually reduced the K562 cell viability by more than a few percent. 
 111 
Fraction 10 (grey line, figure 3.27) appeared to promote K562 cell proliferation, as cell viability 
increased by around 20% at the higher doses of fraction 10. In figure 3.28 it can be seen that 
both fraction 11 (blue bar) and fraction 12 (orange bar) had an increase in cell viability/ 
proliferation in the K562 cell line with increases between 10-20%. Fraction 13 (grey line, figure 
3.28) exerted little effect on the K562 cell line with cell viability failing to drop lower than 98% 
even at the highest treatment dose. Figure 3.29 identifies that treatment with fraction 14 
reduced K562 cell viability by around 5% during the middle treatment doses (0.03mg/ml and 
0.06mg/ml). However cell viability then began to rise with further increasing of fraction 14 
doses (figure 3.29). The runoff treatment (figure 3.30) exerted little effect on the K562 cell 
line with cell viability only dropping below 98% at the treatment dose of 0.25mg/ml.  
 
Figure 3.25 Anti-proliferative activity exerted by cisplatin treatment on the K562 cell line. Average cell 
growth for the K562 cell line treated with increasing doses of cisplatin (with a maximum dose of 15 
µg/ml) and incubation period of 3 days using the MTT assay. Where N=6, changes in cell growth were 
calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.26 Anti-proliferative activity exerted by FPLC fractions 3,4, 5 and 6 (of the whelk extract) 
treatment on the K562 cell line. Average cell growth for the K562 cell line treated with increasing 
doses of whelk extract fractions 3 (blue line), 4 (orange line), 5 (grey line) and 6 (yellow line) (with a 
maximum dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes 
in cell growth were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM. 
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Figure 3.27 Anti-proliferative activity exerted by FPLC fractions 8, 9 and 10 (of the whelk extract) 
treatment on the K562 cell line. Average cell growth for the K562 cell line treated with increasing 
doses of whelk extract fractions 8 (blue line), 9 (orange line) and 10 (grey line) (with a maximum dose 
of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell growth 
were calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.28 Anti-proliferative activity exerted by FPLC fractions 11, 12 and 13 (of the whelk extract) 
treatment on the K562 cell line. Average cell growth for the K562 cell line treated with increasing 
doses of whelk extract fractions 11 (blue line), 12 (orange line) and 13 (grey line) (with a maximum 
dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell 
growth were calculated as a percentage in comparison to untreated control cells. Error bars show 
SEM. 
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Figure 3.29 Anti-proliferative activity exerted by FPLC fraction 14 (of the whelk extract) treatment on 
the K562 cell line. Average cell growth for the K562 cell line treated with increasing doses of whelk 
extract fraction 14 (with a maximum dose of 0.5 mg/ml) and incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell growth were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM. 
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Figure 3.30 Anti-proliferative activity exerted by FPLC run off sample (of the whelk extract) treatment 
on the K562 cell line. Average cell growth for the K562 cell line treated with increasing doses of whelk 
extract run off sample (with a maximum dose of 2 mg/ml) and incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell growth were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM. 
3.3.3.3 U698 cell line assays 
As seen in the other cell lines the fraction treatments exerted little to no effect on the U698 
cell line in comparison to the control treatment cisplatin.  
Cisplatin treatment brought about a steep decline in U698 cell viability towards the last three 
doses used (figure 3.31). Treatment with fraction 3 (blue line), fraction 4 (orange line), 
fraction 5 (grey line) and fraction 6 (yellow line) in figure 3.32 exerted little effect on the U698 
cell line with cell viability dropping by a maximum of 10% (fraction 3, treated cells). Treatment 
with all 4 of these fractions as seen in figure 3.32 mainly led to no change in cell viability which 
remained around 100% in all the fraction treated samples in figure 3.32. In figure 3.33 it can 
be noted that cell viability was reduced by around 10% in the U698 cells at the maximum dose 
of fraction 10 (grey line). While fraction 8 (blue line, figure 3.33) exerted little effect on the 
U698 cells with cell viability around 100%, even at the maximum dose. Fraction 9 treatment 
(orange line, figure 3.33) appeared to promote cell proliferation slightly in the U698 cell line, 
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with viability increasing by around 15-20%. U698 cells treated with fraction 11 (blue line), 
fraction 12 (orange line) or fraction 13 (grey line) (all in figure 3.34) all have cell viability 
reduced by around 15% post treatment. Fraction 14 treated U698 cells (figure 3.35) had cell 
viability reduced by a maximum of 10% (dose 0.06 mg/ml). The U698 cells treated with the 
runoff sample (figure 3.36) have cell viability reduced by a maximum of 10% at dose 0.25 
mg/ml then cell viability began to increase with the increasing dose. Cell viability returned 
back to 100% with the maximum dose of 2 mg/ml of the runoff sample (figure 3.36). 
 
Figure 3.31 Anti-proliferative activity exerted by cisplatin treatment on the U698 cell line. Average cell 
growth for the U698 cell line treated with increasing doses of cisplatin (with a maximum dose of 30 
µg/ml) and incubation period of 3 days using the MTT assay. Where N=6, changes in cell growth were 
calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.32 Anti-proliferative activity exerted by FPLC fractions 3,4, 5 and 6 (of the whelk extract) 
treatment on the U698 cell line. Average cell growth for the U698 cell line treated with increasing 
doses of whelk extract fractions 3 (blue line), 4 (orange line), 5 (grey line) and 6 (yellow line) (with a 
maximum dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes 
in cell growth were calculated as a percentage in comparison to untreated control cells. Error bars 
show SEM. 
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Figure 3.33 Anti-proliferative activity exerted by FPLC fractions 8, 9 and 10 (of the whelk extract) 
treatment on the U698 cell line. Average cell growth for the U698 cell line treated with increasing 
doses of whelk extract fractions 8 (blue line), 9 (orange line) and 10 (grey line) (with a maximum dose 
of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell growth 
were calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.34 Anti-proliferative activity exerted by FPLC fractions 11, 12 and 13 (of the whelk extract) 
treatment on the U698 cell line. Average cell growth for the U698 cell line treated with increasing 
doses of whelk extract fractions 11 (blue line), 12 (orange line) and 13 (grey line) (with a maximum 
dose of 1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=3, changes in cell 
growth were calculated as a percentage in comparison to untreated control cells. Error bars show 
SEM. 
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Figure 3.35 Anti-proliferative activity exerted by FPLC fraction 14 (of the whelk extract) treatment on 
the U698 cell line. Average cell growth for the U698 cell line treated with increasing doses of whelk 
extract fraction 14 (with a maximum dose of 0.5 mg/ml) and incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell growth were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM. 
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Figure 3.36 Anti-proliferative activity exerted by FPLC run off sample (of the whelk extract) treatment 
on the U698 cell line. Average cell growth for the U698 cell line treated with increasing doses of whelk 
extract run off sample (with a maximum dose of 2 mg/ml) and incubation period of 3 days using the 
MTT assay. Where N=3, changes in cell growth were calculated as a percentage in comparison to 
untreated control cells. Error bars show SEM. 
3.3.3.4 Stimulated PBMC assays 
Results were obtained for PBMCs stimulated with PMA/ionomycin and treated with cisplatin 
and fractions 8,9 14 and the run off sample.  
As can be seen in figure 3.37 cisplatin reduced the stimulated PBMC cell viability by a 
maximum of 20%. Figure 3.38 demonstrates that post treatment with fraction 9 (orange bar) 
the stimulated PBMCs had cell viability reduced by around 10%. Treatment with fraction 8 
(blue bar, figure 3.38) demonstrated increases in stimulated PBMC viability of around 20%. In 
a similar way figure 3.39 identifies an increase in cell viability of the stimulated PBMCs of 
between 5-20% post treatment with fraction 14. In the runoff sample treated cells 
demonstrated some slight increases in cell viability, however mainly cell viability remained 
around 100% post treatment (figure 3.40). 
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Figure 3.37 Anti-proliferative activity exerted by cisplatin treatment on PMA/ ionomycin stimulated 
PBMCs. Average cell growth for the stimulated PBMCs treated with increasing doses of cisplatin (with 
a maximum dose of 15 µg/ml) and incubation period of 3 days using the MTT assay. Where N=1, 
changes in cell growth were calculated as a percentage in comparison to untreated control cells. Error 
bars show SEM. 
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Figure 3.38 Anti-cancer activity exerted by FPLC fractions 8 and 9 (of the whelk extract) treatment on 
the PMA/ ionomycin stimulated PBMCs. Average cell growth for the stimulated PBMCs treated with 
increasing doses of whelk extract fractions 8 (blue line) and 9 (orange line) (with a maximum dose of 
1 mg/ml) and incubation period of 3 days using the MTT assay. Where N=1, changes in cell growth 
were calculated as a percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.39 Anti-proliferative activity exerted by FPLC fraction 14 (of the whelk extract) treatment on 
the PMA/ ionomycin stimulated PBMCs. Average cell growth for the stimulated PBMCs treated with 
increasing doses of whelk extract fraction 14 (with a maximum dose of 0.5 mg/ml) and incubation 
period of 3 days using the MTT assay. Where N=1, changes in cell growth were calculated as a 
percentage in comparison to untreated control cells. Error bars show SEM. 
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Figure 3.40 Anti-proliferative activity exerted by FPLC run off sample (of the whelk extract) treatment 
on the stimulated PBMCs. Average cell growth for the stimulated PBMCs treated with increasing doses 
of whelk extract run off sample (with a maximum dose of 2 mg/ml) and incubation period of 3 days 
using the MTT assay. Where N=1, changes in cell growth were calculated as a percentage in 
comparison to untreated control cells. Error bars show SEM. 
From the MTT results obtained it appeared as through some of the isolated FPLC fractions 
had very slight anti-proliferative effects on the cancer cell lines, with some of the fractions 
appearing to have exerted proliferative effects on some of the cell lines. Therefore new doses 
for the FPLC fractions were chosen based on the activity noted in the FPLC fraction MTTs, 
these doses were 10-fold higher than previous ones and were tested in subsequent assays 
carried out by the research group. The new doses are shown below in table 3.7. Fraction 14 
was not carried forward into these tests due to the low sample volume.  
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Table 3.7 The maximum doses (mg/ml) of each fraction number (3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 
run off sample) in the well of an MTT plate. 
Fraction number New maximum dose (mg/ml) 
3 10 
4 10 
5 20 
6 20 
8 7 
9 10 
10 25 
11 10 
12 20 
13 20 
Run off sample 10 
 
3.4 Discussion 
3.4.1 MTT results key findings 
• Confirmed the anti-proliferative effects of the crude cockle extract on the MOLT-4 and 
K562 cell lines as noted by Aldairi, Ogundipe and Pye (2018).  
• For the first time this research identified the antiproliferative activity of the crude 
cockle and whelk GAG extracts on the lymphoblastic lymphoma cell line U698. 
• This study provided significant insight into the effects of novel marine sourced GAG 
compounds isolated from the common cockle and whelk on healthy lymphocytes 
(both activated and naïve). 
3.4.2 Discussion 
Previous studies have demonstrated the potential medicinal properties of marine GAGs 
(DeJesus Raposo, 2015) and the potential anti-cancer activity of GAG like compounds (Afratis 
et, al., 2012). GAG compounds isolated from the common cockle have also been identified as 
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having anti-cancer properties in breast cancer cell lines and the leukemic cell lines MOLT-4 
and K562 (Aldairi, Ogundipe and Pye, 2018). However there were no current studies 
identifying the effects of these marine mollusc derived GAG compounds on healthy 
lymphocytes or on the lymphoblastic lymphoma cell line U698.  
This research identified that GAGs extracted from the common cockle and whelk had a 
significant inhibitory effect on cell viability in the MOLT-4 and U698 cell lines. In the MOLT-4 
cell line post 3-day incubation with the cockle and whelk extract the cell viability was reduced 
by up to 80% and 90% respectively with an IC50 values of 15.56 µg/ml and 10.4 µg/ml 
respectively as can be seen in figures 3.1 and 3.2 and table 3.1. The U698 cell viability was 
significantly reduced by both the cockle and whelk extract treatment (p= 0.0117 and p= 
0.0001 respectively), with IC50 values ranging 7.51 µg/ml and 102.55 µg/ml (table 3.3). U698 
cell line viability was reduced by up to 90% post treatment with both the cockle and whelk 
extracts (figures 3.8 and 3.9). Some level of activity was also noted in the K562 cell line with 
growth inhibition of up to 50% and Ic50 values ranging 32.8 µg/ml and 186.06 µg/ml (Figures 
3.5 and 3.6 and table 3.2). The whelk extract reduced K562 cell viability significantly post 3 
day incubation period with an IC50 value of 71.49 µg/ml (p=0.047). In the K562 cell line the 
IC50 values of the cockle extract treated cells increased post 5 day incubation in comparison 
to the 4 day incubation period, which could suggest that the cell line had potentially 
developed some level of immunity to the treatment. Interestingly neither the cockle or whelk 
GAG isolates exerted a cytotoxic effect on the healthy lymphocytes (either active or naïve), 
both extracts failed to reduce cell viability by 50% and thus did not produce an IC50 value 
(tables 3.4 and 3.6; figures 3.11, 3.12 3.17, 3.18). In this regard the cytotoxic effects noted in 
the cancer cell lines of the novel GAG compounds appeared to be acting in a selective manner 
towards the MOLT-4, K562 and U698 leukemic and lymphoma cell lines and non-toxic to the 
healthy lymphocytes either the naïve or proliferating lymphocytes (stimulated). It would have 
been interesting to have determined the nature of the seemingly selective nature of the GAG 
compounds, however that was beyond the scope of this research but should be considered 
in future work towards the possibility of the use of mollusc derived GAG compounds for use 
in the clinic. Our data supports that found by Aldairi, Ogundipe and Pye (2018) that the 
mollusc derived GAGs appear to show specificity towards the leukemic and lymphoma cells 
as opposed to the healthy lymphocytes and would further support the potential therapeutic 
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use of these GAG compounds in the clinic. The effects of cisplatin on PBMCs noted in this 
research was similar to the anti-proliferative effects noted by Sakai et al., (2013), however 
incubation times were different in this research and so there was some level of difference in 
the noted activity.  
Understanding the structural and specific biological roles of the mollusc derived GAGs may 
help lead to the development of the novel therapeutic approaches (Afratis et al., 2012). In 
order to further identify the structural properties of the whelk extract, the crude extract was 
purified by ion exchange chromatography and the resulting fractions were then tested for 
anti-proliferative activity on the cancer cell lines through the MTT assay (figures 3.20-3.40). 
All eluted fractions appeared to be non-toxic to the MOLT-4, K562 or U698 cell lines, with no 
obtainable IC50 values even at maximum dose. Aldairi, Ogundipe and Pye (2018) identified 
the cytotoxic effect of ‘fraction E’ on a breast cancer cell line but also noted a lack of toxicity 
in the MOLT-4 and K562 cell lines. Their results suggested selectivity against breast cancer 
cell lines as was noted in the crude extracts, suggesting that fraction E may be responsible for 
the cytotoxic effects of the crude whelk extract. However in this research no eluted fraction 
exerted a toxic effect on any of the cancer cell lines. This could be due to low levels of GAGs 
in the isolated fractions, which could be combated by doing further FPLC runs using a higher 
initial weight of the crude GAG compounds. It could also be that as demonstrated by Aldairi, 
Ogundipe and Pye (2018) the isolated GAG compounds are not active in the MOLT-4 or the 
K562 cell lines and may not be toxic to the U698 cell line at low doses; as the new suggested 
doses appeared to exert an effect on the MOLT-4 and U698 cell lines in placement student 
studies. Further understanding into the exact structural features seen in ‘fraction E’ by Aldairi, 
Ogundipe and Pye (2018) may open a new therapeutic approach to cancer therapy.   
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CHAPTER 4- ANNEXIN V/PI APOPTOSIS ASSAY AND CFSE PROLIFERATION ASSAY 
4.0 Annexin V/ Propidium Iodide apoptosis assay and CFSE proliferation assay results 
4.1 Introduction 
4.1.1 Annexin V/ Propidium Iodide apoptosis assay 
The work carried out by Aldairi, Ogundipe and Pye (2018) identified that in the MOLT-4 cell 
line cells accumulated in the G1 and G2/M phase of the cell cycle and a subsequent drop in 
the S phase of the cell cycle, 24 hours post treatment with extracted cockle polysaccharides. 
They suggested that this could indicate a complex cell death mechanism potentially mediated 
by apoptosis. The annexin V/ propidium iodide apoptosis assay is commonly used to assess 
apoptotic cells (Cornelissen, Phillippe, De sitter and De Ridder, 2002). Significant increases in 
late apoptotic cells (annexin V+/PI+) were identified by Aldairi, Ogundipe and Pye (2018) in the 
MOLT-4 cell line post cockle polysaccharide treatment. They also identified little changes in 
necrotic cells (annexin V-PI+) post cockle polysaccharide treatment. The results of the research 
group therefore indicated apoptosis potentially as the cause of cytotoxicity in MOLT-4 cells 
post treatment with cockle polysaccharides (Aldairi, Ogundipe and Pye, 2018). The results in 
chapter 3 identified limited decreases in cell viability (MTT) in healthy lymphocytes, however 
in activated, especially in the PHA activated, cells some level of activity on cell viability was 
noted. Therefore it is important to establish the mechanism of cell death induced by 
treatment with the cockle and whelk extract. This research aimed to use the annexin V/ PI 
assay (BD Bioscience, UK) to identify any apoptotic effects of the GAGs isolated from the 
common cockle and the common whelk on healthy lymphocytes (naïve and stimulated), in 
order to establish possible side effects from GAG treatment. Annexin V and propidium iodide 
are used in conjunction with each other in order to evaluate cell viability and the presence of 
apoptotic or necrotic cells (Vermes, Haanen, Steffens-Nakken and Reutelingsperger, 1995). 
Propidium iodide is often used to indicate cell viability as it has the ability to omit living cells 
(Reiger, Nelson, Konowalehuk and Barreda, 2011). PI can only enter a cell if the membrane is 
compromised, therefore as early apoptotic and living cells possess intact cell membranes PI 
does not stain them (Vermes et al., 1995). Whereas in late apoptotic and necrotic cells the 
integrity of the cell membrane is disrupted, and so PI can cross the membrane and intercalate 
itself with nucleic acids (Reiger et al., 2011). 
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4.1.2 CFSE proliferation assay 
The CFSE (carboxyfluorescein succinimidyl ester) proliferation assay was designed to allow 
the monitoring of cell activity occurring over a longer period of time thus increasing sensitivity 
of detecting cell death (up to 5 days) (Jedema, Van der Werff, Barge, Willemze and 
Falkenburg, 2004). CFSE is a long lived fluorescent cell label; upon division of that cell, the 
daughter cells possess half the amount of CFSE tagged molecules (Quah and Parish, 2010: 
Jedema et al., 2004). The halving of florescence during mitosis is the principle the assay uses 
to the monitor the number of cell divisions labelled cells have undergone, through the 
identification of the decrease in the fluorescence of a cell through flow cytometry analysis 
(Quah and Parish, 2010). The proliferative or anti-proliferative activity of the common cockle 
and common whelk GAG extracts was unknown in healthy lymphocytes. This research utilised 
the CFSE proliferation assay in order to build on the information gained in the annexin V/PI 
apoptosis assays, and to further the identification of potential side effects from the GAG 
extracts. The CFSE proliferation assay is compatible for use with other fluorescent dyes and 
therefore allows for the identification of cell replications within individual cell types (Jedema, 
2004). In order to identify the actions of cisplatin, the cockle and the whelk extract treatments 
on the naïve and memory T-helper and cytotoxic T-cell populations, this research used 
fluorescently stained antibodies to identify individual cell types (naïve (CD45RA) and memory 
(CD45RO), T-helper (CD4) and cytotoxic T-cells (CD8)), as were used in the apoptosis assay.  
The CD45 RA (naïve) and RO (memory) antibodies were used in order to evaluate whether 
the cockle and whelk derived GAG extracts exerted different potencies on cells which had 
come into contact with and responded to antigens previously and those which had no prior 
encounters with antigens. 
4.2 Method 
4.2.1 Annexin V/ Propidium Iodide apoptosis assay 
The annexin V/ propidium iodide apoptosis assay was carried out as set out in method 2.5.1 
as per the manufacturer’s instructions. Antibody staining was also performed (as per method 
2.5) for the annexin V/PI assays, in order to get detailed information as to the type of cell 
death occurring and the individual cell types within the PBMC samples (both naïve and 
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stimulated) which may be affected by apoptosis, post treatment with either the cockle or 
whelk extracts or the cisplatin treatment. The annexin V/PI assays were carried out using all 
three cancer cell lines (MOLT-4, K562 and U698) and the naïve and PMA/ Ionomycin 
stimulated PBMCs. In all assays, cells were seeded at 1 x 106 cells/ml, and cisplatin was used 
as a control treatment comparison. The PBMC assays were carried out in line with the cancer 
cell assays and were dosed using the IC50 values obtained from the MTT assays. Doses used 
for the annexin V/PI assay were 6 µg/ml for cisplatin, 12 µg/ml for both the cockle extract and 
whelk extract treatments.  
As the K562 cell line has been described as having T-cell properties (Klein et al., 1976), the 
research stained for CD3+ populations of the K562 cell line, in order to gain insight into the 
effects of GAG isolates on T-cell specifically. However characterisation of the K562 cell line 
showed that very few K562 cells were positive for CD3 and so the whole population data only 
is displayed in the results section 4.3.1.1.2. The results obtained from the CD3+ K562 cells are 
demonstrated in the appendix section 8.2. 
All annexin V/PI assays were carried out in triplicate and repeated three times. Therefore the 
data displayed in the figures represents average values and the error bars shown represent 
SEM.  
4.2.2 CFSE proliferation assay 
The CFSE proliferation assay was carried out as per the manufacturers recommendations and 
as set out in method 2.5.2, antibody staining for individual cell types was also carried out as 
per method 2.5. Cells were seeded to 1 x 106 cells/ml for the cancer cell assays and for the 
PBMC assays. Cisplatin was used as a control treatment in all assays and was used at a dose 
of 6 µg/ml as per the IC50 value obtained from the MTT assays. The cockle and whelk extract 
treated cells were dosed with 12 µg/ml as per the IC50 values calculated from the MTT results.  
All CFSE proliferation assays were carried out in triplicate and repeated 3 times, therefore the 
data shown in the figures represents the averages of the repeats and error bars shown are 
representative of SEM.          
  
 133 
4.2.3 Annexin V/ Propidium Iodide apoptosis assay gating method  
Figure 4.1 and 4.2 show the gating process performed in order to establish the individual cell 
types present in the cancer cell lines (figure 4.1) or the PBMCs (figure 4.2).  
 
Figure 4.1 Raw data graph obtained from cancer cell line annexin V/PI apoptosis assay and the gating 
process involved. Identifies the raw data graph and gates drawn in a typical cancer cell line apoptosis 
assay, identifying the process of gating and how the stages of apoptosis were determined e.g. UL= late 
stage apoptosis, UR= mid stage apoptosis, LR= early stage apoptosis and LL= no apoptosis. The 
example shown is untreated and not stained with antibody in order to represent the initial placing of 
the gates. All apoptosis assays had a 3-day incubation period and N=3.  
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Figure 4.2 Raw data obtained from PBMC annexin V/PI apoptosis assay and the gating process 
involved. Identifies the raw data and gates drawn in a typical PBMC apoptosis assay in order to 
determine cell types and quantities and stage of apoptosis; where UL= late stage, UR= mid stage, LR= 
early stage and LL= no apoptosis. The example shown is untreated and antibody free in order to 
represent the initial placing of the gates. All apoptosis assays had a 3-day incubation period and N=3.  
For the labelling of the graphs Late (UL)= late, Mid (UR)= mid stage apoptosis, early (LR) = 
early stage apoptosis and no apoptosis (LL)= no cell death occurring.  
4.2.4 Method of obtaining peak numbers through the raw data graphs 
Figure 4.3 and 4.4 show the typical graphs obtained for the cancer cell lines (figure 4.3) or the 
PBMCs (figure 4.4). Proliferation results were obtained via the determination of the number 
of peaks in the control graphs. The peak number was then determined for the three 
treatments (cisplatin, cockle extract and whelk extract). Percentage proliferation was 
obtained by assuming the control cells were at 100% proliferation and then obtaining 
percentage proliferation for the treatment was done by dividing the proliferation peak 
number by the control peak number and multiplying by 100. 
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Figure 4.3 Raw data graphs obtained from cancer cell line using CFSE proliferation assay. The raw data 
graphs obtained in a typical cancer cell line proliferation assay, identifying the quantity of replications 
(each peak) each cell type has performed i.e. CD3+, in comparison to the untreated control. The 
example shown is untreated but stained with antibodies in order to represent the control number of 
replications for the cell line and treated with cisplatin. All cancer cell CFSE proliferation assays had a 
3-day incubation period and for cancer cell assays N=2. 
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Figure 4.4 Raw data obtained from PBMC CFSE proliferation assay. Identifies the raw proliferation 
peak data obtained from a typical unstimulated/ naïve PBMC assay in order to determine the 
proliferation in each cell type. The example shown is untreated and contains the antibodies in order 
to represent the control number of proliferations and cisplatin treated cells. All PBMC CFSE 
proliferation assays were incubated for a 3-day period and N=3. 
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4.3 Results  
4.3.1 Annexin V/ Propidium Iodide apoptosis assay results 
4.3.1.1 Cancer cell assays 
The annexin V/ propidium iodide apoptosis assay was carried out on all three cancer cell lines 
in order to establish any apoptotic responses to the treatment with novel GAG compounds. 
4.3.1.1.1 MOLT-4 cell line 
4.3.1.1.1.1 Entire MOLT-4 cell population 
Cisplatin (figure 4.5) demonstrated a 7.3% increase in MOLT-4 cell death, with the largest 
increase being in early stage apoptotic cell death (figure 4.5, p=0.4317). Whelk extract 
treatment (figure 4.5) caused the largest increase in cell death (13.8%) within the MOLT-4 cell 
line out of all three treatment methods. The largest increases were in mid stage apoptosis 
(p=0.0179) and early stage apoptosis (p=0.0310). This can be seen by the decrease in cells not 
undergoing cell death (figure 4.5, p=0.008). In figure 4.5 it can be noted that the cockle extract 
treatment brought about a 6% increase in MOLT-4 cells undergoing some stage of apoptosis. 
It can also be seen in figure 4.5 that the treatment with the cockle extract resulted in a 
decrease in the percentage of cell in the early apoptotic stages (p=0.0003), and an increase 
in late apoptotic cells (p=0.0345).  
The results of the entire MOLT-4 apoptosis assays correspond to that of the MTT assay, in 
that the whelk extract brought about the largest effect on the MOLT-4 cells compared with 
the cisplatin and cockle extract treatment. However, the cockle extract did bring about similar 
results to that of cisplatin with the largest increase in the percentage of cells undergoing late 
stage apoptosis compared to cisplatin; therefore, both GAG extracts appear to be effective 
when compared with cisplatin. 
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Figure 4.5 Average cell death activity in MOLT-4 cells obtained using the annexin V/PI apoptosis assay. 
Average percentage population graphs for MOLT-4 cells treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, absence of * indicates no significance.  
4..3.1.1.1.2 CD3+ MOLT-4 cell population 
As MOLT-4 cells are T-cell derived (McCaffrey, Smoler & Baltimore, 1973), the research 
focused on the CD3+ population of MOLT-4 cells to gain further insight on GAG effects on T-
cells specifically. Approximately 86% of untreated/ control MOLT-4 cells tested positive for 
CD3. Cisplatin (figure 4.6) identified an 81.5% increase in the percentage of MOLT-4 CD3+ cells 
that were not undergoing any form of cell death (p=0.0109). This was due to a large decrease 
in the percentage of cells undergoing early stage apoptosis (p=0.0576) and a decrease in mid 
stage apoptosis (p=0.1097). Figure 4.6 also identifies a large increase in cells not undergoing 
cell death post treatment with the cockle extract (figure 4.6, p=<0.0001).Figure 4.6 also 
identifies that the cockle extract resulted in a decrease in early apoptotic cells (p=0.0478) In 
a similar way the CD3+ MOLT-4 cells experienced a 31% increase in cells which weren’t in any 
stage of cell death post whelk extract treatment (figure 4.6, p=0.4549) and a decrease in the 
percentage of early apoptotic cells (figure 4.6, p=0.0478).  
* 
* 
*** 
* 
** 
 139 
The results in figure 4.6 identify that all three treatment methods resulted in increases in non-
apoptotic CD3+ MOLT-4 cells. Treatment of CD3+ MOLT-4 cells with the cockle extract resulted 
in the largest increase in non-apoptotic cells in comparison to the cisplatin treatment and 
treatment with the whelk extract. The whelk extract treated CD3+ MOLT-4 cells however, 
experienced the least percentage increase in non-apoptotic cells in comparison to the 
cisplatin and cockle extract treatments (figure 4.6). As from the results shown in figures 4.5 
and 4.6 the GAG extracts exerted similar and in the case of whelk treatment better effects on 
the entire MOLT-4 cell populations and the CD3+ MOLT-4 cell population (in the case of the 
whelk extract treatment), which was supported by the MTT assay results. 
 
Figure 4.6 Average cell death activity in CD3+ MOLT-4 cells obtained using the annexin V/PI apoptosis 
assay. Average percentage population graphs for CD3+ MOLT-4 cells treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 
3 days. Where N=3, error bars show SEM, significance is denoted by *, absence of * indicates no 
significance. 
 
 
* * 
* 
*** 
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4.3.1.1.2 K562 cell line 
4.3.1.1.2.1 Entire K562 cell line 
As K562 cells have a tendency to aggregate they proved to be problematic when performing 
flow cytometry analysis on them. Therefore firm pipetting and careful gating was employed 
in order to separate cells and avoid duplicate readings when performing flow cytometric 
analysis. 
Figure 4.7 shows that cisplatin treatment (figure 4.7) brought about the largest increase in 
cells undergoing some stage of apoptosis (9.5%); this is noted through the corresponding drop 
in cells which were not undergoing any form of cell death (p=0.0756). There was also a slight 
drop in cells experiencing late stage apoptosis (p=0.0497). There was also a corresponding 
rise in the percentage of cells in the early stages of apoptosis (p=0.1540) which saw the largest 
increase however there was also a slight increase in the percentage of cells in the mid stages 
of apoptosis (p=0.1464). Treatment with the cockle extract brought about a 3.6% increase in 
apoptosis (seen in figure 4.7). This increase was seen mainly in the early stage of apoptosis 
(p=0.0925) but there was also a slight rise in the percentage of cells in the mid stages of 
apoptosis (p=0.0848). In a similar way to cisplatin treatment the cockle extract brought about 
a small decrease in the percentage of late apoptotic cells (p=0.0713). Finally figure 4.7 
identifies the whelk extract treatment (figure 4.7) resulted in a small increase in the 
percentage of cells which were not undergoing any stage of apoptosis (p=0.5835). Whelk 
extract treatment also brought about small decreases in the percentage of cells undergoing 
late stage apoptosis (figure 4.7, p=0.0497), mid stage apoptosis (figure 4.7, p=0.0292) and 
early stage apoptosis (figure 4.7, p=0.022) This also corresponds to the MTT assay results as 
the whelk extract did not elicit much of a response after a 3-day incubation period in the K562 
MTT assays either.  
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Figure 4.7 Average cell death activity in K562 cells obtained using the annexin V/PI apoptosis assay. 
Average percentage population graphs for K562 cells treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, absence of * indicates no significance. 
Although the GAGs did appear to exert some effect on the K562 cell line cisplatin treatment 
appeared to be the most effective treatment method on the K562 cell line in the apoptosis 
assay. However the tendency of K562 cells to aggregate may have potentially caused some 
issues with the flow cytometry assays.  
4.3.1.1.3 U698 cell line 
4.3.1.1.3.1 Entire U698 cell population 
In the U698 cell population cisplatin treatment (figure 4.8) brought about a 1.3% decrease in 
cells which were not undergoing cell death (p=0.4781). Figure 4.8 also demonstrates slight 
decreases in the percentage of U698 cells that were undergoing late stage apoptosis 
(p=0.0544) or mid stage apoptosis (p=0.0046). This decrease constituted to the 5% rise in 
U698 cells undergoing early stage apoptosis also noted in figure 4.8, (p=0.083).  
* * 
* 
* 
* 
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The cockle extract treatment (figure 4.8) brought about slight increases in the percentage of 
mid stage apoptotic (p=0.0516) and late stage apoptotic (p=0.0904) U698 cells. There was 
also a slight decrease in the percentage of U698 cells undergoing the early stages of apoptosis 
post cockle extract treatment (figure 4.8, p=0.1523). The whelk extract treatment brought 
about the greatest effect on the U698 cell line with a 15% decrease in cells not undergoing a 
form of cell death (figure 4.8, p=0.0426). Post treatment with the whelk extract there was a 
9.5% increase in U698 cells undergoing early stage apoptosis (figure 4.8, p=0.5557) and a 4.6% 
rise in the percentage of U698 cells undergoing the mid stages of apoptosis (figure 4.8, 
p=0.0165). There was also a slight rise in the percentage of U698 cells undergoing late stage 
apoptosis post whelk extract treatment (figure 4.8, p=0.3688).  
These results correspond to what was noted in the MTT assay results; the whelk extract 
exerted a profound effect on the cell line even when compared to the known drug cisplatin.  
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Figure 4.8 Average cell death activity in U698 cells obtained using the annexin V/PI apoptosis assay. 
Average percentage population graphs for U698 cells treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, absence of * indicates no significance. 
4.3.1.1.3.2 CD19+ U698 population  
The U698 cell line has been described as being of B-cell origin (Godal, 1982), therefore the 
research focused on the CD19+ populations of the U698 cell line, in order to establish GAG 
isolate effects on B-cells specifically. Approximately 99% of U698 cells tested positive for 
CD19. Figure 4.9 demonstrates that cisplatin treatment resulted in around a 1.4% increase in 
the percentage of CD19+ U698 cells undergoing a form of cell death; this can be seen through 
the decrease in cells which were not undergoing any form of cell death (figure 4.9, p=0.2184). 
This resulted in a 1.4% increase in the percentage of CD19+ U698 cells undergoing early stage 
apoptosis (figure 4.9, p=0.0264), there were also minor increase and a minor decrease in the 
percentage of cells undergoing mid stage apoptosis (p=0.3612) and late stage apoptosis 
(p=0.1290) respectively (figure 4.9).  
* 
* 
* 
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The treatment with cockle extract resulted in a larger increase in the percentage of CD19+ 
U698 cells which were undergoing a form of cell death, which can be mainly seen in the 
percentage of CD19+ U698 cells undergoing the early stages of apoptosis (figure 4.9, 
p=0.4121). The whelk extract treatment elicited the largest increase in cell death in the CD19+ 
U698 cell population post treatment; this can be seen in the decrease in the percentage of 
cells which were not undergoing a form of cell death (figure 4.9, p=0.1884). The whelk extract 
brought about increases of 1.8%, 0.7% and 5% in the percentages of CD19+ U698 cells which 
were undergoing early (p=0.3143) and mid stage (p=0.5577) apoptosis and late stage 
apoptosis (p=0.5089) respectively (figure 4.9). 
These results support the initial findings of the MTT assay, that the whelk extract exerts the 
most effect on the U698 cell population. 
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Figure 4.9 Average cell death activity in CD19+ U698 cells obtained using the annexin V/PI apoptosis 
assays. Average percentage population graphs for CD19+ U698 cells treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 
3 days. Where N=3, error bars show SEM, significance is denoted by *, absence of * indicates no 
significance. 
4.3.1.2 Isolated PBMC assays 
4.3.1.2.1 Unstimulated/naïve PBMC assays 
The use of flow cytometry allowed for the evaluation of 6 colours at once, therefore the 
research characterised the potency of GAGs to both naïve (CD45RA+) and memory (CD45RO+) 
T-cells. Therefore these antibodies were used in a panel with CD8 and CD4 to differentiate 
cytotoxic and helper T-cells specifically and use remaining fluorescence channels for the 
annexin V and PI apoptosis detection in all these populations. For logistical reasons this study 
focussed on T-cells therefore, the B cell marker CD19 was not used during the PBMC assays; 
however, it is noted that the U698 (B-cell line) did show sensitivity to the GAG isolates, 
therefore this would be a future line of interest for the lab research team. 
* 
 146 
Figure 4.10 shows that cisplatin treatment decreased the percentage of lymphocytes not 
undergoing cell death by around 14% (p=0.3400). This decrease corresponded to increases in 
the percentage of lymphocytes which were undergoing late stage apoptosis (p=0.4923), mid 
stage apoptosis (p=0.9309) and early stage apoptosis (p=0.2082) of 7%, 6.5% and 0.57% 
respectively (figure 4.10).  
Cockle extract treatment (figure 4.10) resulted in a rise of around 11.9% in lymphocytes 
undergoing a form of cell death (p=0.4158). Smaller increases of 1.8% and 0.95% could be 
seen in the percentage of lymphocytes undergoing early stage apoptosis (figure 4.10, 
p=0.1804) and late stage apoptosis respectively (figure 4.10, p=0.4248). Finally figure 4.10, 
identifies that whelk extract treatment results in the smallest decrease in the percentage of 
cells which were not undergoing cell death with a drop of 10.97% (figure 4.10, p=0.3417). This 
treatment method also resulted in a small drop of 3% in the percentage of lymphocytes which 
were undergoing late stage apoptosis (figure 4.10, p=0.4957). In a similar way to the cockle 
extract treatment, the largest increase in cell death was seen in the mid stages of apoptosis 
post whelk extract treatment (figure 4.10, p=0.7155); this accounted for 13% of the increase 
in cell death. Finally, whelk extract treatment brought about a 1% rise in the percentage of 
lymphocytes which were undergoing the early stages of apoptosis (figure 4.10, p=0.1629). 
From these results it can be determined that the whelk extract elicited the least damage to 
the lymphocyte population of the naïve PBMCs. Although the largest increase in mid stage 
was post whelk extract treatment it can be seen in figure 4.10 that some of this increase was 
related to a decrease in the percentage of lymphocytes undergoing late stage apoptosis. The 
cockle extract treatment also resulted in less damage to the naïve PBMC lymphocytes than 
the known drug cisplatin; this could suggest that the GAG extracts may provide a beneficial 
treatment option which results in less damage to healthy cells. Although as cell death levels 
were similar to those in the MOLT-4 cell population seen in figures 4.6 and 4.5, it is important 
to identify which cell populations are sensitive to the GAG treatment.  
 147 
 
Figure 4.10 Average cell death activity in the lymphocyte population of naïve PBMCs obtained using 
the annexin V/PI apoptosis assays. Average percentage population graphs for the lymphocyte 
population of naïve PBMCs treated with the IC50 dose of cisplatin, cockle extract and whelk extract (6 
µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell death that the cells are in where 
early= early stages of apoptosis, mid= mid stages of apoptosis, Late= late stage apoptosis and no 
apoptosis= no cell death. Using an incubation period of 3 days. Where N=3, error bars show SEM, 
significance is denoted by *, the absence of * indicates no significance. 
Figure 4.11 identifies that post cisplatin treatment there was a 6.59% increase in the 
percentage of memory T-helper cells (CD4+CD45RO+) experiencing a form of cell death. Late 
stage apoptotic cells (figure 4.11, p=0.4226) had the largest increase in memory T-helper cells 
with a 5.6% increase in the percentage of memory T-helper cells in this stage of apoptosis. 
There were also minor increases in the percentage of memory T-helper cells experiencing the 
early (p=0.1986) and mid stages (p=0.8410) of apoptosis (as represented in figure 4.11).  
The cockle extract treatment (figure 4.11) resulted in a 4.23% increase in the percentage of 
memory T-helper cells experiencing cell death. There was also a minor decrease in the 
percentage of memory T-helper cells experiencing mid stage apoptosis (p=0.0712) and no 
change in the percentage of late stage apoptotic cells (p=0.4807) (figure 4.11). Treatment 
with the whelk extract (figure 4.11) resulted in a small 1.73% decrease in the percentage of 
memory T-helper cells which were not experiencing cell death (p=0.6579). Figure 4.11 also 
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demonstrates a minor increase in the percentage of memory T-helper cells in the early stages 
of apoptosis (figure 4.11, p=0.1789). The memory T-helper cell population also resulted in a 
0.31% decrease in the percentage of cells in the mid stages of apoptosis (p=0.5631) and a 
1.98% increase in the percentage of late stage apoptotic (p=0.4226) memory T-helper cells 
post whelk extract treatment (figure 4.11).  
In terms of memory T-helper cells both the GAG extracts exerted less of an effect on the 
induction of cell death than the known anti-cancer drug cisplatin. Although all the changes in 
the memory T-helper cell population were small, the whelk extract treatment resulted in 
almost six times less cell death induction compared to cisplatin. This again could suggest that 
GAG treatment could provide a kinder treatment method. Healthy lymphocytes are made up 
of around 30-50% memory cells and so to capture any difference in sensitivity to GAG action 
between naïve and memory cells, both antibodies were used.  
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Figure 4.11 Average cell death activity in the memory T-helper cell population (CD4+CD45RO+) of naïve 
PBMCs obtained using the annexin V/PI apoptosis assay. Average percentage population graphs for 
the memory T-helper cell population of naïve PBMCs treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, the absence of * indicates no significance. 
Cisplatin treatment (figure 4.12) resulted in a 9.5% decrease in the percentage of cells not 
experiencing cell death (p=0.1641), corresponding to this there was an 8.8% increase in naïve 
T-helper cells (CD4+CD45RA+) experiencing late stage apoptosis (p=0.5031) post cisplatin 
treatment. There were also minor increases in the percentage of naïve T-helper cells 
undergoing mid stage apoptosis (p=0.6977) and early stage apoptosis (p=0.1788) post 
cisplatin treatment (figure 4.12).  
The cockle extract treatment (figure 4.12) resulted in decreases in the percentage of naïve T-
helper cells not experiencing cell death (p=0.5525), experiencing mid stage apoptosis 
(p=0.2302) and early stage apoptosis (p=0.1788) of 5.24%, 0.31% and 0.02% respectively 
(seen in figure 4.12). These decreases resulted in a 5.57% increase in the percentage of late 
apoptotic naïve memory T-cells (figure 4.12, p=0.2302). In a similar pattern to the cockle 
extract the whelk extract treatment (figure 4.12) resulted in decreases in the percentage of 
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naïve T-helper cells experiencing early apoptotic stages (p=0.1808), mid apoptotic stages 
(p=0.2582) and cells which were not experiencing cell death (p=0.4384). These decreases 
were 0.02%, 0.18% and 5.19% respectively. In correspondence with this the percentage of 
naïve T-helper cells experiencing late stage apoptosis increased by 5.39% (figure 4.12, 
p=0.2505) post whelk extract treatment.  
From these results again, the GAG extracts appear to cause less damage to the naive T-helper 
cell population when compared to cisplatin. Suggesting that GAG extract treatment may 
result in less damage to healthy cells and therefore may provide a kinder treatment option 
compared to current chemotherapy drugs.  
 
Figure 4.12 Average cell death activity in the naïve T-helper cell population (CD4+CD45RO+) of naïve 
PBMCs obtained using the annexin V/PI apoptosis assay. Average percentage population graphs for 
the naïve T-helper cell population of naïve PBMCs treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, the absence of * indicates no significance. 
In figure 4.13 it can be seen that cisplatin treatment results in a 26.41% decrease in the 
percentage of memory cytotoxic T-cells (CD8+CD45RO+) not undergoing any form of cell death 
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(p=0.2927). There was also a 7% decrease in the percentage of memory cytotoxic T-cells 
which were experiencing late stage apoptosis (p=0.3217). These declines resulted in a 26% 
increase in the percentage of memory cytotoxic T-cells in the mid stages of apoptosis (figure 
4.13, p=0.3155) and a 7.4% rise in the percentage of memory cytotoxic T-cells in the early 
stages of apoptosis (figure 4.13, p=0.0399).  
Treatment with the cockle extract (figure 4.13) resulted in the largest decrease in the 
percentage of memory cytotoxic T-cells not undergoing apoptosis of 30.72% (p=0.3590). The 
memory cytotoxic T-cell population experienced a 19% increase in the population of cells in 
the early stages of apoptosis (figure 4.13, p=0.0399) post cockle extract treatment. The 
memory cytotoxic T-cells in the mid stages of apoptosis also increased by 21.28% (figure 4.13, 
p=0.3279). Finally, there was a 9.6% decrease in the percentage of memory cytotoxic T-cells 
in the late stages of apoptosis (figure 4.13, p=0.3487). Whelk extract treatment (figure 4.13) 
resulted in the least induction of cell death in the memory cytotoxic T-cell population. There 
was a minor decrease in cells which were not undergoing any form of cell death of 0.29% 
(figure 4.13, p=0.9538). Late stage apoptosis in memory cytotoxic T-cells was decreased by 
12.41% (figure 4.13, p=0.1880). Memory cytotoxic T-cells in mid apoptotic stages increased 
by 9.25% (figure 4.13, p=0.6272); while cells in the early stages of apoptosis increased by 
3.46% (figure 4.13, p=0.0379).  
In terms of memory cytotoxic T-cells the cockle extract resulted in the largest decrease in cells 
which were not undergoing a form of cell death when compared to other treatment methods 
tested. The whelk extract has consistently been the mildest treatment method again proving 
to cause the least damage to the PBMC population. 
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Figure 4.13 Average cell death activity in the memory cytotoxic T-cell population (CD8+CD45RO+) of 
naïve PBMCs obtained using the annexin V/PI apoptosis assay. Average percentage population graphs 
for the memory cytotoxic T-cell population of naïve PBMCs treated with the IC50 dose of cisplatin, 
cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of 
cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, 
Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. 
Where N=3, error bars show SEM, significance is denoted by *, absence of * indicates no significance. 
In figure 4.14 it can be seen that cisplatin treatment results in a 26% decline in the percentage 
of naïve cytotoxic T-cells (CD8+CD45RA+) experiencing no form of cell death (figure 4.14, 
p=0.2457). This decline brought about a 7% increase in the percentage of naïve cytotoxic T-
cells in the early stages of apoptosis (figure 4.14, p=0.1652). Also, cisplatin treatment resulted 
in a 15.7% increase in the percentage of cells in the mid stages of apoptosis (figure 4.14, 
p=0.3767). Finally, the treatment with cisplatin resulted in a 3.27% increase in the percentage 
of late apoptotic naïve cytotoxic T-cells (figure 4.14, p=0.3900).  
As was seen in the memory cytotoxic T-cells the cockle extract treatment (figure 4.14) also 
resulted in the largest decline of naïve cytotoxic T-cells not undergoing any form of cell death 
(p=0.3590); this decline was of 33.78%. there was also a minor increase in the percentage of 
naïve cytotoxic T-cells in the early stages of apoptosis (p=0.1471) and in cells experiencing 
late stage apoptosis (p=0.4226) of 0.6% and 0.5% respectively, post treatment with the cockle 
* 
* 
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extract (figure 4.14). The cockle extract treatment also brought about a 0.65% decline in the 
percentage of naïve cytotoxic T-cells in the mid stages of apoptosis (figure 4.14, p=0.4125). 
Whelk extract treatment again resulted in the least induction of cell death in the naïve 
cytotoxic T-cell population. The whelk extract treatment reduced the cells which were not 
undergoing any form of cell death by 2.55% (figure 4.14, 0.6556) and reduced the percentage 
of cells in mid stage apoptosis by 0.12% (figure 4.14, 0.4472). Also figure 4.14 identifies that 
the whelk extract treatment increased the population of early apoptotic naïve cytotoxic T-
cells by 0.95% (figure 4.14, p=0.1586). Also, there was a 1.73% increase in late apoptotic naïve 
cytotoxic T-cells post whelk extract treatment (figure 4.14, p=0.1835).  
As with what was seen in the memory cytotoxic T-cell population the whelk extract also 
induced the least amount of cell death when compared to cisplatin and cockle extract 
treatments. However, when compared to cisplatin the cockle extract did elicit slightly more 
cell death compared to cisplatin in the naïve cytotoxic T-cell population. The cytotoxic T-cell 
populations appear to be more susceptible to chemotherapy treatments than T-helper cell 
populations with the memory population appearing the most susceptible. The whelk extract 
however induced the fewest changes in the populations and so appears to be the more 
favourable therapeutic possibility.  
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Figure 4.14 Average cell death activity in the naïve cytotoxic T-cell population (CD8+CD45RA+) of naïve 
PBMCs obtained using the annexin V/PI apoptosis assay. Average percentage population graphs for 
the naïve cytotoxic T-cell population of naïve PBMCs treated with the IC50 dose of cisplatin, cockle 
extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell 
death that the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= 
late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by * the absence of * indicates no significance. 
4.1.3.2.2 PMA/ ionomycin stimulated PBMC assays 
All the naïve lymphocyte (unstimulated) assays were repeated using activated T-cells in order 
to assess if naturally proliferating cells (a model of infection/inflammation) were targeted.  
The treatment with cisplatin (figure 4.15) caused a small reduction in the percentage of 
lymphocytes which were either late stage apoptotic (1.07%, P= 0.2466), in mid stage 
apoptosis (5.64%, p= 0.3663) or which were not experiencing any form of cell death (1.94%, 
p=0.4571) as can be seen in figure 4.15. In line with those decreases the percentage of 
lymphocytes which were experiencing early apoptotic stages (figure 4.15) increased by 8.65% 
post cisplatin treatment (p=0.027). 
The lymphocyte population had minor decreases in late stage apoptotic and mid stage 
apoptotic cells by 0.92% (p=0.2369) and 0.72% (p=0.3977) respectively post cockle extract 
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treatment (figure 4.15). The percentage of lymphocytes not experiencing cell death also 
decreased by 1.73% post cockle treatment (figure 4.15, p=0.4656). In correspondence to 
these decreases the percentage of lymphocytes experiencing the early stages of apoptosis 
increased by 3.37% (figure 4.15, p=0.027). Upon treatment with the whelk extract the 
lymphocyte population experienced a 0.56% decrease in late stage apoptotic lymphocytes 
(figure 4.15, p=0.6808). There were also decreases of 0.13% and 2.05% in the population of 
lymphocytes undergoing either mid stage apoptosis (p=0.4162) or which were not 
undergoing any form of cell death (p=0.0892) respectively, which can be in figure 4.15 
respectively. Post whelk extract treatment there was also a 2.75% increase in the percentage 
of lymphocytes undergoing the early stages of apoptosis (figure 4.15, p=0.0309).    
Figure 4.15 Average cell death activity in the lymphocyte population of stimulated PBMCs obtained 
using the annexin V/ PI apoptosis assay. Average percentage change graphs for the lymphocyte 
population of stimulated PBMCs treated with the IC50 dose of cisplatin (A), cockle extract (B) and 
whelk extract (C) (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the stage of cell death that 
the cells are in where early= early stages of apoptosis, mid= mid stages of apoptosis, Late= late 
stages of apoptosis and no apoptosis= no cell death. Using an incubation period of 3 days. Where 
N=3, error bars show SEM, significance is denoted by *, the absence of * indicates no significance. 
Cisplatin treatment (figure 4.16) caused a minor increase (0.03%) late stage apoptotic 
memory T-helper cells (p=0.4226) as well as a minor decrease in memory T-helper cells which 
* 
* * 
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were undergoing mid stage apoptosis (0.26%, p=0.3188), as can be seen figure 4.16. There 
was also a decrease of 3.35% in the cells which were not undergoing any form of cell death 
(p=0.0970); this decrease corresponded with a 3.57% increase in the percentage of memory 
T-helper cells experiencing early apoptotic stages post cisplatin treatment (noted in figure 
4.16, p=0.0502).  
Upon treatment with the cockle extract the memory T-helper cell population had no change 
in the percentage of cells undergoing late stage apoptosis (figure 4.16, p=0.4411). The 
treatment resulted in minor decreases in the percentage of memory T-helper cells 
undergoing mid stage apoptosis or the early stages of apoptosis, these decreases were 0.37% 
(p=0.2302) and 0.32% (p=0.0502) respectively (figure 4.16). After treatment with the cockle 
extract the percentage of memory T-helper cells which were not undergoing any form of cell 
death increased by 0.7% (figure 4.16, p=0.1196). There was no change in the percentage of 
late stage apoptotic memory T-helper cells post treatment with the whelk extract (figure 4.16, 
P=0.4411). There was a 0.14% decrease in the percentage of memory T-helper cells 
undergoing mid stage apoptosis post whelk treatment (figure 4.16, P=0.3002). After whelk 
extract treatment there was a 3.18% increase in the percentage of memory T-helper cells 
experiencing the early stages of apoptosis, this is represented in figure 4.16, P=0.0502. The 
treatment with the whelk extract resulted in a 3.04% decrease in the percentage of memory 
helper T-cells which were not currently undergoing any stage of cell death (figure 4.16, 
P=0.0603).   
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Figure 4.16 Average cell death activity in the memory T-helper cell (CD4+CD45RO+) population of 
stimulated PBMCs obtained using the annexin V/ PI apoptosis assay. Average percentage population 
graphs for the memory T-helper cell population of stimulated PBMCs treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stages of apoptosis and no apoptosis= no cell death. Using an incubation period 
of 3 days. Where N=3, error bars show SEM, significance is denoted by *, the absence of * indicates 
no significance. 
The naïve T-helper cell population showed minor increases of 0.04% (p= 0.4226) and 0.06% 
(p=0.1962) in the populations of cells which were late stage apoptotic or in the mid stages of 
apoptosis respectively post treatment with cisplatin (figure 4.17). The naïve T-helper cell 
population which were not undergoing a form of cell death were also decreased by 10.02%, 
as seen in figure 4.17, p=0.0429. Post cisplatin treatment the population of naïve T-helper 
cells undergoing early stage apoptosis increased by 9.93% (figure 4.17, p=0.2662).  
The cockle extract treatment (figure 4.17) instigated no change to the percentage of naïve T-
helper cells undergoing either late stage apoptosis (p= 0.4411) or the mid stages (p=0.1962) 
of apoptosis. The treatment resulted in an equal 3.48% decrease in naïve T-helper cells which 
were not undergoing cell death (p=0.0429), to the 3.48% increase in naïve T-helper cells in 
the early stages of apoptosis (p=0.4732) (figure 4.17). The naïve T-helper cell population 
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identified no change in the percentage of cells experiencing either late stage apoptosis 
(p=0.4411) or mid stage apoptosis (p= 0.1962) post whelk extract treatment (figure 4.17). 
After treatment with the whelk extract there was a 3.78% increase in naïve T-helper cells 
which were undergoing the early stages of apoptosis (figure 4.17, p=0.1174). Corresponding 
to this there was a 3.78% drop in the percentage of cells not undergoing cell death (figure 
4.17, p=0.0429).  
 
Figure 4.17 Average cell death activity in the naïve T-helper cell (CD4+CD45RA+) population of 
stimulated PBMCs obtained using the annexin V/ PI apoptosis assay. Average percentage population 
graphs for the naïve T-helper cell population of stimulated PBMCs treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 
3 days. Where N=3, error bars show SEM, significance is denoted by *, the absence of * indicates no 
significance. 
The memory cytotoxic T-cell population experienced a 2% decline in the number of late stage 
apoptotic cells (p=0.2432) and a 6.51% decrease in the percentage of cells undergoing mid 
stage apoptosis (p=0.3835) post cisplatin treatment (figure 4.18). The percentage of memory 
cytotoxic T-cells which experienced no form of cell death increased by 0.6% (figure 4.18, 
* 
* * 
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p=0.2285) and those in the early stages of apoptosis increased by 7.91% upon treatment with 
cisplatin (figure 4.18, p=0.0593). 
After treatment with the cockle extract (figure 4.18) the memory cytotoxic T-cell population 
had a 1.74% (p=0.2356) and a 0.57% (p=0.4071) decrease in the percentage of cells 
undergoing late stage apoptosis and mid stage apoptosis respectively (figure 4.18).  Post 
treatment there was also a 0.9% decrease in the memory cytotoxic T-cells undergoing no form 
of cell death (p=0.0634). The percentage of memory cytotoxic T-cells in early stage apoptosis 
increased by 3.21% post cockle extract treatment (figure 4.18, p=0.0445).  Upon treatment 
with the whelk extract (figure 4.18) the memory cytotoxic T-cell population experienced 
1.19% (p=0.2649), 0.11% (p=0.4188) and 1.67% (p=0.0171) declines in the percentages of cells 
undergoing late stage apoptosis, mid stage apoptosis or no cell death respectively (figure 
4.18).The memory cytotoxic T-cell population also had a 2.97% increase in cells in the early 
stages of apoptosis post whelk treatment (p=0.0448).  
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Figure 4.18 Average cell death activity in the memory cytotoxic T-cell (CD8+CD45RO+) population of 
stimulated PBMCs obtained using the annexin V/ PI apoptosis assay. Average percentage population 
graphs for the memory cytotoxic T-cell population of stimulated PBMCs treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stages of apoptosis and no apoptosis= no cell death. Using an incubation period 
of 3 days. Where N=3, error bars show SEM, significance denoted by *, the absence of * indicates no 
significance. 
The naïve cytotoxic T-cell population had a 0.88% (p=0.2619) increase in the percentage of 
cells not undergoing cell death after cisplatin treatment; this is shown in figure 4.19. The naïve 
cytotoxic T-cell population also experienced drops in the percentage of cells undergoing both 
late stage apoptosis (2.2%, p=0.2430) and mid stage apoptosis (5.57%, p=0.3841). The 
declines were in line with a 6.9% increase in the percentage of naïve cytotoxic T-cells which 
were experiencing early apoptotic stages which are represented figure 4.19, p=0.0453.  
The treatment with the cockle extract (figure 4.19) resulted in 2.05% (p=0.2329) and 0.91% 
(p=0.3943) decreases in the percentages of naïve cytotoxic T-cells undergoing late stage 
apoptotic cell death or mid stage apoptosis respectively, this can be seen in figure 4.19. Post 
treatment with the cockle extract the percentage of cells in early stage apoptosis increased 
by 3.65% (p=0.0334). Figure 4.19 identifies the naïve cytotoxic T-cell population not 
* * 
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undergoing cell death decreased by 0.7% (p=0.0922) post cockle extract treatment. After 
treatment with the whelk extract the naïve cytotoxic T-cell population experienced a 1.49% 
(p=0.2529) and 2.35% (p= 0.0171) decline in the percentage of cells undergoing late stage 
apoptosis or no cell death respectively (figure 4.19). While the percentages of naïve cytotoxic 
T-cells undergoing mid stage apoptosis (p= 0.4436) or early stage apoptosis (p=0.0409) 
increased by 0.68% and 3.16% respectively post whelk extract treatment (figure 4.19). 
 
Figure 4.19 Average cell death activity in the naïve cytotoxic T-cell (CD8+CD45RA+) population of 
stimulated PBMCs obtained using the annexin V/ PI apoptosis assay. Average percentage population 
graphs for the naïve cytotoxic T-cell population of stimulated PBMCs treated with the IC50 dose of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing the 
stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 
3 days. Where N=3, error bars show SEM, significance is denoted by *, the absence of * indicates no 
significance. 
Minimal changes in cell death in the lymphocyte population (figure 4.15) occurred which is 
further reflected in the family populations with small changes in cell death and larger 
variations in stages indicate that the naturally proliferating cells CD4, CD8, RO and RA 
populations are not targeted by GAG extract treatments. The whelk extract appeared to exert 
* * * 
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the most beneficial effect on the cancer cells while exerting minimal effect on the naïve and 
activated PBMC populations.  
 4.3.2 CFSE Proliferation assay results 
The CFSE proliferation assays were carried out on the MOLT-4 and U698 cell lines, the K562 
cell line was ruled out of subsequent assays at this stage due its nature to aggregate. 
4.3.2.1 Cancer cell assays 
4.3.2.1.1 MOLT-4 cell line 
4.3.2.1.1.1 Entire MOLT-4 population 
Figure 4.20 identifies that the whelk extract (yellow bar) treatment reduced proliferation by 
the largest amount in the entire MOLT-4 population. A reduction of 6.8% in comparison to 
the control (blue bar), this can also be seen in the blue bar in the control: whelk section of 
figure 4.21 (p=0.8743). Both the cockle extract (grey bar, figure 4.20) and cisplatin treatment 
(orange bar, figure 4.20) have increases in proliferation in comparison to the control (blue 
bar, figure 4.20). This can also be seen in the blue bars in the control: cis (p=0.5) and control: 
cockle sections (p=0.8743) of figure 4.21. In figure 4.21 it can be seen that the cockle extract 
treatment increased proliferation in the MOLT-4 cell line by the least amount in comparison 
to the cisplatin treatment (blue bar, cockle: cis section, p=0.6575). 
The results of the CFSE proliferation assay in the entire MOLT-4 cell population further 
confirm that the whelk extract treatment exerted the most potent effect on the MOLT-4 cell 
line, as was also seen in both the MTT and annexin V/PI apoptosis assays. 
4.3.2.1.1.2 CD3+ MOLT-4 cell population 
In figure 4.20 it can be noted that cisplatin had the lowest percentage of proliferation (orange 
bar, p=0.0704). While the cockle extract had the second lowest proliferation percentage 
compared to the control (figure 4.20, grey bar, p=0.0424). The whelk extract treatment 
(yellow bar, figure 4.20, p=0.9576) had the largest percentage proliferation in comparison to 
the cisplatin (p=0.458) and cockle extract treatment, which can also be seen in the orange bar 
in figure 4.21.  
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The results of the CD3+ proliferation assays identify that, although in the annexin V/ PI 
apoptosis assay the whelk extract exerted the least increase in non-apoptotic cells, the whelk 
extract results in the largest amount of proliferation in the CD3+ MOLT-4 cells. While the 
cisplatin treatment in the apoptosis assays resulted in the largest increase in non-apoptotic 
CD3+MOLT-4 cells, in the CFSE proliferation assay the cisplatin treatment resulted in the least 
percentage proliferation in the CD3+MOLT-4 cells. 
 
Figure 4.20. Average proliferation in MOLT-4 cells obtained using the CFSE proliferation assay. Average 
percentage proliferation graph for MOLT-4 cells treated with the IC50 dose of Cisplatin (orange bars), 
cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml and 12 µg/ml 
respectively). Control/ untreated cells (blue bars) were used as a comparison and were therefore 
considered to be 100% proliferation. Using an incubation period of 3-days. Where N=2, percentage 
proliferation was calculated in relation to the untreated cells and error bars show SEM, significance is 
denoted by *, the absence of * indicates no significance.  
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Figure 4.21. Average proliferation differences in MOLT-4 cell line obtained using the CFSE proliferation 
assay. Average percentage proliferation differences and treatment comparison graph for MOLT-4 cells 
treated IC50 doses of cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml 
respectively). Showing proliferation differences against treatment comparisons between the three 
treatment types and the untreated control cells. Using an incubation period of 3 days. Where N=2, 
percentage difference in cells was calculated based on the comparison treatment e.g. where cis: whelk 
is a comparison of the whelk extract proliferation to the proliferation in cisplatin treated cells, and 
error bars show SEM, significance is denoted by *, the absence of * indicates no significance.  
4.3.2.1.2 U698 cell line 
4.3.2.1.2.1 Entire U698 population 
Figure 4.22 identifies that cockle extract treated U698 cells had the lowest percentage of 
proliferation in the entire cell population (grey bar, figure 4.22) in comparison to the control 
(p=0.0182) and the other treatment methods. Figure 4.23 also shows that the cockle extract 
has the largest percentage difference in proliferation when compared to the other treatment 
methods and the control (blue bars in control: cockle, cockle: cis, p=0.3057, and cockle: whelk 
sections of figure 4.23). The whelk extract treatment also had a low percentage of 
proliferation in comparison to the cisplatin treatment (p=0.3346) and the control (p=0.0243) 
(figure 4.22, yellow bar) this can also be seen in the control: whelk and cis: whelk sections of 
figure 4.23 (blue bars). Both the cockle and the whelk extract treatments exhibit less than half 
the proliferation percentage in the entire U698 population in comparison to cisplatin 
treatment (orange bar figure 4.22). Cisplatin treatment did however show a decrease in 
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proliferation in comparison to the untreated cells as can be seen by the orange and blue bars 
in figure 4.22 respectively and can also be seen in the control: cis section of figure 4.23 (blue 
bars) (p=0.4455).  
4.3.2.1.2.2 CD19+ U698 cell population 
As seen in the entire U698 cell population, in the CD19+ population the cockle extract treated 
cells (grey bar, figure 4.22, p=0.0487) exhibited the lowest level of proliferation. Similar to the 
entire population the whelk extract treated CD19+ U698 cells (yellow bar, figure 4.22) also 
had a lower percentage proliferation compared to the control (blue bar figure 4.22, p=0.0487) 
and cisplatin treated cells (orange bar, figure 4.22, p=0.0706).  Cisplatin treated CD19+ U698 
cells (orange bar, figure 4.22) did show a very slight reduction in percentage proliferation in 
comparison to the control (orange bar, control:  cis section, figure 4.23, p=0.8986). However, 
it did have larger levels of proliferation in comparison to both the cockle and whelk extract 
treated cells as can be seen in figure 4.23 (orange bars, sections cockle: cis and cis: whelk). 
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Figure 4.22. Average proliferation in U698 cells obtained using the CFSE proliferation assay. Average 
percentage proliferation graph for U698 cells treated with the IC50 dose of Cisplatin (orange bars), 
cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml and 12 µg/ml 
respectively). Control/ untreated cells (blue bars) were used as a comparison and were therefore 
considered to be 100% proliferation. Using an incubation period of 3-days. Where N=2, percentage 
proliferation was calculated in relation to the untreated cells and error bars show SEM, significance is 
denoted by *, the absence of * indicates no significance. 
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Figure 4.23. Average proliferation differences in U698 cell line obtained using the CFSE 
proliferation assay. Average percentage proliferation differences and treatment comparison 
graph for U698 cells treated IC50 doses of cisplatin, cockle extract and whelk extract (6 µg/ml, 
12 µg/ml and 12 µg/ml respectively). Showing proliferation differences against treatment 
comparisons between the three treatment types and the untreated control cells. Using an 
incubation period of 3 days. Where N=2, percentage difference in cells was calculated based 
on the comparison treatment e.g. where cis: whelk is a comparison of the whelk extract 
proliferation to the proliferation in cisplatin treated cells, and error bars show SEM, 
significance is denoted by *, absence of * indicates no significance. 
4.3.2.2 Isolated PBMC assays 
4.3.2.2.1 Unstimulated PBMC assays  
4.3.2.2.1.1 Entire population 
As can be seen in figure 4.24 cisplatin treatment (orange bar) exhibited an increase in 
proliferation compared to the control/ untreated cells (figure 4.24, blue bar, p=0.3221), this 
can also be seen in figure 4.25 (mid blue bars, cockle: cis, cis: whelk sections). There are 
decreases in proliferation percentage in the all event populations when cockle extract 
treatment (p=0.0626) and whelk extract (p=0.9985) treatment are compared to cisplatin 
treatment. The whelk extract treatment (yellow bar, figure 4.24) does not have any change 
in proliferation in comparison to the control (blue bar, figure 4.24). This can also be seen by 
the lack of mid colour blue bar in the control: whelk section of figure 4.25, p=0.3251. Cockle 
* * * * 
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extract treatment (grey bar, figure 4.24) had a slight reduction in proliferation percentage in 
comparison to the control/untreated cells. This can also be seen through the mid blue colour 
bar in the control: cockle section of figure 4.25, p=0.0626.  
4.3.2.2.1.2 Lymphocyte population 
Figure 4.24 identifies that the cockle extract treatment (grey bar, p=0.5) and whelk extract 
treatment (yellow bar, p=0.5) result in slight increases in proliferation percentage of 
lymphocytes post treatment. This can be seen also in figure 4.25 (orange bars). All 
comparisons for the cockle extract against the control, cisplatin treatment and whelk extract 
treatment show increases in proliferation (orange bars, figure 4.25). While the whelk extract 
has increases in proliferation in comparison to the control or cisplatin (p=0.5) treated cells 
but slight decrease in proliferation when compared to the cockle extract treatment (orange 
bars, figure 4.25). The cockle extract exerted the largest percentage of proliferation in the 
unstimulated lymphocytes as seen in figure 4.24. Figure 4.24 shows cisplatin treatment 
(orange bar, p=>0.05) had a similar level of proliferation compared to the control (blue bar). 
This is supported by the lack of orange bar in the control: cis section of figure 4.25.  
4.3.2.2.1.3 CD4+/ T-helper cells 
In the T-helper cell population the whelk extract, p=0.4226, increased proliferation by around 
50% as can be seen by the yellow bar in figure 4.24. This is also seen in figure 4.25, by the 
grey bar in section control: whelk. Cisplatin treatment (p=0.4226) (orange bar, figure 4.24) 
and cockle extract treatment (p=0.4226) (grey bar, figure 4.24) increased proliferation in the 
T-helper cell population by the same amount. This can also be demonstrated by the lack of 
grey bar in figure 4.25 in the comparison of the cockle extract and the cisplatin treatment 
(cockle: cis, p=>0.9999).  
4.3.2.2.1.3.1 CD4+CD45RA+/ Naïve T-helper cells 
In the naïve T-helper cell populations the cockle extract treatment increased proliferation by 
150% in comparison to the control (p=0.0152), this can be seen by the grey bar in figure 4.24. 
Also, this is identified in figure 4.25 by the yellow bar in the comparison of the cockle extract 
to the control (control: cockle) section. Whelk extract treatment (yellow bar, figure 4.24) 
increased proliferation in comparison to the control (blue bar, figure 4.24) by 50%. This is also 
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noted by the yellow bar in the comparison of the whelk extract to the control section in figure 
4.25 (control: whelk) (p=0.2959). Figures 4.25 and 4.26 also identify that cisplatin treatment 
increased proliferation in the naïve T-helper cell population (orange bar, figure 4.24 and 
yellow bar, control: cis, figure 4.25, p=0.4226). However, cisplatin treatment increased 
proliferation by less than the increases of those cells treated with either the cockle extract or 
the whelk extract (cockle: cis (p=0.0257) and cis: whelk (p=0.3702) sections of figure 4.25, 
yellow bars).     
4.3.2.2.1.3.2 CD4+CD45RO+/ Memory T-helper cells 
In the memory T-helper cell population there were small differences between the treatment 
types and the control (blue bar, figure 4.24). The cisplatin treatment (orange bar figure 4.24) 
increased proliferation by the most in the memory T-helper cell population (light blue bars, 
control: cis, p=0.6209, cockle: cis and cis: whelk sections) as can be seen in figure 4.25. The 
whelk extract also had a slight increase in proliferation in the memory T-helper cell population 
in comparison to the control (yellow bar, figure 4.24). This can also be seen in the light blue 
bar in the control: whelk section of figure 4.25, p=0.9468. Post cockle extract treatment (grey 
bar, figure 4.24) there was no difference in proliferation percentage in the memory T-helper 
cell population in comparison to the untreated control cells (blue bar, figure 4.24). This is also 
seen through the lack of light blue bar in figure 4.25, section: control: cockle, p=>0.05.  
4.3.2.2.1.4 CD8+ cytotoxic T-cells 
Figure 4.24 identifies that the cockle extract (grey bar) (p=0.0341) had the largest percentage 
proliferation in cytotoxic T-cells in comparison to the control (blue bar), cisplatin treatment 
(orange bar) (p=0.6209) and whelk extract treatment (yellow bar), this can also be seen in the 
green bars in figure 4.25. Whelk extract treatment (yellow bar, figure 4.24) also had 
approximately 150% more proliferation in comparison to the control (blue bar, figure 4.24), 
seen also in the green bars (section: control: whelk, p=0.0228) in figure 4.25. Cisplatin 
treatment (orange bars, figure 4.24) also had an increase in percentage of proliferation in the 
cytotoxic T-cell population in comparison to the control (blue bars, figure 4.24). This was also 
seen in figure 4.25 in the section comparing cisplatin treatment to the untreated control cells 
(control: cis, green bar, p=0.0343).  
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4.3.2.2.1.4.1 CD8+CD45RA+/ Naïve cytotoxic T-cells 
In the naïve cytotoxic T-cells the cockle extract had the largest percentage proliferation as 
can be seen by the grey bar in figure 4.24. This was around a 175% increase in proliferation 
in comparison to the control (dark blue bar, figure 4.25, section: control: cockle, p=0.0194). 
Whelk extract treatment also brought about around 200% proliferation in the naïve cytotoxic 
T-cell population (yellow bar, figure 4.24). This is around a 100% increase in naïve cytotoxic 
T-cells in comparison to the control sample as can be seen by the dark blue bar in figure 4.25 
(section control: whelk, p=0.059). Cisplatin treatment brought about the smallest increase in 
proliferation in the naïve cytotoxic T-cells as can be seen by the dark blue bars in figure 4.25, 
p=0.0544. Cisplatin treatment did however have a larger percentage proliferation in the naïve 
cytotoxic T-cell population than the untreated control cells as can be seen by the orange bar 
in figure 4.24.  
4.3.2.2.1.4.2 CD8+CD45RO+/ Memory cytotoxic T-cells 
In the memory cytotoxic T-cell population there were very little changes in proliferation post 
treatment with either cisplatin (p=0.3800), whelk extract (p=0.4263) or cockle extract 
(p=0.7482). Whelk extract treatment and cisplatin treatment (yellow bar and orange bar 
respectively, figure 4.24) both had larger percentages of proliferation in comparison to the 
control (blue bar, figure 4.24). There was no difference between the percentage of 
proliferation in the memory cytotoxic T-cell population post whelk extract treatment and post 
cisplatin treatment, as can be seen in figure 4.25 by the lack of red bar in the comparison of 
cisplatin treatment to whelk extract treatment (cis: whelk, p=0.9462). Cockle extract 
treatment brought about no change in proliferation compared to the control which can be 
seen by the lack of red bar in figure 4.25, section control: cockle, p=0.7482 Therefore, there 
was still 100% proliferation in the memory cytotoxic T-cells treated with the cockle extract 
(grey bar, figure 4.24).  
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Figure 4.24. Average proliferation in unstimulated PBMCs obtained using the CFSE proliferation assay. 
Average percentage proliferation graph for unstimulated PBMCs treated with the IC50 dose of 
Cisplatin (orange bars), cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml 
and 12 µg/ml respectively). Control/ untreated cells (blue bars) were used as a comparison and were 
therefore considered to be 100% proliferation. Using an incubation period of 3-days. Where N=3, 
percentage proliferation was calculated in relation to the untreated cells and error bars show SEM, 
significance is denoted by *, absence of * indicates no significance. 
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Figure 4.25. Average proliferation differences in unstimulated PBMCs obtained using CFSE 
proliferation assay. Average percentage proliferation differences and treatment comparison graph for 
unstimulated PBMCs treated IC50 doses of cisplatin, cockle extract and whelk extract (6 µg/ml, 12 
µg/ml and 12 µg/ml respectively). Showing proliferation differences against treatment comparisons 
between the three treatment types and the untreated control cells. Using an incubation period of 3 
days. Where N=3, percentage difference in cells was calculated based on the comparison treatment 
e.g. where cis: whelk is a comparison of the whelk extract proliferation to the proliferation in cisplatin 
treated cells, and error bars show SEM, significance is denoted by *, absence of * indicates no 
significance. 
4.3.2.2.2 Stimulated PBMC assays 
4.3.2.2.2.1 Entire population 
In the entire stimulated PBMC population the whelk extract (yellow bar) treatment had the 
most percentage proliferation in comparison to cisplatin (orange bar) and cockle extract 
treatment (grey bar) as can be seen in figure 4.26. In comparison to the control as can be seen 
in the control: cis (p=0.1057), control: cockle (p=0.1258) and control: whelk (p=0.7155) 
sections of figure 4.27 (mid blue bars). Whelk extract treatment reduced proliferation the 
least in comparison to the control. Cockle extract treated (grey bars) cells had the next highest 
levels of proliferation in comparison to other treatment methods (figure 4.26). this can also 
be seen in figure 4.27 in the sections control: cockle and cockle: cis (p=0.3345) (mid blue bars). 
Cisplatin treatment reduced the proliferation in the entire stimulated PBMC population by 
* 
* 
* 
* 
* 
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the most in comparison to other treatment methods and the control (figure 4.26, orange bar 
and figure 4.27 sections control: cis, cockle: cis and cis: whelk (p=0.4067), mid blue bars).  
4.3.2.2.2.2 Lymphocyte population 
In the lymphocyte population cisplatin treated cells had the largest percentage proliferation 
(orange bar, figure 4.26) in comparison to the other treatments and the control (orange bars, 
figure 4.27, p=0.0065). The whelk extract treatment also brought about more proliferation 
(yellow bar, figure 4.26) in comparison to the control and cockle extract treatment (figure 
4.27, orange bars, sections: control: whelk, p=0.5718 and cockle: whelk). Cockle extract 
treatment (grey bar, figure 4.26) also exhibited a larger proliferation percentage than the 
control (blue bar, figure 4.26). However, cockle extract treatment increased proliferation in 
the lymphocyte population by the least amount as seen in figure 4.27 sections: control: cockle 
(p=0.6983), cockle: cis (p=0.2733) and cockle: whelk (orange bars).  
4.3.2.2.2.3 CD4+/ T-helper cells  
In the T-helper cell population the treatment with the whelk extract (yellow bar, figure 4.26) 
had the largest percentage proliferation in comparison to the other treatment methods. 
Whelk extract treatment also had the least reduction in proliferation in comparison to the 
control (figure 4.27, grey bar, section: control: whelk, p=0.5997). Cisplatin treatment (orange 
bar, figure 4.26) had a reduced level of proliferation in the T-helper cell population in 
comparison to the control and whelk extract treatment (figure 4.27, grey bars, sections: 
control: cis, p=0.0383 and cis: whelk, p=0.957). The cockle extract treatment reduced the 
percentage proliferation in the T-helper cell population by the most in comparison to the 
other treatments and the control (figure 4.27, control: cockle, p=0.3095, cockle: cis, p=0.6283 
and cockle: whelk sections, grey bars). The cockle extract treated T-helper cells had the lowest 
percentage proliferation (grey bars, figure 4.26).  
4.3.2.2.2.3.1 CD4+CD45RA+/ Naïve T-helper cells 
In the naïve T-helper cells the whelk extract treated cells had the largest percentage 
proliferation (yellow bar, figure 4.26). Whelk extract treatment increased proliferation in the 
naïve T-helper cells in comparison to the control and cisplatin and cockle extract treated cells 
(figure 4.27, sections: control: whelk, p=0.0384, cockle: whelk and cis: whelk, p=0.3957, 
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yellow bars). Cisplatin treatment had the smallest reduction in proliferation in the naïve T-
helper cells (orange bar, figure 4.26) in comparison to the control and cockle extract treated 
cells (figure 4.27, yellow bars, sections: control: cis, p=0.6738, cockle: cis, p=0.6638). The 
cockle extract treated cells had the largest decrease in proliferation in the naïve T-helper cells 
(grey bar, figure 4.26) as can be seen in figure 4.27 (yellow bars, sections: control: cockle, 
p=0.948, cockle: cis, cockle: whelk).  
4.3.2.2.2.3.2 CD4+CD45RO+/ memory T-helper cells  
In the memory T-helper cell population the whelk extract treatment had the most percentage 
proliferation in comparison to the other treatments (yellow bar, figure 4.26). The whelk 
extract treatment reduced the proliferation percentage in the memory T-helper cells in 
comparison to the control cells, cisplatin treated and cockle extract treated cells (figure 4.27, 
light blue bars, sections: control: whelk, p=0.503, cis: whelk, p=0.7794 and cockle: whelk). 
Cisplatin treatment (orange bars, figure 4.26) resulted in a decrease in memory T-helper cell 
population in comparison to the control and whelk extract treatment (figure 4.27, sections: 
control: cis, p=0.2399 and cis: whelk, p=0.7794). Cockle extract treatment brought about the 
largest decrease in memory T-helper cells (grey bar, figure 4.26) in comparison to the control 
and other treatment methods. This can also be seen in figure 4.27 in the light blue bars 
(sections: control: cockle, p=0.2399, cockle: cis, p=0.4974 and cockle: whelk).  
4.3.2.2.2.4 CD8+/ cytotoxic T-cells 
In the cytotoxic T-cell population cisplatin treated cells (orange bar, figure 4.26) had the same 
percentage proliferation as the control (blue bar, figure 4.26). This can be seen through the 
lack of green bar in the control: cis section in figure 4.27, p=0.8609. The whelk extract 
treatment resulted in a decrease in proliferation (yellow bar, figure 4.26) in comparison to 
the control and cisplatin treatment. This can be seen in the green bars in the comparison 
sections control: whelk, p=0.3248 and cis: whelk, p=0.4738 of figure 4.27. Cockle extract 
treated cytotoxic T-cells experienced the least percentage proliferation as seen by the grey 
bar in figure 4.26. The decrease in proliferation post cockle extract treatment in cytotoxic T-
cells was the largest in comparison to the control and cisplatin and whelk extract treatments 
(figure 4.27, green bars, sections: control: cockle, p=0.0068, cockle: cis, p=0.1475 and cockle: 
whelk). 
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4.3.2.2.2.4.1 CD8+CD45RA+/ naïve cytotoxic T-cells 
Figure 4.26 demonstrates that in the naïve cytotoxic T-cells both cisplatin treatment (orange 
bar) and whelk extract treatment (yellow bar) resulted in higher levels of proliferation than 
the control (blue bar). Cisplatin had the most increase in proliferation in comparison to the 
control cells and whelk extract treated cells (dark blue bars, sections: control: cis, p=0.0435, 
cis: whelk, p=0.3101, figure 4.27). In figure 4.27 it can be seen that whelk extract treatment 
increased proliferation in naïve cytotoxic T-cells in comparison to the control (dark blue bars, 
control: whelk, p=0.4226). It can also be seen that whelk extract treatment did not increase 
naïve cytotoxic T-cell proliferation more than cisplatin treatment (dark blue bar, cis: whelk 
figure 4.27). Cockle extract treatment (grey bar, figure 4.26) had the lowest percentage 
proliferation in the naïve cytotoxic T-cells. This can also be seen in the dark blue bars in figure 
4.26 (sections: control: cockle, p=0.1966, cockle: cis, p=0.0845 and cockle: whelk). 
4.3.2.2.2.4.2 CD8+CD45RO+/ memory cytotoxic T-cells 
In the memory cytotoxic T-cells cisplatin treatment brought about the largest percentage 
proliferation (figure 4.26, orange bar), also an increase in proliferation in comparison to the 
control, cockle extract and whelk extract treated cells (figure 4.27, red bars, sections: control: 
cis, p=0.1828, cockle: cis, p=0.5163 and cis: whelk, p=0.9462). Cockle and whelk extract 
treatments brought about the same level of proliferation (grey and yellow bars respectively, 
figure 4.26). Figure 4.27 identifies that the cockle (p=0.1563) and whelk extract (p=0.3708) 
treated memory cytotoxic T-cells experienced a decrease in proliferation in comparison to 
the control and cisplatin treatments (red bars).   
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Figure 4.26. Average proliferation in stimulated PBMCs obtained using the CFSE proliferation assay. 
Average percentage proliferation graph for stimulated PBMCs treated with the IC50 dose of Cisplatin 
(orange bars), cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml and 12 
µg/ml respectively). Control/ untreated cells (blue bars) were used as a comparison and were 
therefore considered to be 100% proliferation. Using an incubation period of 3-days. Where N=3, 
percentage proliferation was calculated in relation to the untreated cells and error bars show SEM, 
significance is denoted by *, absence of * indicates no significance. 
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Figure 4.27. Average proliferation differences in stimulated PBMCs obtained using the CFSE 
proliferation assay. Average percentage proliferation differences and treatment comparison graph for 
stimulated PBMCs treated IC50 doses of cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml 
and 12 µg/ml respectively). Showing proliferation differences against treatment comparisons 
between the three treatment types and the untreated control cells. Using an incubation period of 3 
days. Where N=3, percentage difference in cells was calculated based on the comparison treatment 
e.g. where cis: whelk is a comparison of the whelk extract proliferation to the proliferation in cisplatin 
treated cells, and error bars show SEM, significance is denoted by *, absence of * indicates no 
significance. 
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4.4 Discussion  
4.4.1 Annexin V/ propidium iodide apoptosis assay 
4.4.1.1 Annexin V/ propidium iodide apoptosis assay results key findings  
• Cockle and whelk extracts exert significant cell death induction in both the MOLT-4 
and U698 cell lines. 
• Whelk extract treatment effects were consistently milder in naïve PBMC cellular 
family populations in comparison to treatment with the cockle extract and treatment 
with cisplatin. 
• Stimulated PBMCs treated with the whelk extract exerted little effect on T-helper cell 
populations but induced more cell death in the cytotoxic T-cell populations in 
comparison to treatment with cisplatin.  
• Treatment with the cockle extract in stimulated PBMCs exerted less of an effect on 
the cytotoxic T-cell populations compared to treatment with either the whelk extract 
or cisplatin. 
4.4.1.2 Discussion 
Apoptosis is a molecular target for new anti-cancer therapies, as during cancer the balance of 
cellular proliferation and apoptosis shifts towards proliferation (Wesselborg et al., 1999). 
Therefore the search for the most efficient anti-cancer treatment with the least side effects, 
which targets apoptosis, is ever pressing (Coppola et al., 2008). Apoptosis has a vital 
protective mechanism against cancer (Zhou et al., 2009). Apoptosis can be characterised by 
cell shrinkage, nuclear chromatin condensation and nuclear and apoptotic body 
fragmentation (Kroemer et al., 1997). Apoptosis can also be characterised by membrane 
damage which leads to the subsequent leakage of phosphatidylserine into the outer 
membrane layers of cells. Annexin V is a recombinant phosphatidylserine-binding protein that 
specifically and strongly binds to phosphatidylserine residues (Cornelissen et al., 2002; 
Vermes et al., 1995).  
This research identified that both the cockle and whelk extracts exerted significant inductions 
of apoptosis in the MOLT-4 cell line, with the largest increases being in the early stages of 
apoptosis (p= 0.0179 and p= 0.003 respectively) (figure 4.5). In the CD3+ MOLT-4 cells the 
both the whelk and the cockle extract resulted in an increase in non-apoptotic cells, with the 
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cockle extract increase in early apoptotic CD3+ MOLT-4 cells being significant (p= 0.0478) 
(figure 4.6). In the K562 cells both the cockle and whelk extracts resulted in non-significant 
rises in the percentage of non-apoptotic cells (figure 4.7). With the whelk extracts resulting 
in significant decreases in the percentage of early (p= 0.022), mid (p= 0.0292) and late (p= 
0.0497) apoptotic cells. In the U698 cells the whelk extract resulted in significant increases in 
the induction of apoptosis (p= 0.0426), particularly with the mid stage apoptosis increases 
(p= 0.0165) (figure 4.8). The cockle extract also resulted in an increase in apoptotic U698 cells, 
but this was not a significant increase. There were also reductions in the percentage of CD19+ 
U698 cells which were non-apoptotic post treatment with both the cockle and whelk extracts, 
these were not significant (figure 4.9).   
The results from this research correspond to the results obtained in the MTT assay, with the 
whelk extract exerting a significant and profound effect on both the MOLT-4 and U698 cell 
lines, which was more effective than those noted in cisplatin treated cells. Ogundipe (2015) 
identified marginal induction of early apoptosis in the MOLT-4 cell line post treatment with 
the whelk extract, which was also demonstrated in this research. Aldairi, Ogundipe and Pye 
(2018) also noted a significant induction of apoptosis in the MOLT-4 cell line and a small but 
significant increase in the percentage of late apoptotic cells post treatment with the cockle 
extract, which was also independently confirmed by this research lab.  
In the unstimulated PBMC assays (figures 4.10- 4.14) the whelk extract consistently exerted 
the mildest effect on the lymphocyte populations and the T-helper and cytotoxic T-cell 
subpopulations (naïve and memory). Although cytotoxic T-cell populations appeared to be 
more affected by the treatment with the whelk extract by the most, with a significant increase 
in the percentage of early stage apoptotic memory cytotoxic T- cells (p= 0.0379). The cockle 
extract treated unstimulated PBMCs exerted little effect on the lymphocytes and T-helper cell 
populations. However the cockle extract also induced more cell death in the cytotoxic T-cell 
populations with a significant decrease in the memory cytotoxic T-cell populations (p= 
0.0399). In the stimulated PBMC assays (figures 4.15- 4.19) the T-helper cell subpopulations 
remained mainly unaffected by treatment with the whelk extract, with a significant increase 
in the percentage of naïve T-helper cell death (p= 0.0429). In the lymphocyte and cytotoxic T-
cell populations the whelk extract resulted in more induction of apoptosis than the treatment 
with cisplatin, with significant increases in the percentage of early stage apoptotic memory 
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and naïve cytotoxic T-cells (p= 0.0448 and p= 0.0409 respectively). The cockle extract 
treatment resulted in the least induction of cell death overall the stimulated PBMC 
populations. In the cytotoxic T-cell populations the cockle extract resulted in the mildest 
induction of apoptosis. In the unstimulated PBMC assays the whelk extract proved to be 
consistently milder than the cockle and cisplatin treatments. This could suggest that the 
whelk extract may be acting in a selective manner towards the cancer cell lines whilst not 
targeting healthy lymphocytes, as was also suggested by the MTT assay results, which could 
suggest that the novel GAG extracts could provide a more favourable therapeutic treatment 
option. In the stimulated PBMC assays the whelk extract appeared to be targeting the 
cytotoxic T-cell populations more than the other treatment methods. The increased activity 
against the CD8+ cells may potentially blunt any immune responses to viral infections during 
chemotherapy treatment. Despite these observations, relative changes compared to the 
potency towards cancer cell lines suggests that the novel marine mollusc derived GAG 
extracts could provide a treatment option that shows some specificity towards tumour cells 
whilst not targeting healthy lymphocytes. It is encouraging to note that the novel GAG 
compounds may be acting in a more specific manner and may consequently exert fewer side 
effects for the patient.  
4.4.2 CFSE proliferation assay 
4.4.2.1 CFSE proliferation assay results key findings 
• Treatment with both the cockle and whelk extracts exerted significant 
antiproliferative effects in both the MOLT-4 and U698 cell lines. 
• In the unstimulated PBMC assays the cockle and whelk extract treatments appeared 
to exert proliferative effects on some subpopulations of T-helper cells and cytotoxic 
T-cells. 
• In the stimulated PBMC assays there were some antiproliferative effects noted in 
some of the subpopulations of T-helper cells and cytotoxic T-cells post treatment with 
the cockle and whelk GAG extracts.  
4.4.2.2 Discussion 
In recent years the analysis of cell cycle had been used in order to identify a molecular target 
for new anti-cancer therapies (Ogundipe, 2015; Basappa et al., 2012). As cellular proliferation 
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is primarily mediated by via the cell cycle, which consists of four stages; G0/G1, S, G2 and M 
(Yang, 2012). Each stage of the cell cycle is controlled by various cellular signalling 
mechanisms which have varying levels of expression depending on the stage of the cell cycle 
(Roos and Kaina, 2006; Schafer, 1998). There are several therapeutic agents which aim to 
target various points in the cell cycle such as the regulation of checkpoints, this ultimately 
leads to the arrest of cellular proliferation or the induction of apoptosis in cancer cells 
(Schafer, 1998). Rapid cellular proliferation is a major factor in describing cancer and there is 
now evidence to identify that GAGs and proteoglycans play a role in the control of cellular 
proliferation (Yip, Smollich and Gotte, 2006). Changes in GAG structure such as heparan 
sulphate on the surface of tumour cells appears to modulate the effects that they exert on 
the cells, through the regulation of growth factor signalling, metastasis and cellular 
proliferation (Liu et al., 2002).  
The CFSE assay is designed to monitor cellular activity for long periods of times and can detect 
cell death with increased insensitivity (Jedema et al., 2004). Mitosis is the process of the 
parent cell splitting into two daughter cells, therefore the fluorescence of CFSE halves during 
the process of mitosis and allows the monitoring of the number of times the cell goes through 
proliferation (Quah and Parish, 2010).  
In the MOLT-4 cell line assays (figures 4.20 and 4.21) the whelk extract was the only treatment 
to reduced proliferation in the cell line however the reduction was not significant. Treatment 
with the cockle extract exerted a non-significant increase in the proliferation of the MOLT-4 
cell line. In the CD3+ MOLT-4 population both the cockle and whelk extracts reduced the level 
of proliferation in the population, with the cockle extract treatment reducing the proliferation 
level significantly (p= 0.0424). Treatment with both the cockle and whelk extracts significantly 
reduced the proliferation in the U698 cell line (p= 0.0182 and p= 0.0243 respectively). Both 
treatment with the cockle and whelk extracts had less than half the proliferation in the U698 
cell line than the proliferation in cisplatin treated cells (figure 4.22 and 4.23). In the CD19+ 
U698 cell population, as with the entire U698 cell population, both the cockle and whelk 
treatments both reduced the proliferation significantly (p= 0.0487 and p= 0.0487 
respectively).  
In the unstimulated PBMC assays (figures 4.24 and 4.25) both the cockle and whelk extracts 
increased the level of proliferation in the lymphocyte and T-helper cell populations, with the 
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cockle extract significantly increasing the level of proliferation in the naïve T-helper cell 
populations (p= 0.0152). In the cytotoxic T-cell populations of the unstimulated PBMCs both 
the cockle and whelk extract significantly increased the percentage of proliferation in the 
total cytotoxic T-cell population (p= 0.0341 and p= 0.0228 respectively). In the naïve cytotoxic 
T-cell population the cockle extract significantly increased the proliferation (p= 0.0194). In the 
stimulated PBMC assays (figures 4.26 and 4.27) the whelk extract exerted small decreases in 
the proliferation of the lymphocyte and T-helper cell and cytotoxic T-cell populations. The 
decrease in proliferation noted in the naïve T-helper cell population was significant (p= 
0.0384). In all the cytotoxic T-cell populations the whelk extract resulted small decreases in 
the proliferation percentage, all of which were non-significant. The cockle extract treated 
stimulated PBMCs experienced the largest decrease in proliferation in all the T-helper cell 
populations and in the cytotoxic T-cell populations, all the decreases in proliferation were 
non-significant.  
The results of the proliferation assay demonstrated that the whelk extract exerted a 
significant effect on both the MOLT-4 and U698 cell lines; whilst also exerting minimal effects 
on the stimulated PBMC populations and actually exerted a proliferative effect on the 
unstimulated PBMCs. The cockle extract results demonstrated that there was a proliferative 
effect also in the unstimulated PBMCs, but an anti-proliferative effect was also noted on the 
stimulated PBMCs. In the cancer cell assays the cockle extract treatment resulted in a 
proliferative effect in the MOLT-4 cell line but did exert a significant anti-proliferative effect 
in the U698 cell line. These results indicate that the cockle extract may exert some level of 
targeting towards healthy vastly proliferating cells. However the whelk extract treatment 
results suggest that the whelk extract may exert a selective nature towards cancer cells whilst 
not targeting healthy lymphocytes (activated or unstimulated), therefore may provide a 
potential treatment method with minimal side effects. These results confirm the findings of 
Aldairi, Ogundipe and Pye (2018) and Ogundipe (2015) that GAGs isolated from the common 
cockle and common whelk exhibit anti-proliferative effects in the MOLT-4 cell line. The results 
also support the suggest put forward by Basappa et al., (2012) that there are certain GAG 
chains which may be useful in cancer treatment which could result in fewer side effects for 
patients.         
  
 183 
CHAPTER 5- CYTOKINE AND T-REGULATORY RESPONSE ASSAY 
5.0 Cytokine and T-regulatory response results 
5.1 Introduction 
Cancer cells have the ability to modify the microenvironment of a tumour to become 
immunosuppressive (Sompayrac, 2015), therefore it is important to understand how a 
potential anti-cancer therapy interacts with the cells and cytokines responsible for this 
immunosuppressive nature. Many cancer cells exhibit the expression of immunosuppressive 
proteins such as CTLA-4, which are responsible for the restraint of cytotoxic T-lymphocytes 
(CTLs), thus shielding the cancer cell from any potential destruction by tumour specific CTLs 
(Sompayrac, 2015). Cancer cells also increase the production of T-regulatory (Treg) cells to the 
tumour microenvironment (Facciabene et al., 2012: Elkord, 2010), which in turn excrete 
increased levels of TGF-β and IL-10 which create the immunosuppressive environment in 
which CTLs fail to function (Sompayrac, 2015). Raised Treg cell levels in cancer have been linked 
to poor prognosis and negative impacts on immunotherapy, thus aiding in tumour 
progression (Elkord, 2010). This research therefore focussed on the impact of GAG treatment 
on Treg cell levels in both stimulated and unstimulated PBMCs. 
Chapters 3 and 4 indicated that the GAG isolates are both cytotoxic to lymphocytes but also 
induce proliferation to an extent in unstimulated PBMCs. Given that the mode of action of 
marine mollusc GAGs has not yet been fully established, the research evaluated any actions 
of the GAGs on cytokine production and T-regulatory cell numbers and phenotypic properties. 
In order to gain an insight into the longer term consequences of GAG use in the clinic. 
The antibodies for CD4 and CD8 were used to identify T-helper cell and cytotoxic T-cell 
populations respectively in the lymphocyte population of PBMCs.  
T-regulatory cells were identified in CD4+ T-cells through the characterisation of the 
expression of the transcription factor FOXP3, which is necessary for the development and 
function of Treg cells (Wang et al., 2009: Probst-Kepper, 2009). FOXP3 is a forkhead/winged-
helix transcription factor (Lal and Bromberg, 2009) which is located in the thymus where Treg 
cells develop. Various intracellular signalling molecules and extracellular stimuli such as IFN-
γ, IL-4 and IL-27 aid with the both the function and development of Treg cells (figure 5.1), this 
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is done through the regulation of FOXP3 (Lal and Bromberg, 2009). FOXP3 can be linked to 
the potency of Treg cells as mutations in or deficiencies of FOXP3 lead to the development of 
autoimmune diseases (Lal and Bromberg, 2009). FOXP3 was used to identify the Treg cell 
populations as its expression in CD4+ T-cells is specific to Treg cells (Probst-Kepper, 2009). In 
the thymus populations of FOXP3+CD4+ T-cells develop which are commonly referred to as 
natural Tregs (nTreg), whereas in peripheral lymphoid organs TGF-β can induce the 
development of FOXP3+CD4+ T-cells from populations of naïve CD4+ T-cells which are referred 
to as induced Tregs (iTreg) (Zhang and Zhao, 2007). The function of nTreg and iTreg cells are similar 
with natural T-regulatory cells proving to be more stable (Lal and Bromberg, 2009). 
 
Figure 5.1 The regulation of FOXP3 from extracellular signals. The regulation of FOXP3 from 
extracellular signals: TGFβ, TLR, IL-2, IL-4, IL-6 and IFN-γ. Red arrows are representative of negative 
signals and green arrows are representative of positive signals responsible for FOXP3 expression (Lal 
and Bromberg, 2009). 
Wang et al., (2009) and Probst-Kepper et al., (2009) identified that activated T-regulatory cells 
expressed a transmembrane protein known as glycoprotein A repetitions predominant 
(GARP). They also noted that the presence of GARP could be correlated with the suppressive 
activity of Treg cells and that GARP was highly expressed in FOXP3+ Treg cells. Therefore, the 
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GARP antibody was used to further identify Treg cells in FOXP3 positive cells, due to its specific 
induction in CD4+FOXP3+ (Treg) cells (Probst-Kepper et al., 2009). 
Interferon-γ (IFN-γ) is a cytokine which is secreted by thymus-derived T-cells such as natural 
killer (NK) cells, activated T-helper cells and activated cytotoxic T-cells (Boehm, Klamp, Groot 
and Howard, 1997). IFN-γ plays a role in many cellular functions which include aspects of the 
immune response as well as cell proliferation and apoptosis (Boehm et al., 1997). IFN-γ also 
plays a role in the phosphorylation of STAT1 which leads to interactions with the FOXP3 
proximal promotor in CD4+ T-cells (figure 5.1) (Lal and Bromberg, 2009). Ultimately leading to 
the expression of FOXP3 thus promoting Treg cell development. 
Interleukin-4 (IL-4) is a cytokine which plays an important role in the immune system (Takeda 
et al., 1996) and is secreted by activated T-lymphocytes, basophils and mast cells (Hou et al., 
1994). IL-4 also has an important role in controlling the balance of T-helper cells (Hou et al., 
1994). Figure 5.1 identifies IL-4 as being an opposing cytokine to IFN-γ, in that IL-4 inhibits the 
expression of FOXP3 through the promotion of the phosphorylation of STAT6 (Lal and 
Bromberg, 2009).   
The common cockle and common whelk extracts effects on cytokine and Treg cell responses 
were unknown, this research aimed to identify any responses that the extracts may have on 
cytokines (IL-4 and IFN-γ) and Treg cell responses in healthy PBMCs (+/- stimulation). 
5.2 Method 
Antibody staining for surface: GARP, CD4 and CD8 and intracellular: IFN-γ, IL-4 and FOXP3, 
was carried out as per the manufacturer recommendations and as set out in method 2.6. To 
assess cytokine and T-regulatory cell responses to treatment with the cockle extract and 
whelk extract in comparison to untreated control cells and cells treated with the control drug 
cisplatin. In all assays cells were seeded to 1 x 105/ml and cisplatin was used as a control drug. 
PBMCs (stimulated and unstimulated) were incubated with the IC50 doses obtained in the 
MTT assays: cisplatin, 6 µg/ml, and cockle and whelk extracts both at 12 µg/ml, for a 3-day 
period. Treg response assays were only carried out using naïve and stimulated PBMCs. 
In figure 5.2 the gating process used for the Treg and cytokine response assays in order to 
establish the individual cell types present in the PBMC populations. Where the CD4 (T-helper 
 186 
cell) and CD8 (cytotoxic T-cell) populations were obtained in relation to the lymphocyte 
population. From the CD4 and CD8 gating, quad gates were then set up based on either the 
CD4 or CD8 populations in order to obtain the percentage of T-regulatory cells. Once the T-
regulatory cell population had been identified histogram plots were drawn and gated upon in 
order to determine the effects of treatment on cytokine production in Treg cells. 
 
Figure 5.2 Raw data graph and gates drawn in a typical PBMC Treg and cytokine response assays and 
the gating process involved. Raw data graph and gates drawn in a typical PBMC Treg and cytokine 
response assays in order to determine cell types and quantities and cytokine production from Treg 
cells. The example shown is a cisplatin treated stimulated PBMC assay. All Treg and cytokine response 
assays were performed using a 3-day incubation period and N=3. 
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5.3 Results: isolated PBMC assays  
The results displayed in the T-regulatory cell and cytokine response assay figures demonstrate 
average data obtained from three repeats each performed in triplicate. The percentage 
change graphs were obtained by comparing each treatment method with either the control 
or another treatment method. 
5.3.1 Unstimulated PBMCs 
The lymphocyte population in unstimulated PBMCs was reduced the most by the cockle 
extract treatment in comparison to the control, as can be seen by the blue bar (control) and 
grey bar (cockle extract) in figure 5.3. It can also be seen in the lymphocyte section, cockle: 
control section of figure 5.4 (dark blue bar, p=0.045). The whelk extract treatment (yellow 
bar, figure 5.3) also reduced the lymphocyte population by more than the cisplatin treatment 
(orange bar, figure 5.3) and in comparison to the control, as can also be seen in the 
lymphocyte section of figure 5.4, p=0.0497. Cisplatin treatment reduced the lymphocyte 
population by the least out of all the treatment methods, as seen in figure 5.4, p=0.1197.  
In the CD4+ populations there was very little difference between the control sample and any 
of the treatments. This can be seen in the CD4 section of figure 5.3. The whelk extract 
treatment resulted in the least reduction in the CD4 population in comparison to the control 
(yellow bar, CD4 section, figure 5.4, p=0.6514). The cockle extract treatment (orange bar, CD4 
section, figure 5.4, p=0.3469) resulted in the next smallest reduction in CD4 population. 
Cisplatin treatment (dark blue bar, section CD4, figure 5.4, p=0.4434) resulted in the largest 
decrease in CD4 populations in comparison to the control and the other treatment methods, 
however the reduction is very small.  
In the CD8+ population cisplatin treatment resulted in an increase in the CD8 population in 
comparison to the control, seen in figure 5.3, orange bar, CD8 section (cisplatin, p=0.3156) 
and dark blue bar (control). There is very little difference in the CD8 population between the 
cockle extract treatment (grey bar, section CD8, figure 5.3, p=0.9079) and the whelk extract 
treatment (yellow bar, section CD8, figure 5.3, p=0.7835) and the control (blue bar, section 
CD8, figure 5.3). This can also be seen by the small bars in the cockle: control and whelk: 
control bars in figure 5.4, section CD8 (orange and yellow bars respectively). 
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There were very small populations of GARP+ cells and very little difference in the GARP 
populations between the control sample, cisplatin treated cells (p=0.4595), cockle extract 
(p=0.3459) and whelk extract treated (p=0.4778) cells. This can be seen through the small 
bars in the GARP section of figure 5.3 and the lack of bars in the GARP section of figure 5.4. 
In the IL-4 population the cisplatin treatment caused the least reduction in the population 
(orange bar, IL-4 section, figure 5.3) in comparison to the control cells (blue bar, section IL-4, 
figure 5.3). This can also be seen in figure 5.4 in the IL-4 section, the cisplatin: control bar 
(p=0.5645) (dark blue bar) is smaller than that of the cockle: control (p=0.358) (grey bar) and 
whelk: control bar (p=0.4844) (yellow bar) in figure 5.4. Both the cockle extract treatment 
and the whelk extract treatment (grey bar and yellow bar respectively, section IL-4, figure 5.3) 
resulted in the same level of reduction in the IL-4 population of the unstimulated PBMCs. This 
can be seen due to the lack of green bar in figure 5.4 in the IL-4 section marking the 
comparison between the cockle extract and the whelk extract treatment. As the bars 
comparing the cockle extract and the control (orange bar, figure 5.4, IL-4 section) and the 
whelk extract treatment and the control (grey bar, figure 5.4, IL-4 section) are also at the 
same level it can be said that the cockle and whelk extract exert the same effect on the IL-4 
population as each other in comparison to the control.  
The populations of IFN-γ positive cells was quite small which can be seen by the small bars in 
the IFN-γ section of figure 5.3. There was also little difference between the cisplatin treatment 
(p=0.3161), the cockle extract treatment (p=0.7125) and whelk extract treatment (p=0.6195) 
in comparison to the control as can be seen through the lack of bars in the IFN-γ section of 
figure 5.4. The cisplatin treatment did however result in a small increase in the IFN-γ 
population which can be seen by the small dark blue bar in figure 5.4.  
The FOXP3+ populations of unstimulated PBMCs were also small and had very little difference 
between the control sample and each of the treatment methods cisplatin (p=0.1983), cockle 
extract (p=0.0502) and whelk extract (p=0.0592). This can identified by the small bars in figure 
5.3, FOXP3 section. It can be noted that the cisplatin treatment resulted in a small increase in 
FOXP3 positive cells post treatment in comparison to the control (dark blue bar, FOXP3 
section, figure 5.4). As there are no other bars in figure 5.4 that are identifiable, there are 
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minimal differences between the cockle extract treated cells, the whelk extract treated cells 
and the control cells.  
 
Figure 5.3. Average cell types (CD4, CD8, GARP, IL-4, IFN-γ and FOXP3) in unstimulated PBMCs. 
Average percentage cell type graph for unstimulated PBMCs treated with the IC50 dose of Cisplatin 
(orange bars), cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml and 12 
µg/ml respectively). Control/ untreated cells (blue bars) were used as a comparison. Using an 
incubation period of 3-days. Where N=3, percentage cell type was in relation to the lymphocyte 
population and error bars show SEM, significance is denoted by *, absence of * indicates no 
significance. 
 
 
 
* 
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Figure 5.4. Average differences in cell type percentage in unstimulated PBMCs. Average percentage 
differences in cell type and treatment comparison graph for unstimulated PBMCs treated IC50 doses 
of cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing 
the differences in cell type percentage in the treatment comparisons between the three treatment 
types and the untreated control cells. Using an incubation period of 3 days. Where N=3, percentage 
difference in cells was calculated based on the comparison treatment e.g. where cis: whelk is a 
comparison of the whelk extract cell population to the cell population in cisplatin treated cells, 
significance is denoted by *, absence of * indicates no significance. 
5.3.1.1 CD4+/T-helper cell populations  
There were very small amounts of cells which tested positive for both CD4 and GARP 
(CD4+GARP+) as can be seen by the bars in figure 5.5- A, section CD4+GARP+. There were also 
no changes in the CD4+GARP+ population between the control cells and the cisplatin treated 
cells (p=0.5324). The was a small increase in CD4+GARP+ cell post treatment with the cockle 
extract (p=0.3378) and CD4+GARP+ cells increased by the most post whelk extract treatment 
(p=0.5326) which can be seen in the CD4+GARP+ section of figure 5.5- B.  
In the CD4+ IFN-γ+ population the cockle extract treatment resulted in the largest increase in 
the population percentage (grey bar, figure 5.5- A, section CD4+ IFN-γ+). This can also be seen 
in the orange bar in figure 5.5- B (section CD4+ IFN-γ+) (p=0.6098). The whelk extract 
treatment also resulted in an increase in the percentage population of CD4+ IFN-γ+ cells 
(yellow bars, figures 5.5- A and 5.5- B, section CD4+ IFN-γ+) (p=0.6648). However the increase 
* 
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was smaller than that of the cockle extract as seen by the green bar in figure 5.5- B (section 
CD4+ IFN-γ+). Cisplatin treatment resulted in the same percentage population as that of the 
control sample as seen by the orange and blue bars respectively in figure 5.5- A (section CD4+ 
IFN-γ+). This is also seen through the lack of dark blue bar in figure 5.5- B (p=0.1029).  
In the CD4+IL-4+ cells the whelk extract treatment resulted in the largest decrease in the 
percentage population (yellow bars, figures 5.5- A and 5.5- B) (p=0.2872). The cockle extract 
also resulted in a decrease in the percentage population of CD4+IL-4+ cells which is identified 
by the grey bar in figure 5.5- A and the orange bar in figure 5.5- B, p=0.306. The cisplatin 
treatment resulted in the least reduction in CD4+IL-4+ cell population in comparison to the 
control (orange bar, figure 5.5- A and dark blue bar, figure 5.5- B, p=0.516).  
5.3.1.1.1 CD4+FOXP3+/ T-regulatory cells 
In the CD4+ T-regulatory cells the whelk extract reduced the population by the largest amount 
in comparison to the control and the other treatment methods, as seen by the yellow bars in 
figures 5.5- A and 5.5- B, p=0.0199. The whelk extract resulted in a 50% decline in the 
percentage of CD4+ Treg cells in comparison to the control. Cisplatin also resulted in a 
reduction in the percentage of Treg cells in comparison to the control (orange and blue bars 
respectively, figure 5.5- A, and dark blue bar, figure 5.5- B, p=0.0297) and a slight reduction 
in comparison to the cockle extract treatment (grey bar, figure 5.5- B). The cockle extract 
resulted in a similar reduction in the level of Treg cells to that of cisplatin, however the 
reduction was slight smaller as can be seen by the orange and grey bars in figure 5.5- B, 
p=0.0362. Cockle extract treatment had a reduced level of Treg cells in comparison to the 
control cells, seen by the grey bar and blue bar in figure 5.5- A respectively. 
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Figure 5.5. A - Average CD4+ cell types (FOXP3, GARP, IFN-γ and IL-4) in unstimulated PBMCs. Average 
percentage CD4+ cell type graph for unstimulated PBMCs. Figure 5.5. B - Average differences in CD4+ 
cell type percentage in unstimulated PBMCs. Average percentage differences in CD4+ cell type and 
treatment comparison graph for unstimulated PBMCs; showing differences cell type percentage 
against treatment comparisons between the three treatment types and the untreated control cells. 
Percentage difference in cells was calculated based on the comparison treatment e.g. where cis: whelk 
is a comparison of the whelk extract cell population to the cell population in cisplatin treated cells. 
Both figures represent unstimulated PBMCs treated with the IC50 dose of Cisplatin, cockle extract and 
whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Control/ untreated cells were used as a 
comparison. Using an incubation period of 3-days. Where N=3, percentage cell type or difference was 
in relation to the lymphocyte CD4+ population and error bars show SEM. Significance is denoted by *, 
absence of * indicates no significance. 
Figure 5.6 identifies that the GARP population of CD4+Treg cells was reduced by the cisplatin 
and whelk extract treatment methods in comparison to the control. Cisplatin treatment had 
the lowest mean fluorescence value in comparison to the control (p=0.5335) (figure 5.6; 
orange bar). The whelk extract had a lower median fluorescence value in comparison to the 
control (p=0.9621) (figure 5.6; yellow bar), however this was not lower than that of the 
cisplatin treated population. The cockle extract treatment resulted in a higher mean 
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fluorescence value than the control in the GARP+CD4+Treg cells (p=0.6405) (figure 5.6; grey 
bar).  
In the IFN-γ+CD4+Treg cells the cisplatin treatment increased the mean fluorescence in 
comparison to the control sample by the largest amount (p=0.0599, figure 5.6; orange bar) of 
all three treatment methods. The cockle extract treatment resulted in an increase in the mean 
fluorescence in comparison to the control (p=0.0048, figure 5.6; grey bar). Whelk extract 
treatment resulted in an increase in the mean fluorescence of IFN-γ+CD4+Treg cells in 
comparison to the control (p=0.9621, yellow bar; figure 5.6).  
In IL-4+CD4+Treg cells the mean fluorescence was increased by treatment with cisplatin extract 
(figure 5.6; orange bar, p=0.7057) and by treatment with the whelk extract (yellow bar; figure 
5.6, p=0.6432). Treatment with the cockle extract resulted in a decrease in the mean 
fluorescence of IL-4+CD4+Treg cells (p=0.1707, figure 5.6; grey bar). 
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Figure 5.6 The average median fluorescence of biomarker/ cytokine levels in unstimulated CD4+Treg 
cells. The average median fluorescence of biomarker/ cytokine levels in unstimulated CD4+Treg cells 
obtained from the histogram gating system observed in figure 5.2. Average data obtained from 
unstimulated PBMCs treated with IC50 values of cisplatin (6 µg/ml), cockle extract (12 µg/ml) and 
whelk extract (12 µg/ml), with an incubation period of 3-days and N=3. Graph displayed was created 
using Prism 8.0 software. Error bars represent SEM, significance is denoted by *, absence of * indicates 
no significance.  
5.3.1.2 CD8+/ Cytotoxic T-cell populations 
There were very small percentages of CD8+GARP+ cells in all samples, which can be seen by 
the small bars in the CD8+GARP+ section of figure 5.7- A. Treatment with cisplatin (p=0.5712) 
resulted in the largest increase in CD8+GARP+ cells (orange bar, figure 5.7- A: blue bar, figure 
5.7- B). Cockle extract treatment (p=0.3463) resulted in an increase in the percentage of 
CD8+GARP+ cells in comparison to the control, as seen by the grey bar in figure 5.7- A and the 
orange bar in figure 5.7- B. The whelk extract (p=0.224) treatment resulted in a decrease in 
the percentage of CD8+GARP+ cells, as seen by the yellow bars in figure 5.7- A and figure 5.7- 
B.  
* 
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In the CD8+IFN-γ+ cells the treatment with cisplatin resulted in an increase in the percentage 
population in comparison to the control (orange and blue bars respectively, figure 5.7- A). 
Which can also be seen in the percentage difference comparison between the control and 
the cisplatin treatment (dark blue bar, figure 5.7- B, p=0.3548). Cockle extract treatment 
resulted in a slight increase in the percentage population of CD8+IFN-γ+ cells in comparison to 
the control (grey bar, figure 5.7- A and orange bar, figure 5.7- B, p=0.57). The increase in 
CD8+IFN-γ+ population was slightly more than that of cisplatin which can be seen by the grey 
bar in figure 5.7- B, which compared the percentage difference in cell population of the 
cisplatin treatment and the treatment with the cockle extract. The whelk extract treatment 
resulted in a decrease in the percentage of CD8+IFN-γ+ cell population in comparison to the 
control (yellow bars, figures 5.7- A and 5.7- B, p=0.2773).  
In the CD8+IL-4+ cell population the treatment with cisplatin resulted in an increase in 
comparison to the control (orange bar and dark blue bar, figures 5.7- A and 5.7- B respectively, 
p=0.63). The cockle extract treatment brought about a decrease in the percentage of CD8+IL-
4+ cells when compared to the control which can be seen by the grey bar in figure 5.7- A and 
the orange bar in figure 5.7- B (p=0.5018). Treatment with the whelk extract resulted in a 
decrease in the percentage of the CD8+IL-4+ population in comparison to the control which 
can be seen in the yellow bars in figures 5.7- A and 5.7- B (p=0.2843). The decrease in whelk 
extract treated populations was slightly more than that of the cockle extract which can be 
seen by the green bar in figure 5.7- B.  
5.3.1.2.1 CD8+FOXP3+/ CD8+Treg cells  
In the CD8+ Treg cells the whelk extract treatment resulted in the largest decrease in 
percentage population in comparison to the control and the other treatment methods 
(yellow bars, figures 5.7- A and 5.7- B, p=0.0361). The decrease was larger than that seen in 
cisplatin as can be seen by the light blue bar in figure 5.7- B and larger than that of the cockle 
extract treated cells as can be seen by the green bar in figure 5.7- B. Cisplatin treatment also 
resulted in a decrease in the percentage of CD8+ Treg cells in comparison to the control as can 
be seen by the orange bar in figure 5.7- A and the dark blue bar in figure 5.7- B (p=0.0727). 
The cockle extract also brought about a decrease in the percentage population of CD8+ Treg 
cells in comparison to the control (grey bar and orange bar, figures 5.7- A and 5.7- B 
 196 
respectively, p=0.0477). The decrease in the population of CD8+ Treg cells was larger in cockle 
extract treated cells than in cisplatin treated cells as can be seen by the grey bar in figure 5.7- 
B.  
  
Figure 5.7. A - Average CD8+ cell types (FOXP3, GARP, IFN-γ and IL-4) in unstimulated PBMCs. Average 
percentage CD8+ cell type graph for unstimulated PBMCs. Figure 5.7. B - Average differences in CD8+ 
cell type percentage in unstimulated PBMCs. Average percentage differences in CD8+ cell type and 
treatment comparison graph for unstimulated PBMCs; showing differences in cell type against 
treatment comparisons between the three treatment types and the untreated control cells. 
Percentage difference in cells was calculated based on the comparison treatment e.g. where cis: whelk 
is a comparison of the whelk extract cell population to the cell population in cisplatin treated cells. 
Both figures represent unstimulated PBMCs treated with the IC50 dose of cisplatin, cockle extract and 
whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Control/ untreated cells were used as a 
comparison. Using an incubation period of 3-days. Where N=3, percentage cell type or difference was 
in relation to the lymphocyte CD8+ population and error bars show SEM. Significance is denoted by *, 
absence of * indicates no significance. 
Figure 5.8 identifies that the mean fluorescence is increased in comparison to the control in 
the GARP+CD8+Treg cells post treatment with all three treatment methods. Cisplatin treatment 
resulted in the smallest increase in the GARP+CD8+Treg cell mean fluorescence (p=0.1465, 
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figure 5.8; orange bar). While the cockle extract also increased the mean fluorescence of 
GARP+CD8+Treg cells (p=0.3497, figure 5.8; grey bar). The whelk extract treatment resulted in 
the largest increase in the mean fluorescence of GARP+CD8+Treg cells in comparison to the 
control (p=0.5451, figure 5.8; yellow bar).  
In the IFN-γ+CD8+Treg cells mean fluorescence was decreased by all three treatment methods, 
with cisplatin treatment reducing the mean fluorescence by the largest amount (p=0.0103, 
orange bar, figure 5.8). Cockle extract treatment (p=0.0011, figure 5.8; grey bar) and whelk 
extract (p=0.0027, figure 5.8; yellow bar) treatment also resulted in decreases in the mean 
fluorescence of IFN-γ+CD8+Treg cells. 
Mean fluorescence in IL-4+CD8+Treg cell populations was decreased by the most post 
treatment with the whelk extract (p=0.3421, figure 5.8; yellow bar). Cisplatin treatment also 
reduced the mean fluorescence of IL-4+CD8+Treg cells post treatment (p=0.3670, orange bar, 
figure 5.8). The treatment with cockle extract resulted in the smallest decrease in the mean 
fluorescence of IL-4+CD8+Treg cells post treatment (p=0.3771, figure 5.8; grey bar).   
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Figure 5.8 The average median fluorescence of biomarker/ cytokine levels in unstimulated CD8+Treg 
cells. The average median fluorescence of biomarker/ cytokine levels in unstimulated CD8+Treg cells 
obtained from the histogram gating system observed in figure 5.2. Average data obtained from 
unstimulated PBMCs treated with IC50 values of cisplatin (6 µg/ml), cockle extract (12 µg/ml) and 
whelk extract (12 µg/ml), with an incubation period of 3-days and N=3. Graph displayed was created 
using Prism 8.0 software. Error bars represent SEM, significance is denoted by *, absence of * indicates 
no significance.  
5.3.2 Stimulated PBMCs 
PBMCs were stimulated as per method 2.7 and incubated with the IC50 value for each drug 
type or plain media for the control cells for 3 days. The control sample for figure 5.9, 5.11-A, 
5.13- A are represented by the blue bar.    
Cisplatin treatment brought about an increase in the percentage of lymphocytes in 
comparison to the control sample (orange bar, figure 5.9 and the dark blue bar in figure 5.10, 
p=0.5127). The cockle extract treatment resulted in a decrease in the lymphocyte population 
in comparison to the control (grey bar, figure 5.9 and orange bar in figure 5.10, p=0.0019) and 
in comparison to the whelk extract (green bar, figure 5.10). Treatment with the whelk extract 
* 
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resulted in a decrease in lymphocyte population in comparison to the control sample (yellow 
bars, figures 5.9 and 5.10, p=0.1234). 
The cisplatin treatment resulted in an increase in the percentage of T-helper cells (CD4+) 
which can be seen by the orange bar in figure 5.9 and the dark blue bar in figure 5.10, 
p=0.2754. The cockle extract treatment caused an increase in T-helper cells in comparison to 
the control (grey bar, figure 5.9 and orange bar 5.10, p=0.135), however the increase was not 
as much as in the cisplatin treated cells as can be seen by the grey bar in figure 5.10. 
Treatment with the whelk extract demonstrated a decrease in the percentage of T-helper 
cells (yellow bars, figure 5.9 and 5.10, p=0.7262). 
In cytotoxic T-cells (CD8+) the cockle extract resulted in the largest decrease in comparison to 
the control (grey bar figure 5.9 and orange bar figure 5.10, p=0.4256), also in comparison to 
cisplatin treatment (grey bar figure 5.10) and whelk extract treated cells (green bar figure 
5.10). The whelk extract and cisplatin treatment resulted in a decrease in the percentage of 
cytotoxic T-cells in comparison to the control (orange bar 5.9 and dark blue bar figure 5.10, 
p=0.4388, yellow bars figures 5.9 and 5.10, p=0.4573, respectively). This reduction was by the 
same percentage in both cisplatin and whelk extract treated cells which can be seen by the 
lack of light blue bar in figure 5.10.  
The whelk extract treated cells had a reduction in the percentage of GARP positive cells in 
comparison to the control (yellow bars figures 5.9 and 5.10, p=0.4366). Cisplatin treatment 
resulted in an increase in the percentage of GARP positive cells in comparison to the control 
(orange bar figure 5.9 and dark blue bar figure 5.10, p=0.3581). In cockle extract treated cells 
the GARP population percentage increased in comparison to the control (grey bar figure 5.9 
and orange bar figure 5.10, p=0.2865) and in comparison to the cisplatin treated cells (grey 
bar figure 5.10).  
 IL-4 positive cell populations experienced an increase post whelk extract treatment in 
comparison to the control (yellow bars, figures 5.9 and 5.10, p=0.302), also in comparison to 
cisplatin treated cells (light blue bar figure 5.10) and in comparison to cockle extract treated 
cells (green bar figure 5.10). Cockle extract treated cells experienced an increase in the 
percentage of IL-4 positive cells in comparison to the control (grey bar figure 5.9 and orange 
bar figure 5.10, p=0.3973) also in comparison to the cisplatin treated cells (grey bar figure 
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5.10). Cisplatin treatment resulted in an increase in the percentage of IL-4 positive 
populations in comparison to the control (orange bar figure 5.9 and dark blue bar figure 5.10, 
p=0.4663).  
Treatment with cisplatin resulted in the largest decrease in the percentage of IFN-γ+ in 
comparison to the control (orange bar figure 5.9 and dark blue bar figure 5.10, p=0.0718), 
also in comparison to cockle extract treatment (grey bar, figure 5.10) and whelk extract 
treatment (light blue bar, figure 5.10). The IFN-γ+ population experienced a decrease in 
population percentage post treatment with the cockle extract in comparison to the control 
(grey bar figure 5.9 and orange bar figure 5.10, p=0.0668) and in comparison to the whelk 
extract treated cells (green bar, figure 5.10, p=0.1027). The whelk extract treatment resulted 
in a decrease in the percentage population of IFN-γ+ cells in comparison to the control (yellow 
bars, figures 5.9 and 5.10).  
FOXP3+ cells experienced a decrease in comparison to the control sample post treatment with 
cisplatin (orange bar figure 5.9, dark blue bar figure 5.10, p=0.0072) and in comparison to 
treatment with either the cockle extract or whelk extract (grey bar and light blue bar 
respectively, figure 5.10). Cockle extract treatment resulted in a decrease in the percentage 
of FOXP3+ cells post treatment in comparison to the control cells (grey bar figure 5.9 and 
orange bar figure 5.10, p=0.0145) and in comparison to treatment with the whelk extract 
(green bar figure 5.10). Treatment with the whelk extract resulted in a decrease in the 
percentage of FOXP3+ cells post treatment in comparison to the control cells (yellow bars, 
figures 5.9 and 5.10, p=0.0191).  
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Figure 5.9. Average cell types (CD4, CD8, GARP, IL-4, IFN-γ and FOXP3) in stimulated PBMCs. Average 
percentage cell type graph for stimulated PBMCs treated with the IC50 dose of Cisplatin (orange bars), 
cockle extract (grey bars) and whelk extract (yellow bars) (6 µg/ml, 12 µg/ml and 12 µg/ml 
respectively). Control/ untreated cells (blue bars) were used as a comparison. Using an incubation 
period of 3-days. Where N=3, percentage cell type was in relation to the lymphocyte population and 
Error bars show SEM, significance is denoted by *, absence of * indicates no significance. 
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Figure 5.10. Average differences in cell type percentage in stimulated PBMCs. Average percentage 
difference in cell type and treatment comparison graph for stimulated PBMCs treated IC50 doses of 
cisplatin, cockle extract and whelk extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing 
differences in cell type against treatment comparisons between the three treatment types and the 
untreated control cells. Using an incubation period of 3 days. Where N=3, percentage difference in 
cells was calculated based on the comparison treatment e.g. where cis: whelk is a comparison of the 
whelk extract cell population to the cell population in cisplatin treated cells, significance is denoted 
by *, absence of * indicates no significance. 
5.3.2.1 CD4+/ T-helper cell populations in stimulated PBMCs 
Treatment with the whelk extract resulted in a decrease in the percentage of CD4+GARP+ 
population in comparison to the control (yellow bars, figures 5.11- A and 5.11- B, p=0.2074), 
cisplatin treatment (light blue bar figure 5.11- B) and cockle extract (green bar figure 5.11- B). 
Cockle extract treatment (p=0.2331) and treatment with cisplatin (p=0.2471) resulted in a 
decrease in the percentage of CD4+GARP+ in comparison to the control (orange and grey bars 
figure 5.11- A and dark blue and orange bars figures 5.11- B, respectively) which can also be 
seen by the lack of grey bar in figure 5.11- B.  
Treatment with the whelk extract resulted in a decrease in the percentage population of 
CD4+IFN-γ+ cells in comparison to the control sample (yellow bars, figure 5.11- A and 5.11- B, 
p=0.0156) and also in comparison to the treatment with cisplatin (light blue bar, figure 5.11- 
B). Cisplatin treatment resulted in a decrease in the percentage of CD4+IFN-γ+ population in 
** 
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comparison to the control (orange bar figure 5.11- A and dark blue bar figure 5.11- B, 
p=0.8861). The cockle extract treatment resulted in an increase in the percentage population 
of CD4+IFN-γ+ cells in comparison to the control (grey bar figure 5.11- A and orange bar in 
figure 5.11- B, p=0.8766).  
In the CD4+IL4+ percentage population the cisplatin treatment resulted in an increase in the 
population in comparison to the control sample (orange bar figure 5.11- A and dark blue bar 
figure 5.11- B, p=0.2141). Also in comparison to the cockle extract treatment (grey bar figure 
5.11- B) and whelk extract treatment (light blue bar figure 5.11- B). The cockle extract treated 
CD4+IL4+ cells experienced an increase in the percentage population post treatment in 
comparison to the control (grey bar figure 5.11- A and orange bar figure 5.11- B, p=0.3915) 
and also in comparison to the whelk extract treatment (green bar figure 5.11- B). Treatment 
with the whelk extract resulted in an increase in the percentage population of CD4+IL4+ cells 
in comparison to the control as can be seen by the yellow bars in figures 5.11- A and 5.11- B, 
p=0.6377.  
5.3.2.1.1 CD4+FOXP3+/ T-regulatory cells 
In the CD4+FOXP3+/ T-regulatory cell population the cisplatin treatment reduced the 
percentage population in comparison to the control (orange bar figure 5.11- A, dark blue bar 
figure 5.11- B, p=0.0499). Treatment with the cockle extract resulted in a decrease in the Treg 
cell population in comparison to the control sample, as can be seen by the grey bar in figure 
5.11- A and the orange bar in figure 5.11- B (p=0.0511), and also in comparison to the cisplatin 
treatment (grey bar figure 5.11- B). The Treg cell population was reduced by the largest 
amount post whelk extract treatment in comparison to the control (yellow bars figures 5.11- 
A and 5.11- B, p=0.0422) and also in comparison to cisplatin treatment (light blue bar figure 
5.11- B) and cockle extract treatment (green bar figure 5.11- B).  
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Figure 5.11. A - Average CD4+ cell types (FOXP3, GARP, IFN-γ and IL-4) in stimulated PBMCs. Average 
percentage CD4+ cell type graph for stimulated PBMCs. Figure 5.11. B - Average differences in CD4+ 
cell type percentage in stimulated PBMCs. Average percentage differences in CD4+ cell type and 
treatment comparison graph for stimulated PBMCs; showing differences in cell type against treatment 
comparisons between the three treatment types and the untreated control cells. Percentage 
difference in cells was calculated based on the comparison treatment e.g. where cis: whelk is a 
comparison of the whelk extract cell population to the cell population in cisplatin treated cells. Both 
figures represent stimulated PBMCs treated with the IC50 dose of cisplatin, cockle extract and whelk 
extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Control/ untreated cells were used as a 
comparison. Using an incubation period of 3-days. Where N=3, percentage cell type or difference was 
in relation to the lymphocyte CD4+ population and error bars show SEM. Significance is denoted by *, 
absence of * indicates no significance. 
Figure 5.12 identifies that the mean fluorescence in stimulated GARP+CD4+Treg cells was 
reduced by both the cisplatin treatment (p=0.0593, orange bar) and by the whelk extract 
treatment (p=0.0354, yellow bar). The treatment with the whelk extract reduced the mean 
fluorescence by the most in comparison to the control and the cisplatin treatment. The 
treatment with the cockle extract resulted in an increase in the mean fluorescence of 
GARP+CD4+Treg cells in comparison to the control (p=0.6095, grey bar, figure 5.12).  
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Cisplatin treatment resulted in a decrease in the mean fluorescence of IFN-γ+CD4+Treg cells 
(p=0.8794, orange bar, figure 5.12). Both treatment with the cockle extract (p=0.4172) and 
whelk extract (p=0.5752) resulted in an increase in the mean fluorescence of IFN-γ+CD4+Treg 
cells post treatment, as can be seen by the grey and yellow bars respectively in figure 5.12. 
Post treatment with cisplatin the mean fluorescence of IL-4+CD4+Treg cells increased by the 
largest amount (p=0.1958, orange bar, figure 5.12) in comparison to the control. Treatment 
with the cockle extract also resulted in an increase in the mean fluorescence of IL-4+CD4+Treg 
cells (p=0.5817, figure 5.12; grey bar) however this increase was not as much as that of 
cisplatin treated cells. In IL-4+CD4+Treg cells treated with the whelk extract mean fluorescence 
decreased in comparison to the control (p=0.2228, figure 5.12; yellow bar).  
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Figure 5.12 The average median fluorescence of biomarker/ cytokine levels in stimulated CD4+Treg 
cells. The average median fluorescence of biomarker/ cytokine levels in stimulated CD4+Treg cells 
obtained from the histogram gating system observed in figure 5.2. Average data obtained from 
stimulated PBMCs treated with IC50 values of cisplatin (6 µg/ml), cockle extract (12 µg/ml) and whelk 
extract (12 µg/ml), with an incubation period of 3-days and N=3. Graph displayed was created using 
Prism 8.0 software. Error bars show SEM, significance is denoted by *, absence of * indicates no 
significance.  
5.3.2.2 CD8+/ Cytotoxic T-cell populations in stimulated PBMCs 
In the CD8+GARP+ percentage population there were only small amounts of cell populations 
which can be seen by the bars in figures 5.13- A. There were also no differences between the 
control sample and either the cisplatin treatment (p=0.2377) or cockle extract treatment 
(p=0.1925) which can be seen by the lack of bars in figure 5.13- B. The whelk extract treatment 
(p=0.1956) resulted in a small increase in the percentage of CD8+GARP+ cells as can be seen 
by the yellow bars in figures 5.13- A and 5.13- B.  
The CD8+IFN-γ+ cell population experienced a decrease in percentage population post 
treatment with the cockle extract in comparison to the control (grey bar figure 5.13- A and 
* 
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orange bar figure 5.13- B, p=0.0829). The decrease in CD8+IFN-γ+ cell population treated with 
the cockle extract was also in comparison to the cisplatin treatment (grey bar figure 5.13- B) 
and the whelk extract treatment (green bar figure 5.13- B). Cisplatin treatment exerted a 
decrease in the percentage population of CD8+IFN-γ+ cells post treatment in comparison to 
the control (orange bar figure 5.13- A and dark blue bar figure 5.13- B, p=0.0154) and in 
comparison to the whelk extract treatment (light blue bar figure 5.13- B). The whelk extract 
treatment resulted in a decrease in the percentage population of CD8+IFN-γ+ cells in 
comparison to the control (yellow bars figures 5.13- A and 5.13- B, p=0.0612).  
The population of CD8+IL4+ cells experienced a decrease in the percentage population post 
treatment with the cockle extract in comparison to the control sample as seen by the grey 
bar in figure 5.13- A and the orange bar in figure 5.13 B, p=0.4754. The population of CD8+IL4+ 
cells was also decreased in comparison to the cisplatin treated cells (grey bar figure 5.13- B) 
and whelk extract treated cells (green bar figure 5.13- B) post treatment with the cockle 
extract. The whelk extract treatment resulted in a decrease in the percentage population of 
CD8+IL4+ cells in comparison to the control sample (yellow bars figures 5.13- A and 5.13- B, 
p=0.2889) and in comparison to the cisplatin treated cells (light blue bar figure 5.13- B). 
Cisplatin treatment resulted in a decrease in the percentage population of CD8+IL4+ cells post 
treatment in comparison to the control sample (orange bar figure 5.13- A and dark blue bar 
figure 5.13- B, p=0.7892).  
5.3.2.2.1 CD8+FOXP3+/ CD8+ Treg cells in stimulated PBMCs 
In the CD8+FOXP3+/ CD8+ Treg population the cockle extract treatment brought about a 
decrease in the population percentage in comparison to the control as can be identified by 
the grey bar in figure 5.13- A and the orange bar in figure 5.13- B, p=0.1415. The cockle extract 
treatment reduced the population of CD8+ Treg cells by three times more than the treatment 
with cisplatin as can be seen by the grey bar in figure 5.13- B. Whelk extract treatment 
resulted in a decrease in the percentage of CD8+ Treg cells in comparison to the control sample 
as can be identified by the yellow bars in figures 5.13- A and 5.13- B, p=0.1845. The whelk 
extract treatment resulted in two times larger a decrease in the population percentage of 
CD8+ Treg cells in comparison to the cisplatin treatment (light blue bar figure 5.13- B). The 
cisplatin treatment resulted in a decrease in the percentage population of CD8+ Treg cells in 
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comparison to the control which can be seen by the orange bar in figure 5.13- A and the dark 
blue bar in figure 5.13- B, p=0.2302. 
 
Figure 5.13. A - Average CD8+ cell types (FOXP3, GARP, IFN-γ and IL-4) in stimulated PBMCs. Average 
percentage CD8+ cell type graph for stimulated PBMCs. Figure 5.13. B - Average differences in CD8+ 
cell type percentage in stimulated PBMCs. Average percentage differences in CD8+ cell type and 
treatment comparison graph for stimulated PBMCs; showing differences in cell type against treatment 
comparisons between the three treatment types and the untreated control cells. Percentage 
difference in cells was calculated based on the comparison treatment e.g. where cis: whelk is a 
comparison of the whelk extract cell population to the cell population in cisplatin treated cells. Both 
figures represent stimulated PBMCs treated with the IC50 dose of cisplatin, cockle extract and whelk 
extract (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Control/ untreated cells were used as a 
comparison. Using an incubation period of 3-days. Where N=3, percentage cell type or difference was 
in relation to the lymphocyte CD8+ population and error bars show SEM. Significance denoted by *, 
absence of * indicates no significance. 
Whelk extract treatment resulted in a mean fluorescence in GARP+CD8+Treg cells equal to that 
of the control as can be seen by the lack of yellow bar in figure 5.14 (p=0.5416). Both 
treatment with cisplatin (p=0.3504, orange bar, figure 5.14) and the cockle extract (p=0.5, 
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grey bar, figure 5.14) resulted in increases in mean fluorescence of GARP+CD8+Treg cells post 
treatment.  
Treatment with cisplatin resulted in a decrease in the mean fluorescence of IFN-γ+CD8+Treg 
cells in comparison to the control cells (p=0.9234, orange bar, figure 5.14). The mean 
fluorescence of IFN-γ+CD8+Treg cells increased post treatment with the cockle extract 
(p=0.3804, grey bar, figure 5.14) and post treatment with the whelk extract (p=0.8016, yellow 
bar, figure 5.14).  
The mean fluorescence of IL-4+CD8+Treg cells increased post treatment with cisplatin 
(p=0.9978, orange bar, figure 5.14), the cockle extract (p=0.5544, grey bar, figure 5.14) and 
the whelk extract (p=0.8219, yellow bar, figure 5.14). With the cockle extract treatment 
resulting in the highest increase in mean fluorescence of IL-4+CD8+Treg cells.  
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Figure 5.14 The average median fluorescence of biomarker/ cytokine levels in stimulated CD8+Treg 
cells. The average median fluorescence of biomarker/ cytokine levels in stimulated CD8+Treg cells 
obtained from the histogram gating system observed in figure 5.2. Average data obtained from 
stimulated PBMCs treated with IC50 values of cisplatin (6 µg/ml), cockle extract (12 µg/ml) and whelk 
extract (12 µg/ml), with an incubation period of 3-days and N=3. Graph displayed was created using 
Prism 8.0 software. Error bars show SEM, significance is denoted by *, absence of * indicates no 
significance.  
5.4 Discussion 
5.4.1 Cytokine and T-regulatory cell response results key findings  
• Treatment with both the cockle and whelk extracts exerted little effect on the healthy 
lymphocyte subpopulations (T-helper and cytotoxic T-cells).  
• T-regulatory cell populations experienced significant reductions in population 
percentage post treatment with both the cockle and whelk extracts in both the 
stimulated and unstimulated PBMC assays.  
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• The whelk extract treatment significantly reduced the population of IFN-γ+ T-helper 
cells in the stimulated PBMCs. While the cockle extract treatment significantly 
increased the population of IFN-γ+ T-helper cells in the unstimulated PBMCs. 
• Both the cockle and whelk extract treatments significantly reduced mean fluorescence 
of IFN-γ+ cytotoxic Treg cells.  
5.4.2 Discussion 
Cancer cells possess the ability to alter the tumour microenvironment in order to become 
immunosuppressive (Sompayrac, 2015), therefore understanding how a potential anti-cancer 
treatment interacts with immune cells and the production of cytokines has become more 
important in recent years. Cancer cells create the immunosuppressive tumour 
microenvironment through increased production of Treg cells, which subsequently increase 
the production of TGF-β and IL-10 (Facciabene et al., 2012; Elkord, 2010). Raised levels of Treg 
cells have been linked to poor prognosis in cancer patient and can also negatively impact on 
immunotherapy thus aiding the progression of cancer (Elkord, 2010). Treg cells can be 
identified through the expression of the winged-helix transcription factor FOXP3 (Lal and 
Bromberg, 2009), as the transcription factor is essential for the development and function of 
Treg cells (Wang et al., 2009; Probst-Kepper et al., 2009). Various intracellular signalling 
molecules and extracellular stimuli can also affect the function and development of Treg cells 
such as IFN-γ and IL-4; this is achieved through the regulation of FOXP3 and their effects on 
the cells of the immune system (Lal and Bromberg, 2009). Probst-Kepper et al., (2009) also 
identified the presence of a transmembrane protein known as glycoprotein A repetitions 
predominant (GARP) which could be linked to the suppressive nature and identification of Treg 
cells. The effect of cockle and whelk derived GAGs on Treg cells was unknown therefore an 
aim of this research was to identify the effects of the marine mollusc derived GAGs on the 
levels of Treg cells in both unstimulated and stimulated (vastly proliferating) PBMCs. 
Interferon-gamma (IFN-γ) is a cytokine which is secreted by T-cells such as NK cells and 
activated T-helper and cytotoxic T-cells (Mojic, Takeda and Hayakawa, 2018; Boehm et al., 
1997). IFN-γ is known to play a role in various cellular functions which include apoptosis and 
cellular proliferation (Boehm et al., 1997). IFN-γ also has an involvement in the 
phosphorylation of STAT1 which ultimately leads to interactions with a FOXP3 promotor in T-
helper cells (Lal and Bromberg, 2009), this interaction stimulates the expression of FOXP3 and 
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therefore upregulates Treg cell development. Interleukin-4 (IL-4) is a cytokine which is 
secreted by activated T-cells, basophils and mast cells (Hou et al., 1994), which play an 
important role in the immune system (Takeda et al., 1996). IL-4 also plays a vital role in the 
balance of T-helper cells (Hou et al., 1994). IL-4 also promotes the phosphorylation of STAT6 
which exerts an inhibitory effect on the expression of FOXP3 therefore can be deemed as an 
opposing cytokine to IFN-γ in its effects on Treg cells (Lal and Bromberg, 2009). It is now known 
that the presence of GAGs on all surfaces allows the interaction of GAGs with cytokines and 
the interaction of GAGs with cytokines is now thought to play a role in the regulation of 
cytokine activity and biological action (Fernandez-Botran, Yan and Justus, 1999). Therefore 
this research also aimed to determine the effects of the novel GAGs isolated from the 
common cockle and common whelk on IFN-γ and IL-4 cytokine levels.  
In the unstimulated PBMC assays both the cockle and whelk extracts exerted small but 
significant decreases in the percentage population of lymphocytes (figures 5.3 and 5.4) (p= 
0.045 and p= 0.0497 respectively). While in the cytotoxic T-cell, T-helper cell, GARP, IFN-γ, IL-
4 and FOXP3 populations experienced very little non-significant effects post treatment with 
both the cockle and whelk extracts. In the population of GARP positive and IFN-γ T-helper 
populations cell both the cockle and whelk extract treatments resulted in non-significant 
increases in the population percentage (figure 5.5). In the IL-4 positive population of T-helper 
cells both the cockle and whelk extract treatment resulted in non-significant reductions in 
population percentage. Treatment with both the cockle and whelk extracts resulted in 
significant decreases in the percentage population of Treg cells (p= 0.0362 and p= 0.0199 
respectively), with the whelk extract treatment resulting in the largest reduction in 
population percentage. In the mean fluorescence of the Treg cell populations (figure 5.6) both 
the cockle and whelk extracts resulted in decreases in the fluorescence of GARP. The mean 
fluorescence of IFN-γ in the Treg cell population increased post treatment with both the cockle 
and the whelk extracts. Treatment with the whelk extract resulted in an increase in the mean 
fluorescence of IL-4 in the Treg cell population, while treatment with the cockle extract 
resulted in a decrease in the mean fluorescence. In the cytotoxic T-cell populations (figure 
5.7) positive for IFN-γ and IL-4 treatment with both the cockle and whelk extract resulted in 
non-significant decreases in the population percentage of the cytotoxic T-cell population. 
Treatment with the cockle extract resulted in a non-significant increase in the population of 
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cytotoxic T-cells positive for GARP, while the whelk extract treatment resulted in a non-
significant decrease in the population percentage of cytotoxic T-cells positive for GARP. In the 
CD8+ Treg cells both the cockle and whelk extract treatments resulted in significant decreases 
in the population percentage (p= 0.0477 and p= 0.0361 respectively). Both treatment with 
the cockle and whelk extracts resulted in an increase in the mean fluorescence (figure 5.8) of 
GARP in the CD8+ Treg cells. The mean fluorescence in the CD8+ Treg cells of IL-4 and IFN-γ 
decreased post treatment with both the cockle and whelk extracts. The decrease in IFN-γ 
mean fluorescence was significant post treatment with both the cockle and whelk extracts 
(p= 0.0027 and p= 0.0011 respectively).  
In the unstimulated PBMCs the reduction noted in IFN- γ post treatment with the whelk 
extract, could suggest a decrease in Treg cell potency, while the increase in IL-4 populations 
could indicate potential increases in FOXP3 production. The information obtained from the 
study suggests that the whelk extract may inhibit the immune evasion of cancer through its 
reduction in Treg cells also through its reduction in cytokine populations which play a role in 
immune evasion and prevention of cells death. The cockle extract treatment also results in 
reductions in those cell types and cytokines however in certain cases the reduction was small 
in comparison to the whelk extract treatment and the control treatment cisplatin. Both GAG 
extract treatments appear to reduce the population of cytotoxic T-cells positive for IL-4 and 
IFN- γ, but this reduction is not significant and would be unlikely to promote a phenotypic 
change in cytotoxic T-cells. The results obtained from the whelk extract treated unstimulated 
PBMCs could suggest a potentially beneficial novel GAG treatment which could help with the 
prevention of immune evasion of cancer, which supports the suggestion of Basappa et al., 
(2012) that GAG chains may exhibit anti-cancer properties whilst exerting minimal side 
effects. 
In the stimulated PBMC assays both the cockle and whelk extract resulted in decreases in the 
population percentages of lymphocytes, cytotoxic T-cells and IFN- γ (figures 5.9 and 5.10). 
Whilst the treatment with both GAG extracts resulted in increases in the population 
percentages of T-helper cells (figure 5.11) and IL-4. In the GARP positive population of the 
stimulated PBMCs the cockle extract treatment resulted in an increase in the population 
percentage and treatment with the whelk extract resulted in a decrease in the percentage 
population. Treatment with both the cockle and whelk extracts resulted in decreases in the 
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percentage population of both GARP positive T-helper cells and in Treg cells. With the 
decreases in the Treg cells treated with both the cockle and whelk extracts being significant 
(p= 0.0145 and p= 0.0191 respectively). Post treatment with the cockle extract the population 
percentage of IL-4 positive T-helper cells and IFN- γ positive T-helper cells was increased. The 
IL-4 positive population of T-helper cells was also increased post treatment with the whelk 
extract, whilst the population of IFN- γ positive T-helper cells was significantly decreased post 
treatment with the whelk extract (p= 0.0156). The mean fluorescence of the Treg cells (figure 
5.12) of IFN- γ increased post treatment with both the cockle and whelk extracts. Treatment 
with the cockle extract resulted in increases in the mean fluorescence of both IL-4 and GARP 
in the Treg cell population. Whelk extract treatment resulted in decreases in the mean 
fluorescence of both IL-4 and a significant decrease in the mean fluorescence of GARP in the 
Treg cell population (p= 0.0354). In the population of GARP positive cytotoxic T-cells the cockle 
extract treatment did not exert an effect on the population percentage, whilst treatment with 
the whelk extract resulted in a small increase (figure 5.13). Treatment with both the cockle 
and whelk extracts resulted in decreases in the population percentages of IFN- γ, IL-4 positive 
cytotoxic T-cells and CD8+ Treg cell populations. Both the cockle and whelk extract treatment 
resulted in increases in the mean fluorescence of IFN- γ, GARP and IL-4 in the CD8+ Treg cell 
populations (figure 5.14).  
The results from this study suggest that both the cockle and whelk extracts may provide a 
therapeutic treatment method that results in small effects on vastly proliferating 
lymphocytes. The GAG extract treatment exerted reductions in Treg cells which may suggest 
that the treatment with the extracts could prevent the immune evasion of cancer cells. The 
decrease in the percentage of cytotoxic T-cells may be linked to the decrease in the 
percentage of IFN- γ cells post treatment with both GAG extracts and may result in less 
proliferation or apoptosis in treated cells. While the increase in the percentage of IL-4 may 
be linked to the increase in the percentage of T-helper cells post treatment with the GAG 
extracts.  
The results from the cytokine and Treg response assays show that the novel marine mollusc 
derived GAG extracts, in particular the whelk extract, resulted in a significant decrease in the 
percentage of Treg cells (in both stimulated and unstimulated PBMCs). Which could suggest 
that treatment with the GAG extracts could help to reduce the immune evasion of tumour 
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cells. Since raised Treg levels have been linked to the progression and immune evasion of 
cancer (Bayer and Schultze, 2006). The results of this research also support the theory put 
forward by Aldairi, Ogundipe and Pye (2018) and Ogundipe (2015) that the marine molluscs 
GAGs derived from the common cockle and whelk appears to target cancer cells but shows 
some selectivity towards healthy lymphocytes.       
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CHAPTER 6- DISCUSSION 
6.0 Discussion and clinical significance 
6.1 Overview of main research findings 
This study for the first time has provided a significant insight into the effects of novel GAG 
compounds isolated from the common cockle and the common whelk on healthy 
lymphocytes (both activated and naïve). This research has also identified for the first time the 
activity of the novel cockle and whelk GAG extracts on the lymphoblastic lymphoma cell line 
(U698). This thesis research has also independently confirmed the cytotoxicity of the cockle 
and whelk extracts on the acute lymphoblastic leukaemia cell line (MOLT-4) and chronic 
myeloid leukaemia cell line (K562) previously published by Aldairi, Ogundipe and Pye (2018) 
and Ogundipe (2015). An overview summary of the main research findings and implications 
follow: 
• Cancer cell line responses: Cockle and whelk extracts exerted a significant and 
profound inhibitory effect (proliferation) on both the MOLT-4 and U698 cell lines 
(MTT assay) and further confirmed via the (CFSE proliferation assay).  Building on 
mechanism of action; both the cockle and whelk extracts exerted significant induction 
of apoptosis in the MOLT-4 and U698 cell lines (annexin V apoptosis assay).  
• In contrast, marine GAGs induced relatively minimal proliferation inhibition in both 
the naïve and stimulated PBMCs (MTT assay).  To consider in further detail: 
o Naïve PBMC responses: The whelk extract induced minimal apoptosis for all 
cell families tested.  Both cockle extract and cisplatin treatment did show 
inhibition of naïve healthy lymphocytes, but the cockle extract was more 
favourable than the standard cisplatin with less apoptosis induction.  In the 
very sensitive proliferation assay (CFSE/FACS) both cockle and whelk extracts 
exerted a proliferative effect in some T-helper and cytotoxic T-cell 
subpopulations indicating the marine GAGs tested are unlikely to negatively 
impact function of healthy naïve immune cells, and therefore provide an 
improved therapeutic approach over current standards. 
o Activated PBMC responses (T helper and cytotoxic): Whelk extracts exerted 
little effect on the T-helper cell populations, but induced apoptosis in the 
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cytotoxic T-cell populations. Cockle extract induced less apoptosis in the 
cytotoxic T-cell populations compared to the whelk extract and cisplatin 
treatment.  These findings (for both cockle and whelk extracts) were 
confirmed via the proliferation assays in some subpopulations of T-helper cells 
and cytotoxic T-cell populations.  These findings indicate the marine GAG 
actions may have impact on an already activated immune system e.g. during 
an infection and thus, similarly to standard chemotherapy treatments may 
compromise immune memory to pathogens and clearance of infections. 
• Lymphocyte cytokine responses: Marine GAG extracts exerted little influence on 
helper T-cell cytokines in naïve or activated healthy lymphocyte population.  GAG 
action on TH1 and/or CD8/CTLs, reduced memory TH1 activity while raising TH1 
activity in naïve cells.  The likely clinical outcome of this is reduced effective immune 
responses during a pre-established infection while undergoing therapy, while not 
influencing naïve T-cell functions. 
• T-regulatory cell responses: Treg numbers were significantly reduced post treatment 
with both the cockle and whelk extracts in both naïve and stimulated PBMCs.  This 
reduced regulation of immunity may prove beneficial and provide protective action to 
reduce tumour immune evasion seen in various forms of cancer (Elkord et al., 2010) 
6.2 The role of glycosaminoglycans in biological processes 
Glycosaminoglycans (GAGs) and Proteoglycans (PGs) are located in the ECM of all cells, PGs 
are made up of a protein core with covalently bonded GAG chains, the specific sulphation 
pattern present on the GAG chains are thought to be responsible for the regulation of several 
physiological functions including: development, inflammation and immunity and pathological 
processes such as: cancer, inflammation, Alzheimer’s disease as well as bacterial and viral 
infections (Morla, 2019; Ghatak et al., 2015). GAGs play a crucial role in the maintenance of 
the structural integrity of both cells and tissues and have also shown to interact with 
chemokines, interleukins and pro-inflammatory cytokines such as IFN-γ (Varki et al., 2009: 
Proudfoot et al., 2001). Interactions with the GAG chains on endothelial cell surface PGs 
contribute to the localisation of chemokines and in the formation of a concentrated 
immobilised gradient of chemokine which facilitates the migration of leukocytes towards a 
site of inflammation or injury (leukocyte chemotaxis) (Proudfoot et al., 2017: Springer, 1995). 
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Chemokine-GAG interaction also contribute to the physical adhesion-resistant barrier 
function of the glycocalyx (carbohydrate coating of cells) and mediates the cell-cell 
interactions required for leukocyte adhesion and transmigration (Nikitovic et al., 2008: 
Constantinescu, Vink and Spaan, 2003). HS interacts with cytokines through ionic interactions 
between the basic amino acids present on the cytokines and the GAG sulphated domain (Pye 
et al., 1998). Longer chain GAGs have shown to exert a higher affinity for chemokines in 
comparison to short chain GAGs (Ziarek et al., 2013). The sulphation pattern of GAGs is also 
a crucial factor for GAG binding of chemokines e.g. 2-O-de-sulphation of heparin results in 
significant loss of chemokine affinity (Ziarek et al., 2013).  
The research of Carter, Ali and Kirby (2003) investigated the role of the modulation of HS 
sulphation in endothelial inflammation. Cater, Ali and Kirby (2003) identified that N-
deacetylase/N-sulfotransferase (NDST) upregulation played an important role in the 
activation of endothelial cells during the process of inflammation and that stimulation with 
proinflammatory cytokines TNF-α and IFN-γ resulted in significant changes to NDST-1 and 
NDST-2 expression in the HMEC-1 endothelial cell line. These changes correlated with 
structural changes in HS on the cell surface (Carter, Ali and Kirby, 2003). Carter, Ali and Kirby 
(2003) concluded that the biological activity of chemokines can be increased through the 
appropriation of chemokines to cell surface GAGs, which is essential in chemokine mediated 
migration of leukocytes across cell monolayers. Post translational modifications (PTMs) of 
chemokines is also known to affect their interactions with GAGs, therefore PTMs in 
chemokines could be a potential mechanism for the regulation of chemokine-dependent cell 
migration (Barker et al., 2017).  
Wound healing is a highly regulated process with several overlapping phases resulting in the 
regaining of tissue integrity (Menke et al., 2007). Failure in the regulation of wound healing 
can result in pathological conditions such as fibrosis and can lead to organ failure and 
ultimately death (Misra et al., 2011). In the process of wound healing the ECM not only 
provides structural support for the tissue but is also a platform for the regulation of inter- and 
intra- cellular signalling (Bissell, Hall and Parry, 1982). ECM molecules such as Hyaluronan 
(HA), PGs such as veriscan and aggrecan and receptors, such as the HA receptor CD44, play a 
role in the regulation of wound healing (Ponta, Sherman and Herrlich, 2003). PGs are involved 
in multiple processes associated with wound healing, versican-V3 (CS-PG) is associated with 
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the transformation of fibroblasts into myofibroblasts, perlecan (HS-PG) is associated with the 
induction of angiogenesis, while the syndecans -1 and -4 (HS-PG) also stimulate angiogenesis 
and the migration of keratinocytes and endothelial cells to the wound site in murine models 
(Cattaruzza and Perris, 2005). In wound healing concentration of GAGs are adjusted 
depending on the stage of the inflammatory response, in the initial stages of inflammation 
production of HA by fibroblasts is high and is followed by increases in both CS and DS PGs 
(Clark, 1998). As the rate of proliferation slows in the later stages of inflammation the volume 
of HS PGs increases at the wound site (Clark, 1998). Proteases also degrade the PGs which 
releases GAG fragments also aiding with the modulation of wound healing (Peplow, 2005). 
The presence of HS in the wound site contributes to the release of proangiogenic factors such 
as IL-1 and IL-6 (Taylor and Gallo, 2006: Ortéga, L’Faqihi and Plouët, 1998). Due to its presence 
on almost all cell types HA plays a crucial role in many biological processes such as cell 
signalling, pathobiology and wound repair and regeneration (Ghatak et al., 2015: Chen and 
Abatangelo, 1999). HA effects on cells can be regulated through interactions with its 
receptors CD44 and RHAMM, through these interactions activation of intracellular signalling 
pathways can occur (Misra et al., 2011). The receptors CD44 and RHAMM are also associated 
with the injury and repair of tissues as well as cancer cell growth and metastasis (Ghatak et 
al., 2014: Ponta, Sherman and Herrlich, 2003). During the inflammatory phase HA regulates 
the early inflammatory response through the concentration of HA in the wound bed, 
regulation occurs through; modulating both inflammatory cell and fibroblast migration to the 
wound site, the synthesis of proinflammatory cytokines and phagocytosis of microbes (Chen 
and Abatangelo, 1999). In the reparative/remodelling phase of wound healing granulation 
tissue, containing endothelial cells, fibroblasts, PGs ad GAGs, fills the wound in order to 
protect the wound from the environment and to support capillary growth and the formation 
of collagen and fibronectin, which must occur before epithelial cells can migrate across to the 
new tissue (Clark, 1998). However excessive accumulation of fibronectin, collagen, PGs and 
GAGs or failure to remove HA fragments can lead to unremitting inflammation and the 
development fibrotic scar tissue (Li et al., 2011). Due to its viscoelastic and hydrated domain 
properties HA can also be used for exogenous application to promote tissue repair and 
regeneration, such as can be seen in the acceleration of wound healing post exogenous 
application of HA to corneal epithelial injury (Nakamura, Hikida and Nakano, 1992). It has also 
been demonstrated that HA is produced by malignant cells in order to promote tumorigenic 
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properties, CD44-V6 is also overexpressed in many cancers and the interaction between HA 
and CD44-V6 plays a crucial role in the onset, survival and growth of many cancers (Misra et 
al., 2011). 
Inflammation is a mechanism of defence utilised by the body to protect against harmful 
stimuli (Parish, 2006). The events which occur during the inflammatory process are regulated 
by GAGs especially those present on the surface of endothelial cells and leukocytes (Parish, 
2006). GAGs play a crucial role in leukocyte rolling, the regulation of chemokine migration 
and activation and in leukocyte migration (Parish, 2006). At the injury or infection site 
macrophages release cytokines and stimulate the activation of endothelial cells which results 
in P-selectin being displayed (Moore et al., 1995). Activated endothelial cells displaying P-
selectin bind with the P-selectin glycoprotein ligand (PSGL-1) on endothelial cells enabling the 
leukocytes to adhere to the endothelial layer (Moore et al., 1995). The first role of GAGs in 
inflammation is to regulate leukocyte rolling, this is done through HS on the surface of 
endothelial cells binding L-selectin on leukocytes (Parish, 2006). Cytokines and chemokines 
such as IL-8 are released at the site of injury/ infection by macrophages and bind with GAGs 
on the surface of endothelial cells and leads to cytokine transcytosis (Webb et al., 1993). 
Syndecan, a HSPG, plays a major role in the migration process, while heparin which is 
produced and stored in mast cells upon inflammation is co-released with histamine and aids 
with vascular permeability (Theoharides et al., 2012). Inflammatory responses can be 
regulated through the proteolysis of chemokines, GAGs can provide protection for 
chemokines from proteolytic degradation thus GAGs play a role in the regulation of 
inflammatory responses (Ziarek et al., 2013: Sadir et al., 2004). Protection of chemokines by 
GAGs could be through steric blockade from the protease binding site or stabilisation of 
chemokine oligomers may also be responsible (Liang et al., 2016: Ziarek et al., 2013). 
Therefore GAG protection of chemokines from proteolysis could provide a mechanism for the 
regulation of intensity and duration of an inflammatory response (Ziarek et al., 2013). Cells 
shed GAGs in many pathological conditions which could inhibit chemokine-receptor 
interactions and subsequently inflammatory responses (Sarrazin, Lamanna and Esko, 2011). 
Interactions between GAGs and chemokines also have the potential for use in the delivery of 
therapeutics, the encapsulation of chemokines in GAG-containing hydrogels has been 
reported to preserve the activity and controlled release of the chemokine in order to promote 
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wound healing (Lohmann et al., 2017: Wang et al., 2013). As GAGs play a vital role in the 
inflammatory process exogenous sulphated GAGs can be used to down regulate inflammation 
(Morla, 2019). Heparin has been identified as a potent anti-inflammatory product, for the 
treatment of bronchial asthma, ulcerative colitis and in burns, in animal models, however due 
to its anticoagulant properties the risk of bleeding is deemed too high for its use as an anti-
inflammatory (Tyrrell et al., 1999). A heparin isolated from shrimp has been found to reduce 
acute inflammation upon injury through the reduction of the migration of inflammatory cells 
to the site of injury and has also been found to be non-anticoagulant (Brito et al., 2008). While 
exogenous DS was found to inhibit P-selectin in inflammation in murine models (Kozlowski, 
Pavao and Borsig, 2011).  
Interactions between cytokines, growth factors and growth factor receptors and GAGs have 
been implicated in the growth progression and metastasis of cancer (Afratis et al., 2012). 
GAGs, such as HSPGs, also play a crucial role in multiple signalling cascades which are essential 
for angiogenesis and the invasion and metastasis of cancer, while other GAGs have been 
identified as potent inhibitors of tumour progression (Theocharis et al., 2010). Levels of HS in 
certain cancers are reduced as HS has the ability to promote cell-cell and cell-ECM adhesion 
thus inhibiting the invasion and metastasis of cancer cells (Nikitovic et al., 2010). While in 
other cancers reduced levels of HS and alterations in sulphation patterns resulted in increased 
invasive activity of malignant cells and thus the promotion of tumour progression (Nikitovic 
et al., 2010). Overexpression of heparinase (HSPE), an enzyme which cleaves HS from HSPGs 
at the β -1 and -4 positions, has been implicated in the promotion of tumour growth and 
metastasis and tumour angiogenesis (Sistla et al., 2019). CS and DS have also been shown to 
have essential roles in the regulation of proliferation, apoptosis, cell migration and adhesion 
and cellular invasion (Mikami and Kitagawa, 2013). Increased levels of versican (CSPG), with 
altered sulphation patterns in the CS GAG chains, is related to the progression of early stage 
breast and prostate cancer (Ricciardelli et al., 1998). Growth factors and chemokines present 
in tumour microenvironments increase the production of HA, increased levels of HA have also 
been noted in multiple types of human cancers such as breast, ovarian and lung (Tammi et 
al., 2011: Auvinen et al., 2000). Heparin has demonstrated anti-cancer properties as well as 
anticoagulant activity (Borsig, 2010). A non-anticoagulant HS isolated from a bivalve mollusc 
which inhibits P-selectin-mediated activities like metastasis in Lewis lung carcinoma cells 
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(Gomes et al., 2014). Heparinase inhibitor Roneparstat has been shown to reduce tumour size 
significantly in preclinical murine models (Ritchie et al., 2011). Necuparanib is a non-
anticoagulant HS and exerts its anti-cancer activity through the inhibition of multiple targets: 
heparinase, VEGF, FGF 2 and P-selectin which are involved in tumour progression and 
metastasis. Heparinase 1 (hep 1) and heparinase 3 (hep 3) produce different GAG fragments 
from the tumour cell surface, hep 1 fragments were found to promote tumour growth while 
hep 3 fragments inhibited tumour cell growth and metastasis (Liu et al., 2002). Fucosylated 
CS (FucCS) sourced from sea cucumber was found to block P- and L- selectin mediated 
activities thus inhibiting malignant cell metastasis (Borsig et al., 2007).     
Our marine mollusc derived GAGs may work in a similar way through interacting with growth 
factors such as VEGF and FGF, or through interactions with P- and L-selectin thus inhibiting 
cellular processes responsible for malignant cell growth and metastasis. It is difficult to 
completely identify why the marine mollusc (cockle and whelk) derived GAGs are exerting 
specific activity in cancer cells, with minimal activity in health lymphocytes, as the overall 
structure of the isolated GAGs remains unknown. However as identified by Zhang (2010) and 
Ghatak et al., (2015) the level and pattern of sulphation in GAGs can affect the activity and 
function of GAGs, thus this could be a potential factor resulting in the cockle and whelk 
derived GAGs being uniquely potent inhibitors of the leukaemia and lymphoma cell lines 
tested in comparison to the activity noted in the healthy lymphocytes and the lack of activity 
noted by Aldairi, Ogundipe and Pye, 2018 and Ogundipe 2015 in commercially available 
mammalian GAGs tested on cancer cell lines. 
Due the heterogenicity of GAGs complete characterisation can be problematic and so GAG 
mimetics are expected to alleviate this problem and are also predicted to act in a more 
selective manner with potentially fewer side effects (Mohamed and Coombe, 2017). There 
are two classes of GAG mimetics which are saccharide based, less heterogenous in 
comparison to GAGs and built on a sugar backbone, and non-saccharide based, homogenous 
and built on a non-sugar based backbone with negative charge coming from sulphates, 
sulfonates, carboxylates and/or phosphates (Desai, 2013). Non-saccharide based mimetics 
are also thought to be advantageous in comparison to saccharide based mimetics. Both 
saccharide and non-saccharide mimetics have been developed for the treatment of cancer 
and inflammation with some already being used in the clinic and others going through the 
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process of clinical trials (Desai, 2013).  Non-anticoagulant heparin mimetics have been 
developed such as 2-O,3-O-desulfated heparin (ODSH) which does not produce anticoagulant 
effects but has shown to reduce inflammation in the airways though inhibiting neutrophil 
elastase (Griffin et al., 2014). Phosphomannopentase sulphate (PI-88) is a HS mimetic 
developed to inhibit heparinase which is an enzyme with a vital role in angiogenesis and 
cancer cell metastasis (Khachigian and Parish, 2004). PI-88 was found to inhibit proangiogenic 
factors VEGF, FGF -1 and -2 through the out competing HS. In addition to the anti-cancer 
activity noted PI-88 also exhibited anticoagulant action, however although well tolerated in 
pre-clinical trials, failure to reach a primary disease free survival end point ended clinical trials 
at the phase 3 stage (Lanzi and Cassinelli, 2018). PG-545 is an analogue of PI-88 and is 
homogenous with a lipid moiety at the reducing end, pharmacokinetic properties of PG-545 
were increased in comparison to PI-88 and the anticoagulant activity was also reduced 
(Dredge et al., 2011). The lipid moiety was found to bind the hydrophobic pocket of 
heparinase and demonstrated a higher affinity for heparinase and demonstrated potent anti-
tumour and anti-metastatic activity in pre-clinical models (Hammond, Handley, Dredge and 
Blytheway, 2013). Other HS mimetics have been developed which have shown to be potent 
inhibitors of growth factors such as FGF and VEGF and which can also inhibit P-selectin all of 
which are implicated in inflammation and metastasis (Freeman et al., 2005). 
6.3 MTT/ cell viability assay 
Research has identified the medicinal properties of marine GAGs in both in vitro and in vivo 
models (de Jesus Raposo, 2015). Studies have also shown the cytotoxic effects of some GAG 
like compounds such as low molecular weight heparin and HS mimetics (Afratis et al., 2012). 
GAG like compounds isolated from the common cockle have also demonstrated anti-cancer 
properties in the leukemic cell lines K562 and MOLT-4 as well as in some breast cancer cell 
lines (Aldairi, Ogundipe and Pye, 2018). No current study had identified the therapeutic 
properties of marine mollusc derived GAGs on the lymphoblastic lymphoma cell line U698 or 
in healthy lymphocytes (activated or naïve).   
The standard put forward by the National Cancer Institute dictates that a crude natural 
product extract can be deemed to be active against the tested cell line if the IC50 value is 20 
µg/ml or lower (Swaya, Aduma, Chelimo & Were, 2017; Chen et al., 1988). In this research 
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GAGs isolated from the common cockle and the common whelk had a significant inhibitory 
effect on the cell viability in both the MOLT-4 and U698 cell lines. In the MOLT-4 cell line, cell 
viability was reduced by up to 80% and 90% post 3-day incubation with the cockle and whelk 
extract the respectively, the recorded IC50 values were 15.56 µg/ml and 10.4 µg/ml 
respectively as can be seen in figures 3.2 and 3.3 and table 3.1. Cell viability in the U698 cell 
line was significantly reduced by both the cockle and whelk extract treatment (p= 0.0117 and 
p= 0.0001 respectively), with IC50 values ranging 7.51 µg/ml and 102.55 µg/ml (table 3.3). 
U698 cell line viability was reduced by up to 90% post treatment with both the cockle and 
whelk extracts (figures 3.8 and 3.9). There were some anti-proliferative effects noted in the 
K562 cell line post treatment with the cockle and whelk extracts. With cell viability inhibitions 
of up to 50% and Ic50 values ranging 32.8 µg/ml and 186.06 µg/ml (Figures 3.5 and 3.6 and 
table 3.2). Cell viability in the K562 cell line was reduced significantly post 3 day incubation 
period with the whelk extract, with an IC50 value of 71.49 µg/ml (p=0.047). The IC50 value 
obtained for the K562 cell line treated with the cockle extract increased post 5 day incubation 
in comparison to the 4 day incubation period, suggesting potential immunity towards the 
cockle extract treatment had developed in the cell line. Remarkably neither the cockle or 
whelk GAG isolates appeared to exert much of a cytotoxic effect on the healthy lymphocytes 
(either active or naïve), with both extracts failing to reduce cell viability by 50% and thus no 
IC50 value was obtained (tables 3.4 and 3.6; figures 3.11, 3.12 3.17, 3.18). This would suggest 
that the cytotoxic effects identified in the cancer cell lines in response to the novel GAG 
compounds appeared to be acting in a selective manner towards the MOLT-4, K562 leukemic 
and U698 lymphoma cell lines and appeared non-toxic to the healthy lymphocytes either the 
naïve or proliferating lymphocytes (stimulated). The seemingly selective nature of the GAG 
compounds would have been interesting to have explored further, that however was beyond 
the scope of this research, but should be considered in future work to further explore the 
possibility of the therapeutic use of mollusc derived GAG compounds in the clinic. 
The results obtained from the MTT assays identified recorded IC50 values of less than 20 
µg/ml for both the MOLT-4 and U698 cell lines treated with both the cockle and whelk 
extracts. Thus according to the guidelines set by the National Cancer Institute both the cockle 
and whelk extracts can be categorised as an active anti-leukemic and anti-lymphoma cancer 
drug. Interestingly neither the cockle or whelk extracts exerted enough of a cytotoxic effect 
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on either the naïve or activated healthy lymphocytes and can therefore be deemed as inactive 
against healthy lymphocytes. 
 Our data supports that found by Aldairi, Ogundipe and Pye (2018) that the mollusc derived 
GAGs appear to show specificity towards the leukemic and lymphoma cells and has also 
demonstrated a lack of activity towards the healthy lymphocytes. Further supporting the 
potential therapeutic use of these GAG compounds in the clinic. In this research the effects 
of cisplatin on PBMCs noted was similar to the anti-proliferative effects noted by Sakai, et al., 
(2013), however incubation times were different in this research and so there was some level 
of difference in the noted activity. 
Presently there is a pressing interest in finding new anti-cancer drugs which not only improve 
the patient response to treatment, thus reducing the number of fatal incidences of cancer, 
but also to find a treatment with reduced side effects. Reports have suggested that certain 
types of GAG chains have been identified as potentially promising in cancer therapy and are 
also predicted to have minimal side effects (Basappa et al., 2012; Aldairi, Ogundipe and Pye, 
2018). Our data which identified potentially selective activity of the cockle and whelk GAG 
extracts against leukemic and lymphoma cell lines and healthy lymphocytes, would support 
this idea. Making the prospect of the therapeutic use of these marine mollusc derived GAGs 
an even more attractive possibility.  
The whelk extract was identified in this research as being the most effective extract in 
comparison to both the cockle extract treatment and in some cases in comparison to the 
control treatment cisplatin. The unique activity noted in the whelk extract across a variety of 
leukemic cell lines and in the U698 lymphoma cell line may prove to be important as a possible 
intervention in patients with hard to treat cancers. The differences in IC50 values and cell 
viability reduction between the cockle extract treated cells and the whelk extract treated cells 
could suggest that the anti-proliferative effect of the whelk extract could be due to unique 
fine structural features present in the whelk extract. The research carried out by Ogundipe 
(2015) and Aldairi, Ogundipe and Pye (2018) found that all commercially available GAGs (HS, 
heparin, CD and DS) had non-toxic activity against cancer cell lines (including K562 and MOLT-
4). Suggesting that the cockle and whelk GAG extracts must therefore possess unique 
structural details which are not present in commercially available GAGs (Ogundipe, 2015). 
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These unique structures may be a pharmacological feature which could make the cockle and 
whelk GAG extracts potential candidates as the basis for a new therapeutic anti-cancer 
treatment. The differences noted in the obtained IC50 values for the MOLT-4, K562 and U698 
cell lines and the lack of IC50 values for the naïve or activated heathy lymphocytes treated 
with the cockle and whelk extracts could suggest that the GAG extracts may be demonstrating 
some level of selectivity to certain cancer cell types and healthy cells. This potential selectivity 
could prove important in the use of marine GAGs as a potential anti-cancer therapy.  
In cancer cell lines there are changes within the expression of GAGs and proteoglycans in the 
ECM and on the cell surface which enable the cancer cells to proliferate and metastasize and 
induce angiogenesis (Koo et al., 2008). Novel exogenous GAG compounds isolated from 
cockles and whelks, which possess unique structural features in comparison to mammalian 
GAGs, may therefore modulate the effects of ECM and cell surface GAGs in various ways, 
which could therefore lead to the reduction in cell viability noted in this research. The novel 
marine mollusc GAGs could potentially act in various manners; through the activation or 
inactivation of protein based receptors, through outcompeting endogenous GAGs and/or 
inhibiting the biosynthesis of GAGs (Gandhi and Mancera, 2010).  
Understanding the fine structures and specific biological roles of GAG compounds could 
potentially lead to the development of novel GAG based therapies (Afratis et al., 2012). In 
order to further identify the fine structures of the whelk GAG extract, the crude extract was 
purified via the use of ion exchange chromatography (FPLC) and the resulting fractions were 
then tested for activity on the cancer cell lines (figures 3.20- 3.40). All eluted fractions 
appeared to be non-toxic towards the cancer cell lines, with no IC50 values being obtained 
even at maximum dose. Ogundipe (2015) identified the cytotoxic effects of ‘fraction E’ a 
breast cancer cell line but also noted a lack of toxicity towards the MOLT-4 and K562 cell lines. 
The results obtained by Aldairi, Ogundipe and Pye (2018) also suggested ‘fraction E’ of the 
cockle extract appeared to be the bioactive component responsible for the activity noted in 
the cockle extract treated cells. However in a similar way to Ogundipe (2015), this research 
identified no activity in any fraction of the whelk extract against either the MOLT-4, K562 or 
U698 cell lines. This could be due to low levels of GAGs in the isolated fractions, which could 
be combatted by doing further FPLC runs using a higher initial weight of the crude whelk 
extract. It could also be that as demonstrated by Ogundipe (2015) the isolated whelk fractions 
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are not active in the MOLT-4 or K562 cell lines and may also be inactive against the U698 cell 
line at low doses. Further understanding into the structural properties of the whelk GAG 
fractions may potentially open a new therapeutic approach to cancer therapy. 
6.4 Annexin V/ propidium iodide apoptosis assay 
As cancer is the result of a shift in the balance of cellular proliferation and apoptosis, which is 
in favour of proliferation, apoptosis has become an interesting target in the development of 
new anti-cancer therapies (Wesselborg et al., 1999). Apoptosis is a major protective 
mechanism against cancer, therefore inducing apoptosis has become a target in the search 
for new therapies which are efficient and exert less side effects in cancer patients (Coppola 
et al., 2008; Zhou et al., 2009). The process of apoptosis can be characterised through several 
processes including; cell shrinkage, nuclear chromatin condensation, fragmentation of the 
nucleus and the formation of apoptotic bodies (Kroemer et al., 1997). During the process of 
apoptosis the cellular membrane becomes damaged and begins to allow the leakage of 
phosphatidylserine into the outer membrane layers, which in turn allows the binding of 
annexin V and eventually propidium iodide can cross the membrane upon the death of the 
cell (Reiger et al., 2011; Cornelissen et al., 2002; Vermes et al., 1995). This process of leaking 
and binding allows for the identification of the stage of apoptosis at which the cell is at.        
This study demonstrated that in the MOLT-4 cell line both novel GAG extracts (cockle and 
whelk) exerted significant increases in apoptosis, particularly in the early stages of apoptosis 
(figure 4.5, p= 0.0179 and p= 0.003 respectively). Treatment with both the whelk and cockle 
crude GAG compounds brought about increases in non-apoptotic CD3+ MOLT-4 cells (figure 
4.6). The results of this study correspond to the results noted in the MTT assays in chapter 3, 
with the whelk and cockle extracts exerting significant increases in apoptosis in the MOLT-4 
cell line. The results obtained by Ogundipe (2015) identified an increase in early apoptotic 
MOLT-4 cells post treatment with the whelk extract which corresponds to the results 
obtained in this research. Aldairi, Ogundipe and Pye (2018) also demonstrated a significant 
induction of apoptosis in the MOLT-4 cell line with a small but significant increase in late 
apoptotic MOLT-4 cells post treatment with the cockle extract, this was also independently 
demonstrated by this research. The increase in CD3+ non-apoptotic MOLT-4 cells could 
suggest that there may be a level of resistance to the novel GAG compound treatment in a 
 228 
population of MOLT-4 cells expressing the T-cell biomarker CD3. The results of the MTT assay 
could also potentially support this as the percentage of viable MOLT-4 cells plateaus at 10-
20% post treatment with the whelk and cockle extracts (figures 3.2 and 3.3). It would have 
therefore been interesting to have delved into potential resistance further and to have tried 
various doses of the novel GAG compounds in order to identify any potential further action, 
however this was beyond the scope of this research, but could be an avenue for further future 
research. In the K562 cell line treatment with both the cockle and whelk extracts resulted in 
non-significant increases in non-apoptotic cells (figure 4.7). Aldairi, Ogundipe and Pye (2018) 
suggested that due to the aggregating nature of the K562 cell line, performing flow cytometry 
assays using the cell line can prove problematic. This could explain the results of the K562 cell 
line apoptosis assays in this research, however the MTT assays also noted little effect in the 
K562 cell line assays post a 3 day incubation period with either the cockle or whelk extract 
treatments. Again had time allowed it could have been enlightening to have tried various 
doses of the GAG extracts to identify whether either extract could exert an apoptotic effect 
on the K562 cell line at higher doses. Treatment of the U698 cell line with the whelk GAG 
compound resulted in a significant increase in apoptotic cells (p= 0.0426), with a significant 
increase in mid stage apoptotic U698 cells (p= 0.0165, figure 4.8). The cockle extract treated 
U698 cells also had a non-significant increase in the percentage of apoptotic cells. The 
treatment with both novel GAG compounds (cockle and whelk) resulted in non-significant 
reductions in the percentage of CD19+ U698 cells not undergoing apoptosis. The results of the 
U698 cell line apoptosis assays correspond to the MTT results with the whelk GAG extract 
exerting a significant and profound effect on the U698 cells, which was more than those noted 
in cisplatin treated cells. This was the first time that apoptosis induction had been 
demonstrated in the lymphoblastic lymphoma cell line (U698) post treatment with the novel 
GAG compounds. 
The results of this research identified the induction of apoptosis in both the MOLT-4 and U698 
cell lines post treatment with the novel GAG compounds. This finding is consistent with the 
research carried out by Erduran et al., (2007) who demonstrated that chemically modified 
GAG chains and heparin exerted apoptotic effects on lymphoblasts and other carcinoma 
types. Erduran et al., (2007) also predicted that the apoptotic effects noted on lymphoblasts 
was exerted via the extrinsic pathway of apoptosis. Levels of caspase 3 and 8 were also 
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monitored and identified that treatment with heparin induced the apoptosis of lymphoblasts 
and activated caspase 3 and 8 (Erduran et al., 2007). These researchers concluded that in 
lymphoblasts low doses of heparin could induce apoptosis significantly and the induction of 
apoptosis increased with increasing levels of heparin (Erduran et al, 2007). It could be 
suggested that the viability inhibition noted in the MOLT-4 and U698 cell MTT assays, could 
be in part due to the induction of apoptosis identified in the subsequent annexin V/ propidium 
iodide apoptosis assays. The apoptotic effect exerted by both the cockle and whelk extracts 
noted in the MOLT-4 and U698 cell lines is consistent with the apoptotic effect of low doses 
of heparin noted by Erduran et al., (2007) on lymphoblasts and may therefore provide an 
insight into the mechanism of action of the apoptotic effect of these novel GAG compounds.          
The unstimulated PBMC assays (figures 4.10- 4.14) identify the whelk extract (in comparison 
to the cockle extract and cisplatin) as having consistently exerted minimal activity on the 
overall lymphocyte populations, as well as the subpopulations (naïve and memory) of both 
the T-helper cells and cytotoxic T-cells. Although in the unstimulated PBMCs the largest effect 
exerted by the whelk extract was on the memory cytotoxic T-cells, with a significant increase 
in early stage apoptotic cells (p= 0.0379). Cockle extract treated unstimulated PBMCs 
experienced little apoptotic induction in the lymphocyte and T-helper cell populations. 
However the cockle extract induced significant levels of apoptosis in the memory cytotoxic T-
cells (p= 0.0399) and induced more apoptosis than other treatment methods in the naïve 
cytotoxic T-cells, but this induction was non-significant. In the stimulated PBMC assays (figure 
4.15- 4.19) the subpopulations of T-helper cells remained mainly unaffected by treatment 
with the whelk extract. There was a significant increase in the percentage of apoptotic naïve 
T-helper cells post treatment with the whelk extract (p= 0.0429). In the lymphocytes and 
subpopulations of cytotoxic T-cells the whelk extract treatment induced more apoptosis than 
cisplatin, with significant increases in the percentage of early stage apoptotic naïve and 
memory cytotoxic T-cells (p= 0.0448 and p= 0.0409 respectively). The treatment with the 
cockle extract resulted in the least induction of apoptosis across the subpopulations of 
stimulated PBMCs. In the subpopulations of cytotoxic T-cells the treatment with the cockle 
extract resulted in the least percentage induction of apoptosis in comparison to the other 
treatment methods.  
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In the unstimulated PBMC assays the whelk extract proved to be consistently milder that 
treatment with either the cockle extract or cisplatin. This could suggest that the whelk extract 
may be acting in a selective manner towards the cancer cell lines whilst not targeting healthy 
lymphocytes, as was initially suggested by the MTT assays. This further supports the 
suggestion that the novel marine mollusc derived GAG extracts could provide a more 
favourable therapeutic treatment option. Basappa et al., (2012) suggested that certain GAG 
chains may have the potential to provide a useful therapeutic treatment option in cancer 
therapy whilst exerting minimal side effects for the patient. The appearance of the selectivity 
of the whelk extract demonstrated in the unstimulated PBMC and cancer cell line apoptosis 
assays identify that the whelk GAG extract may further support this suggestion. The 
stimulated PBMC assays demonstrated that the whelk extract appeared to target the 
cytotoxic T-cell subpopulations more than the other treatment methods (cisplatin and the 
cockle extract). The increased activity noted in the cytotoxic T-cells may potentially blunt any 
immune responses to viral infections during a patient’s chemotherapy treatment. Despite 
these observations, relative changes in the stimulated PBMC assays compared to the potency 
observed in the cancer cell assays suggests that the novel marine mollusc derived GAG 
extracts may be able to provide a treatment option that shows specificity towards tumour 
cells whilst not targeting healthy lymphocytes. It is encouraging to note that the novel GAG 
compounds may be acting in a more specific manner and may consequently exert fewer side 
effects for the patient. Manaster et al., (1996) reported that heparin exerted an apoptotic 
effect on human cells which included neutrophils, lymphoblasts and mononuclear cells. This 
could also suggest that the increased targeting noted in the stimulated PBMCs, which were 
vastly proliferating, could be related to the findings Manaster et al., (1996). The results of the 
apoptosis assays may provide a slight insight into the mechanism of action of the novel GAG 
compounds, however in future studies it may be worth investigating the levels of caspase 3 
and 8 to further the insight into the molecular mechanism associated with the induction of 
apoptosis in cancer cells and in cytotoxic T-cells post treatment with the novel GAG 
compounds.    
6.5 CFSE proliferation assay 
The rapid proliferation of cells is a key characteristic used to describe a malignant 
transformation (cancer) (Yip, Smollich and Gotte, 2006).  Cancer can ensue when the balance 
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of proliferation and apoptosis is shifted in the direction of proliferation (King and Cidlowski, 
1998). There is now ample evidence to suggest that GAGs play an important part controlling 
the proliferation of normal cells as well as malignant cells (Yip, Smollich and Gotte, 2006). 
Therefore novel exogenous GAGs, such as the ones isolated from the common cockle and 
whelk, with unique structural features may be capable of using this activity in various ways 
resulting in the inhibition of proliferation noted in this study. This inhibition may have 
occurred through an agonistic or antagonistic mechanism in protein receptors, via 
outcompeting the endogenous GAGs present on the cell surface and/or inhibiting the 
biosynthesis of the cell surface GAGs (Gandhi and Mancera, 2010). Cellular proliferation is 
primarily mediated via the cell cycle (Yang, 2012), there has been interest recently in the 
development of anti-cancer therapies which aim to target the cell cycle such as anti-
metabolites and DNA-damaging drugs (Schafer,1998). Which take advantage of the 
dysregulation of the normal cell cycle and aim to target cell cycle checkpoints, with the view 
to inducing cell cycle arrest or apoptosis in malignant cells (Roos and Kaina, 2006). GAG 
chains, such as HS, on the cell surface of cancer cells have been demonstrated to possess vital 
roles in many aspects of the phenotype of a tumour, such as development, growth and 
metastasis (Liu et al., 2002). HS has also been linked to the ability of cancer cells to modulate 
the process of angiogenesis (Gandhi and Mancera, 2010). Due to the identified activity of HS 
on tumour cells the avenue of polysaccharide based anti-cancer therapeutics is further being 
explored by several research groups (Linhardt, 2004). 
Whelk extract treatment of the MOLT-4 cell line (figures 4.20 and 4.21) resulted in a non-
significant reduction in proliferation but was the only treatment method to exhibit 
antiproliferative effects in the MOLT-4 cell line. A non-significant proliferative effect on the 
MOLT-4 cell line was noted post treatment with the cockle extract and cisplatin. Treatment 
with both the cockle and whelk extracts resulted in a reduction of proliferation in the CD3+ 
MOLT-4 cell population. Cockle extract treatment exerted a significant antiproliferative effect 
on the CD3+ MOLT-4 cell line (p= 0.0424). In the U698 cell line (figures 4.22 and 4.23) 
treatment with both the cockle and whelk extracts resulted in significant reductions in the 
proliferation of the cells (p= 0.0182 and p= 0.0243 respectively). With proliferation in the 
U698 cells being less than half that of the cisplatin treated cells post treatment with both the 
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cockle and whelk extracts. Cockle and whelk extract treatment resulted in significant 
decreases in the proliferation of the CD19+ U698 cells (p= 0.0487 and p= 0.0487 respectively).  
In the unstimulated PBMC populations (figures 4.24 and 4.25) both the cockle and whelk 
extracts exerted a proliferative effect on lymphocyte, T-helper cell and cytotoxic T-cell 
populations. The cockle extract treatment resulted in significant increases in the proliferation 
of naïve T-helper cells (p= 0.0152), the total population of cytotoxic T-cells (p=0.0341) and in 
the naïve cytotoxic T-cell populations (p=0.0194). Whelk extract treatment resulted in a 
significant increase in the proliferation of the total cytotoxic T-cell population (p=0.0228). In 
the stimulated PBMC populations (figures 4.26 and 4.27) the whelk extract treatment 
resulted in small decreases in the proliferation of the lymphocyte, T-helper and cytotoxic T-
cell populations. The decrease in proliferation in the naïve T-helper cell population was 
significant (p= 0.0384). Treatment with the cockle extract resulted in antiproliferative activity 
in the T-helper and cytotoxic T-cell sub-populations of the stimulated PBMCs all of which were 
non-significant. 
As was noted with the MTT and apoptosis assays, in the proliferation assays the whelk extract 
appears to exert the largest effects on the cancer cell lines whilst exerting minimal effects in 
both the stimulated and unstimulated PBMCs. These results support the findings of Ogundipe 
(2015) that the whelk extract exerts an antiproliferative effect in cancer cell lines. Basappa et 
al., (2012) also reported that certain GAG chains could provide a beneficial therapy for cancer 
patients which were expected to result in fewer side effects, the outcome of this assay would 
support this theory. The cockle extract treatment also exhibited antiproliferative effects in 
the U698 cell line and proliferative effects in the unstimulated PBMCs. The cockle extract did 
however appear to target the vastly proliferating PBMCs more than the whelk extract. GAGs 
and PGs are present in vertebrates and non-vertebrates and have been attributed to 
biological and physiological processes in the body (Raman, Ninomiya and Kuberan, 2011; 
Cross and Claesson-Welsh, 2001), GAGs are also known to play a part in all stages of the 
progression of cancer (Yip, Smollich and Gotte, 2006). It is therefore thought that exogenous 
GAGs, such as the novel cockle and whelk GAGs, may interfere with the function of 
endogenous GAGs and may provide a potential treatment option with fewer side effects 
(Gandhi and Mancera, 2010). The results of the CFSE proliferation assays along with the MTT 
and apoptosis assays would support this theory. Many GAG types have been studied as 
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potential anti-cancer therapies including heparin and heparin analogues as well as HS and CS 
(Yip, Smollich and Gotte, 2006). The results of this study also suggest that these novel cockle 
and whelk GAG compounds, which demonstrate unique structural features in comparison to 
commercially available mammalian GAGs (Khurshid and Pye, 2018), may potentially provide 
an anti-cancer therapy which could exhibit fewer side effects than current chemotherapy 
treatments.     
6.6 Cytokine and Treg response assay 
Cancer cells modify their microenvironment, through the expression of immunosuppressive 
proteins, including CTLA-4, which provide protection from destruction by cytotoxic T-
lymphocytes (Sompayrac, 2015). Cancer cells also stimulate the increased production of Treg 
cells in the microenvironment (Facciabene et al., 2012; Elkord, 2010), these Treg cells then 
upregulate the production of TGF-β and IL-10, which further create an immunosuppressive 
environment in which cytotoxic T-lymphocytes cannot function. The identification of Treg cells 
can be carried out through the determination of the expression of the fork-headed/ winged-
helix transcription factor FOXP3 (Lal and Bromberg, 2009), as the transcription factor is 
necessary for the development and function of Treg cells (Wang et al., 2009; Probst-Kepper et 
al., 2009).There are also various extracellular stimuli and intracellular signalling molecules 
which also aid with the function and development of Treg cells which include; IL-27, IL-4 and 
IFN-γ, this is done via the regulation of FOXP3 (Lal and Bromberg, 2009). FOXP3 has also been 
linked to the potency of Treg cells and deficiencies or mutations in FOXP3 can lead to the 
development of autoimmune diseases (Lal and Bromberg, 2009). Therefore FOXP3 can be 
used to specifically identify Treg cell populations as its expression on T-helper cells is exclusive 
to Treg cells (Probst-Kepper et al., 2009). Probst-Kepper et al., (2009) and Wang et al., (2009) 
identified that glycoprotein A repetitions predominant (GARP), a transmembrane protein, 
was highly expressed on activated FOXP3+ Treg cells and correlated with the suppressive 
activity of Treg cells.  Poor prognosis and negative responses to immunotherapy have been 
linked with raised Treg levels in cancer, thus raised levels of Treg cells aids the progression of 
cancer (Elkord, 2010). Therefore it is important to understand the effects of any potential 
anti-cancer therapies on cytokine production and Treg cells, this research aimed to determine 
the effects of the marine mollusc derived cockle and whelk extract on cytokine production 
and Treg cell levels in unstimulated and stimulated PBMCs. 
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Interferon- gamma (IFN-γ) is a cytokine which several cell types from both the adaptive and 
innate immune system produce, but is primarily secreted by thymus derived T-cell including; 
natural killer cells (NK) and activated T-helper cells and cytotoxic T-cells (Mojic, Takeda and 
Hayakawa, 2018; Boehm et al., 1997). Thus the cytokine is indispensable to many 
physiological processes such as; aspects of the immune regulation, cellular proliferation and 
apoptosis, anti-microbial and anti-viral defence and IFN-γ has also been shown to play roles 
in pregnancy allergies and cancer (Mojic, Takeda and Hayakawa, 2018; Boehm et al., 1997). 
The expression of FOXP3, thus the development of Treg cells, also has links to IFN-γ as the 
cytokine is involved in the phosphorylation of STAT 1 leading to interactions with the FOXP3 
proximal promotor in T-helper cells (Lal and Bromberg, 2009). IFN-γ is also a cytokine which 
is capable of suppressing tumour cell growth via several mechanisms (Mojic, Takeda and 
Hayakawa, 2018). However IFN-γ can also be linked to the vast proliferation and immune 
evasion of tumour cells suggesting IFN-γ also has tumour promoting capabilities (Mojic, 
Takeda and Hayakawa, 2018). In early studies it was thought that IFN-γ was an anti-cancer 
cytokine, however it was found that IFN-γ not only had the ability to control the progression 
or initiation of tumours but could create tumour immunosuppressive environments, thus 
promoting the proliferation and growth of tumour cells (Mojic, Takeda and Hayakawa, 2018). 
Therefore it can be said that in terms of cancer IFN-γ has a dual role in the outcome of cancer. 
The anti-cancer activity of IFN-γ is in part due to its ability to downregulate cellular 
proliferation through the upregulation of P21 and P27 molecules which induce cell cycle 
arrest, IFN-γ can also mediate apoptotic cell death (Mojic, Takeda and Hayakawa, 2018). 
Through the targeting of non-malignant cells in the tumour microenvironment IFN-γ can exert 
a potent anti-tumour effect via the recruitment of immune cells and the modulation of 
tumour cells in the tumour microenvironment (Spear, Barber, Rynda-Apple and Sentman, 
2012). Garbe et al., (1990) demonstrated that in melanoma IFN-γ was able to inhibit cancer 
cell growth, however they also noted expression of advanced melanoma markers increased, 
thus IFN-γ may have the potential to promote the development of aggressive phenotypes in 
cancer cells. Therefore it is now more evident that although IFN-γ does have anti-tumour 
capabilities it also is able to facilitate cancer cell proliferation and has a key role in the 
promotion of immunosuppression in the microenvironment of cancer cells (Mojic, Takeda 
and Hayakawa, 2018).  
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Interleukin-4 (IL-4) is a cytokine with a vital role in the immune system (Takeda et al., 1996) 
and is secreted by T-lymphocytes, mast cells and basophils (Hou et al., 1994). The balance of 
T-helper cells is also partially controlled by IL-4 (Hou et al., 1994). IL-4 plays a vital role in 
immunoregulation and has also been detected at high levels in the microenvironment of 
some tumour cells, where concentrations of IL-4 can be directly linked to the grade of 
malignancy (Nappo et al., 2017). IL-4 could also be described as an opposing cytokine to IFN-
γ in terms of FOXP3 as IL-4 inhibits the production of FOXP3 via the phosphorylation of STAT 
6 (Lal and Bromberg, 2009). Inflammation can also be linked to cancer development; chronic 
inflammation has been associated with immune cells producing a variety of cytokines 
including IL-4 (Nappo et al., 2017). In the same way as IFN-γ, IL-4 can have dual roles in cancer 
progression. Nagai and Toi (2000) described the anti-tumour properties of IL-4 in breast 
cancer cells. IL-4 can stimulate the production of antigen specific cytotoxic T-cells and 
enhance the ability of immune cells to present antigens and induce the anti-cancer activity of 
macrophages (Nagai and Toi, 2000). Maerten et al., (2005) identified that Treg cells exposed 
to IL-4 became more potent in suppressing T-helper cells and also inhibited the production of 
IFN-γ by T-helper cells. Cytokines can exert actions on immune cells and can also modulate 
the types of cells within the tumour microenvironment and are able to induce both cellular 
malignancy and apoptosis (Mojic, Takeda and Hayakawa, 2018; Nappo et al., 2017). The 
activity of cytokines has also been noted to be controlled by GAGs and the binding of 
cytokines to GAGs (Fernandez-Botran, Yan and Justus, 1999). GAGs therefore play a role in 
the modulation of cytokine activity (Fernandez-Botran, Yan and Justus, 1999). This study 
therefore looked to identify the effects of GAG treatment on cytokine (IL-4 and IFN-γ) 
production in stimulated and unstimulated PBMCs.    
Both the cockle and whelk GAG extract treatments resulted in small but significant reductions 
in the lymphocyte population of unstimulated PBMCs (figures 5.3 and 5.4) (p= 0.045 an p= 
0.0497 respectively). Post treatment with the cockle and whelk extracts small non-significant 
effects were noted in; cytotoxic T-cells, T-helper cells, IFN-γ, IL-4 and FOXP3 populations. In 
the T-helper cells positive for GARP and IFN-γ both treatment with the cockle and whelk 
extracts resulted in non-significant increases in percentage population (figure 5.5). In T-helper 
cells positive for IL-4 both the cockle and whelk extract treatments resulted in non-significant 
population percentage reductions. Both the cockle and whelk extract treatments resulted in 
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significant reductions in the population percentage of Treg cells (p= 0.0362 and p= 0.0199 
respectively), treatment with the whelk extract resulted in the largest reduction in the 
percentage population. The mean fluorescence of Treg cells (figure 5.6) both treatment with 
the cockle and whelk extract resulted in reductions in the fluorescence of GARP. Mean 
fluorescence in IFN-γ of Treg cells was increased post treatment with the cockle and whelk 
extracts. Whelk extract treatment resulted in resulted in an increase an increase in the mean 
fluorescence of IL-4 Treg cells, while cockle extract resulted in a decrease in mean fluorescence 
of IL-4 in Treg cells. In cytotoxic T-cells (figure 5.7) positive for IL-4 and IFN-γ both cockle and 
whelk extract treatments resulted in non-significant declines in population percentage of 
cytotoxic T-cells. In GARP positive cytotoxic T-cell populations the whelk extract treatment 
resulted in a non-significant decrease in the population percentage, while cockle extract 
resulted in a non-significant increase in population percentage. Treatment with both the 
cockle and whelk extracts resulted in significant decreases in the population percentage of 
CD8+ Treg cells (p= 0.0477 and p= 0.0367 respectively). Cockle and whelk extract treatments 
resulted in increases in the mean fluorescence (figure 5.8) of GARP in CD8+ Treg cells. In the 
CD8+ Treg cells the mean fluorescence of IL-4 and IFN-γ was decreased after treatment with 
both the cockle and whelk extracts. The decrease noted in IFN-γ mean fluorescence was 
significant post treatment with both the cockle and whelk extracts (p= 0.0027 and p= 0.0011 
respectively).  
The unstimulated PBMC assays whelk extract treatment demonstrated a reduction in IFN-γ 
and could suggest a decrease in Treg cell potency (Lal and Bromberg, 2009). The decrease in 
IFN-γ could also be linked to the slight changes in T-helper cell and cytotoxic T-cell 
populations, due to its role in immune cell regulation (Mojic, Takeda and Hayakawa, 2018; 
Boehm et al., 1997). The reduction of IFN-γ noted in the whelk extract treated cells may also 
prove to be beneficial as an anti-cancer therapy due to the role of IFN-γ in cancer proliferation 
and progression (Mojic, Takeda and Hayakawa, 2018). While the increase in IL-4 cytokine 
population noted post treatment with the whelk extract, could indicate potential increases in 
FOXP3 production (Lal and Bromberg, 2009). As with IFN-γ the decline in IL-4 could be linked 
to the observed changes in T-helper cell and cytotoxic T-cells, due to the vital role IL-4 plays 
in in immunoregulation (Nappo et al., 2017). An increase in IL-4 may play a beneficial role in 
the use of marine mollusc derived GAGs as an anti-cancer therapy, as IL-4 has the ability to 
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induce increased antigen presentation and the anti-cancer activity of macrophages (Nagai 
and Toi, 2000). Maerten et al., (2005) also identified that IL-4 could increase the potency of 
Treg cells at suppressing T-helper cells and IFN-γ production. Our results would support this 
due to the noted decrease in IFN-γ population percentage. The results of this study 
demonstrate the potential of the whelk extract to inhibit the immune evasion of cancer 
through the significant reduction in Treg cells noted (Facciabene et al., 2012; Elkord, 2010). 
Also through the reduction in cytokines which play a role in the promotion of immune evasion 
and prevention of cell death (Mojic, Takeda and Hayakawa, 2018; Nappo et al., 2017) post 
treatment with the whelk extract. The cockle extract treatment also resulted in similar 
reductions in Treg cells and cytokine changes, however in some cases the reductions were 
small in comparison to those noted in the whelk extract and the control treatment cisplatin.  
Both GAG extract treatments appear to reduce the population of cytotoxic T-cells positive for 
IL-4 and IFN-γ. These reductions may be beneficial in the use of GAGs as an anti-cancer 
therapy as although increased levels of IL-4 has been linked to anti-cancer activity in some 
cell lines, in other cancer cell lines lower levels of IL-4 have been linked to decreased 
malignancy (Nappo et al., 2017) and lower levels of IFN-γ have been linked to decreased Treg 
potency and decreased cellular proliferation (Mojic, Takeda and Hayakawa, 2018; Lal and 
Bromberg, 2009). The reductions noted in cytotoxic IFN-γ and IL-4 levels were non-significant 
and would be unlikely to promote a phenotypic change in cytotoxic T-cells. The results 
obtained from the whelk extract treated unstimulated PBMCs assays could suggest a 
potentially beneficial novel marine mollusc derived GAG treatment, which could help with 
the prevention of cancer immune evasion. Supporting the idea that GAG chains may exhibit 
anti-cancer properties whilst exerting minimal side effects (Basappa et al., 2012).    
In the stimulated PBMC assays treatment with both the cockle and whelk extracts resulted in 
decreases in the population percentages of lymphocytes, cytotoxic T-cells and IFN-γ (figures 
5.9 and 5.10). Treatment with both the GAG extracts exerted an increase in the T-helper cell 
population percentage (figure 5.11) and IL-4. The GARP population of stimulated PBMCs 
experienced an increase in population percentage post treatment with the cockle extract, 
while treatment with the whelk extract resulted in a decrease in the population percentage. 
Both the cockle and whelk extract treatments resulted in reductions in both the GARP T-
helper cells and Treg cells. The reductions in the Treg cell populations exerted by the cockle and 
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whelk extract treatments were significant (p= 0.0145 and p= 0.0191 respectively). The 
population of IL-4 positive T-helper cells and IFN-γ positive T-helper cells was increased post 
cockle extract treatment. In whelk extract treated cells the IL-4 positive T-helper cells 
increased, while the IFN-γ positive T-helper cells significantly decreased post treatment with 
the whelk extract (p= 0.0156). The mean fluorescence (figure 5.12) of IFN-γ in the Treg cell 
population increased post treatment with both the cockle and whelk extracts. The cockle 
extract treatment exerted increases in IL-4 and GARP mean fluorescence in Treg cells. The 
mean fluorescence of IL-4 decreased and GARP mean fluorescence significantly decreased (p= 
0.0354) post treatment with the whelk extract. Treatment with the cockle extract did not 
exert an effect on the population GARP cytotoxic T-cells, whilst whelk extract treatment 
exerted a small population increase (figure 5.13). Both cockle and whelk extract treatments 
demonstrated decreases in the population percentage of IFN-γ, IL-4 cytotoxic T-cells and CD8+ 
Treg cell populations. The mean fluorescence of IFN-γ, GARP and IL-4 in the CD8+ Treg cells 
increased post treatment with both the cockle and whelk extracts (figure 5.14).  
The results demonstrated in this study suggested that both the cockle and whelk extracts may 
provide a therapeutic treatment method that results in small effects on vastly proliferating 
lymphocytes is in support of the theory put forward by Basappa et al., (2012). The treatment 
with both the GAG extracts demonstrated reductions in the percentage of Treg cells, this could 
suggest that treatment with the novel marine mollusc derived GAGs may potentially prevent 
the immune evasion and prevention of cell death in cancer cells (Facciabene et al., 2012; 
Elkord, 2010). The noted decrease in cytotoxic T-cells could potentially be linked to the 
decrease in percentage IFN-γ, as IFN-γ is partially responsible for the regulation of immune 
cells (Mojic, Takeda and Hayakawa, 2018); it may also result in less proliferation and apoptosis 
in treated healthy lymphocytes (Mojic, Takeda and Hayakawa, 2018). Declines in IFN-γ can 
also be linked to anti-cancer activity in some cancers (Mojic, Takeda and Hayakawa, 2018) 
which could further support the use of marine mollusc derived GAGs as an anti-cancer 
therapy. The increase noted in the percentage of IL-4 may be linked to the increase in the 
percentage of T-helper post treatment with the GAG extracts. This is down to the ability of IL-
4 to regulate that levels of T-helper cells and its role in the recruitment of immune cells 
(Nappo et al., 2017). The increase in IL-4 in some cancers can also be linked to the production 
of antigen specific cytotoxic T-cells and enhanced antigen presenting ability as well as an 
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increase in the anti-cancer activity of macrophages (Nagai and Toi, 2000). However increased 
levels of IL-4 have also been linked to increased malignancy in some cancers (Nappo et al., 
2017). Therefore the effects of GAG extract treatment on vastly proliferating lymphocytes 
may need to be further explored.  
The results from the cytokine and Treg response assays identify the novel marine mollusc 
derived GAG extracts, in particular the whelk extract, resulted in a significant reduction in the 
percentage of Treg cells (in both stimulated and unstimulated PBMCs). This could suggest that 
treatment with the GAG extracts could aid with the reduction of the immune evasion of 
cancer cells; since raised levels of Treg cells has been attributed to the progression of cancer 
and the ability of cancer to evade the immune system (Bayer and Schultze, 2006). Further 
research to identify different dose and time responses of cancer cells and healthy 
lymphocytes (stimulated and unstimulated) to both the GAG extract treatments in the 
apoptosis and proliferation assays may further increase the knowledge on the effects of these 
novel GAG compounds on healthy lymphocytes. Also further research into the effects on IFN-
γ and IL-4 and the effects on Treg cells of both the GAG extracts in healthy lymphocytes, could 
potentially further determine whether the GAG extracts could provide a treatment option for 
cancer patients that would elicit fewer side effects. Further investigation into the effects of 
the FPLC fractions on the cancer cell lines and healthy lymphocytes in the apoptosis, 
proliferation and cytokine and Treg response assays would further aid to determine the 
potential use of the GAG extracts as an anti-cancer therapy. This however was all beyond the 
scope of this research study. The results of the cytokine and Treg response assays teamed with 
the results of the MTT, apoptosis and proliferation assays also supports the idea put forward 
by Aldairi, Ogundipe and Pye (2018) and Ogundipe (2015) that the marine mollusc GAGs 
derived from the common cockle and common whelk appear to selectively target cancer cells 
as opposed to targeting healthy lymphocytes (in both stimulated and unstimulated PBMCs). 
This study therefore furthers the potential for the future use of the marine mollusc derived 
GAGs for therapeutic use in the clinic.  
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6.7 Timeline of previous and current work on GAG isolates 
Figure 6.1 identifies previous work carried out on both the cockle and whelk GAG extracts, 
where the results of this study fit with the research carried out on the cockle and whelk 
extracts and finally the expected progression of the research. 
 
Figure 6.1 The timeline of previous and current work being carried out on GAG isolates. 
 
 
 
 
 
 
 
Aldairi, Ogundipe and Pye (2018) 
Initial testing for carcinogenic potency 
and initial fractionation experiments on 
epithelial cancer cell lines and MOLT-4 
leukaemia cell line 
C Jones and L Smyth  
U698 (new cell line) and PBMC -/+ 
stimulation, T-cell families, Treg 
response assays to cockle and whelk 
isolates 
Initial animal studies complete: 
identified cancer shrinkage 
Next step: Multiple dose regimes 
following further purification of the 
active polysaccharide to reduce toxicity 
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Appendix 
FPLC optimisation results 
The complex nature of the whelk extract crude mixture limits the ability to identify any 
particular components responsible for the anti-cancer activity identified. In sight of this ion-
exchange chromatography (FPLC) was performed in order to attempt to identify a particular 
component responsible for the activity. Elution was spectrophotometrically monitored at 
232nm in order to detect fragments of the crude extract.  
The FPLC technique was carried out using a variety of linear gradient protocols as set out in 
the methods section, in order to ascertain the highest possible level of separation in the crude 
extract to allow the identification of the most potent fraction. 
An initial FPLC run was carried out using a 3M-3M NaCl gradient in 50mM phosphate buffer 
pH 7.0, achieved over a 120-minute time frame. The graph presented in figure 8.1 identifies 
one solid peak (P1) with a small shoulder peak (S1) to the left-hand side. This demonstrated 
that the entire sample had been eluted at a single time point. This identified the initial 
gradient as being insufficient to separate out the individual components of the GAG extract.  
 
Figure 8.1 FPLC absorbance vs time graph of whelk extract sample method 1. Whelk sample applied 
to a DEAE-sepharose packed X16-20cm column, eluted using a 0-3M NaCl gradient over a 120-minute 
time period. Elution was monitored at 232nm. 
Due to the lack of separation a further method was created using a 0-0.75M NaCl gradient, 
which was obtained over a 60-minute period and after a 5-minute hold period was further 
increased to 2M. This increase occurred over a 30-minute period. It was hoped that through 
S1 P1 
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extending the period of time taken to reach the gradient point where the previous sample 
peak had been eluted, further separation may occur.  
Figure 8.2 identifies still one predominant main peak (P1), however the initial shoulder now 
appeared broader and further migrated. This suggested the start of some separation not seen 
in the initial run. 
 
Figure 8.2 FPLC absorbance vs time graph of whelk extract sample method 2. Whelk sample applied 
to a DEAE-sepharose packed X16-20cm column, eluted using a 0-75M and 0.75M-2M NaCl step 
gradient over a 100-minute time period. Elution was monitored at 232nm. 
The previous gradient appeared sufficient although the final gradient was further reduced for 
the subsequent run as no sample appeared to be eluted at a higher gradient. This reduction 
would also prolong the time taken for the gradient to be reached, thus further separation 
may be noted as the longer time it takes to get to a gradient the more likely it is to pull the 
individual components of the GAG extracts through the column at different speeds due to 
their different levels of negativity. Therefore, the subsequent run still used the initial 0-0.5M 
NaCl gradient achieved over a 60-minute period with a 5-minute hold. Then a further NaCl 
gradient increase to 1.5M over a 30-minute time point was executed.  
In figure 8.3 further separation can be noted with the initial predominant peak starting to split 
into 2 separate peaks (P1 and P2), the second peak also feature two further signs of 
separation shoulder peaks S1 and S2. The further level of separation identifies a longer time 
frame to reach the gradients proved beneficial in promoting a higher level of separation in 
the whelk extract. 
S1 
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Figure 8.3 FPLC absorbance vs time graph of whelk extract sample method 3. Whelk sample applied 
to a DEAE-sepharose packed X16-20cm column, eluted using a 0-75M and 0.75M-1.5M NaCl step 
gradient over a 100-minute time period. Elution was monitored at 232nm.  
As the previous run demonstrated a higher level of separation with the increased time taken 
to obtain the final gradient, further prolongation of the time taken to achieve the initial 
gradient was decided on after analysis. Therefore, the subsequent run an initial 0-0.25M NaCl 
was obtained over a 30-minute period and held for 5 minutes. Over a further 30-minute 
period the NaCl gradient was increased from 0.25M to 0.5M NaCl and again held for 5 
minutes. The gradient was then further increased to 1M NaCl over a 60-minute period.   
As can be seen in figure 8.4 the new method of achieving a gradual gradient step wise 
provided a level of separation in the whelk extract that had not previously been achieved. In 
figure 8.4 14 peaks can be identified (P1-14), with some peaks still identifying small shoulders 
suggesting there could be further separation still to be achieved. As this was the highest level 
of separation achieved this method was used to collect and pool the peak fractions. The 
fractions were de-salted using the PD-10 column gravity method and isolates were freeze 
dried in order to obtain a powder which was used in subsequent MTT assays. These assays 
aimed at identifying which peak was responsible for the anti-cancer activity noted in the crude 
extract assays. 
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P2 
S1 
S2 
 276 
Figure 8.4 FPLC absorbance vs time graph of whelk extract sample method 4. Whelk sample applied 
to a DEAE-sepharose packed X16-20cm column, eluted using a 0-25M, 0.25M-0.5M and 0.5M-1M NaCl 
step gradient over a 130-minute time period. Elution was monitored at 232nm. 
CD3+ K562 cell line populations obtained from Annexin V/ PI apoptosis assay 
As the K562 cell line has been described as having T-cell properties (Klein et al., 1976), the 
research homed in on the CD3+ populations of the K562 cell line, in order to gain insight into 
the effects of GAG isolates on T-cell specifically. However only approximately 4% of K562 cells 
tested positive for CD3. In figure 8.5 section A cisplatin can be identified as having brought 
about the largest increase in CD3+ K562 apoptotic cells of around 15%; seen through the 
corresponding drop in cells not undergoing cell death (p=0.1317). There was also a decrease 
in late stage apoptotic cells post cisplatin treatment (green bar, section A of figure 8.5, 
p=0.3385). The largest increase was seen in the early stage apoptotic cells (blue bar, section 
A figure 8.5, p=0.6667). This follows the pattern noted in the entire K562 cell population 
(figure 8.5 section A).  
The cockle extract elicited a small decrease in the percentage of CD3+ K562 cell not 
undergoing apoptosis (p= 0.9398) and a small decrease in late stage apoptotic CD3+ K562 cells 
(p=0.2934) (figure 8.5, section B). Cockle extract treatment also brought about small increases 
in the percentage of CD3+ K562 cells undergoing mid (p=0.4542) and early stage apoptosis 
(p=0.4362) (red and blue bars respectively, section B of figure 8.5). The whelk extract 
treatment (section C of figure 8.5) resulted in a minor increase of around 1.3% of CD3+ K562 
cells which were not undergoing any form of cell death (p=0.8810); this increase 
corresponded with the decrease of cells undergoing late stage apoptosis (p=0.3961) seen in 
figure 8.5 (section C, green bar).  
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Figure 8.5 Average cell death activity in CD3+ K562 cells obtained using the annexin V/PI apoptosis 
assay. Average percentage change graphs for CD3+ K562 cells treated with the IC50 dose of cisplatin 
(A), cockle extract (B) and whelk extract (C) (6 µg/ml, 12 µg/ml and 12 µg/ml respectively). Showing 
the stage of cell death that the cells are in where early= early stages of apoptosis, mid= mid stages of 
apoptosis, Late= late stage apoptosis and no apoptosis= no cell death. Using an incubation period of 
3 days using the Annexin V/ PI apoptosis assay. Where N=3, percentage change in cells were calculated 
in relation to untreated cells and Error bars show SEM, significance is denoted by *, absence of * 
indicates no significance. 
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